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Innate lymphoid cells (ILCs) are relatively newly identified cells that have a 
lymphoid-like morphology, but lack antigen specific receptors. Similarly to T cells, 
they can be divided into three main groups (1, 2 and 3), which produce distinct 
combinations of cytokines to mediate their functions, and whose development 
depends on different transcriptional factors. Group 3 ILCs (ILC3s) are enriched at 
mucosal surfaces, where they act as key effector cells. They can be further 
subdivided into lymphoid tissue inducer (LTi) cells, and NCR+ or NCR- ILC3s based 
on whether or not they express natural cytotoxicity receptors. NCR- ILC3s, which 
co-produce IL-22 and IL-17A, remain poorly understood, especially with regards to 
their function in the colon.   
In this thesis it was shown that NCR- ILC3s were the dominant ILC3 subset in the 
healthy colon, as well as during colonic inflammation, and that NCR- ILC3s drived 
colitis in Tbx21-/- x Rag2-/- Ulcerative Colitis (TRUC) mice with IL-22 being their 
effector cytokine. NCR- ILC3 derived IL-22 triggered endoplasmic reticulum (ER) 
stress in colonic epithelial cells and induced CXCL1 and CXCL5 secretion that 
subsequently led to neutrophil recruitment to the inflamed colon. These pro-
inflammatory actions of IL-22 were augmented by IL-17A, another cytokine 
produced by NCR- ILC3s that is strongly implicated in inflammatory bowel disease 
(IBD) pathogenesis. Whole transcriptome analysis of colonic biopsies from patients 
with Ulcerative colitis (UC) and healthy individuals revealed compelling evidence 
that these pro-inflammatory, IL-22 dependent pathways may be relevant in human 
disease.  
Taken all together these data shed more light into TRUC disease, and possibly 
provides new insights into the immunopathology of chronic colitis. Targeting the 
pro-inflammatory pathways mediated by NCR- ILC3s may represent a novel 
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1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a medical term used to describe chronic 
intestinal inflammation. IBD can be divided into two main distinct conditions: 
Crohn’s disease (CD) where inflammation can affect any part of the gastrointestinal 
tract, and Ulcerative colitis (UC) where inflammation is limited to the colon 
(Baumgart, Sandborn 2007).  Both forms are characterized by alternating phases of 
clinical relapse and remission, and are commonly presented with symptoms such as 
diarrhoea, rectal bleeding, mucus discharge and abdominal pain (Baumgart, 
Sandborn 2007). In some cases, inflammation can also extend to organs beyond the 
digestive system, including the eyes (Mintz, Feller et al. 2004), joints (Orchard, 
Wordsworth et al. 1998), skin (Lebwohl, Lebwohl 1998) and liver (Raj, Lichtenstein 
1999). IBD patients are at greater risk of developing another chronic inflammatory 
disorder such as ankylosing spondylitis, psoriasis (Loftus 2004) and colorectal cancer 
(Eaden, Abrams et al. 2001, Rutter, Saunders et al. 2006). Despite the severity of 
these symptoms that undoubtedly have a negative impact on psychology (Graff, 
Walker et al. 2009, Trachter, Rogers et al. 2002) and quality of life (Jelsness-
Jorgensen, Bernklev et al. 2011, Bernstein, Kraut et al. 2001) many IBD patients 
may have to undergo disfiguring surgery (Baumgart, Sandborn 2007).  Although IBD 
incidence is generally thought to spike in the western world countries (more than 3 
million people affected in Europe and North America), it is now progressively rising 
in the developing world (Loftus 2004, Lakatos 2006). 
The etiology of IBD is complex and remains poorly understood. Familial studies 
show that first-degree relatives have higher risk of developing IBD than the rest of 
the population (Tysk, Lindberg et al. 1988, Orholm, Munkholm et al. 1991). 
Furthermore, monozygotic twins are more likely to be affected than dizygotic twins, 
especially in CD (Orholm, Munkholm et al. 1991) suggesting genetic predisposition. 
In a landmark study done by the Wellcome Trust Case Control Consortium in 2007, 
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CD was found to have the highest relative-sibling risk among the 7 diseases studied 
(Wellcome Trust Case Control Consortium 2007). More recent data show single 
nucleotide polymorphisms (SNPs) shared by CD and UC, while other variants are 
unique for CD or UC (Fisher, Tremelling et al. 2008, Franke, Balschun et al. 2008a). 
In spite of the compelling evidence that IBD is a genetic-associated disease, genetic 
factors are insufficient to be the sole cause, as concordance between monozygotic 
twins is generally less than 50% (Halfvarson, Bodin et al. 2003, Jess, Riis et al. 2005, 
Spehlmann, Begun et al. 2008). Environmental factors such as diet (Hansen, Jess et 
al. 2011, Jakobsen, Paerregaard et al. 2013, Turner, Zlotkin et al. 2009), smoking 
(Sutherland, Ramcharan et al. 1990), or exposure to gastrointestinal infections 
(Hansen, Jess et al. 2011, Garcia Rodriguez, Ruigomez et al. 2006, Gradel, Nielsen 
et al. 2009, Porter, Tribble et al. 2008) may also contribute to IBD pathogenesis. 
Moreover, many studies show a role for the microbiome, with antibiotics used to 
prevent recurrence in CD patients undergoing surgery, or to treat pouchitis in UC 
patients following colectomy (Rutgeerts, Hiele et al. 1995, Shen, Achkar et al. 2001). 
Overall, it appears that both genetic and environmental factors have an impact on the 
development of IBD.  
1.1.1 Genetic contributions to IBD pathogenesis 
In the last decade, great progress has been made in unravelling genetic factors that 
are associated with altered IBD risk, or even contribute to IBD pathogenesis. 
Genome-wide association studies (GWAS) lead the field by providing unbiased 
correlations between gene variations and disease occurrence. More than one hundred 
and sixty genetic loci are associated with IBD susceptibility so far, including genes 
involved in bacterial recognition, epithelial barrier integrity and immune activation 
(Jostins, Ripke et al. 2012).  Some genes are shared between the two forms of IBD, 
while others are only associated with either CD or UC susceptibility (Jostins, Ripke 
et al. 2012). Genetic loci associated with IBD risk also overlap with susceptibility to 
other immune mediated diseases such as primary sclerosing cholangitis, ankylosing 
spondylitis and psoriasis (Bernstein, Wajda et al. 2005), as well as 
immunodeficiencies and infections (Jostins, Ripke et al. 2012).  
The first ever described polymorphisms associated with risk for Crohn’s disease 
were found in the nucleotide-binding oligomerization domain-containing protein 2 
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(NOD2) locus (Hugot, Chamaillard et al. 2001, Ogura, Bonen et al. 2001). NOD2 
gene encodes for an intracellular pattern recognition receptor that senses bacterial 
peptidoglycans and can be activated by a small peptidoglycan component known as 
muramyl dipeptide (MDP) resulting in the activation of nuclear factor κB (NF-κB) 
and mitogen-activated protein (MAP) kinase signalling pathways (Girardin, 
Travassos et al. 2003, Inohara, Ogura et al. 2003, Kobayashi, Chamaillard et al. 
2005).  Each one of the three SNPs that are located near or within the leukine-rich 
repeat region of the NOD2 protein (the domain needed for bacterial sensing) are 
highly associated with CD susceptibility (Abraham, Cho 2006). Interestingly, they 
are found in European descent individuals, but not in Japanese, Chinese and Korean 
affected individuals (Croucher, Mascheretti et al. 2003, Leong, Armuzzi et al. 2003, 
Yamazaki, Takazoe et al. 2002), while they are rare in African American IBD 
patients (Kugathasan, Loizides et al. 2005).  Disease penetrance is yet limited even 
for homozygous individuals (Hugot, Zaccaria et al. 2007) suggesting that NOD2 
mutations alone are insufficient to induce CD, which is also corroborated by the fact 
that NOD2 KO mice do not develop intestinal inflammation (Kobayashi, 
Chamaillard et al. 2005, Pauleau, Murray 2003).  
In addition to NOD2 gene, GWAS have identified many more genetic loci of the 
innate immune system to be associated with IBD risk. Great examples include genes 
involved in autophagy, a cellular process important for degradation of intracellular 
pathogens, antigen processing and cell signalling regulation. A SNP in the ATG16L1 
gene that leads to the conversion of the amino acid alanine to threonine (Ala281Thr) 
is found to be highly associated with CD susceptibility (Hampe, Franke et al. 2007, 
Prescott, Fisher et al. 2007, Rioux, Xavier et al. 2007). CD patients with the 
ATG16L1 SNP have abnormal Paneth cell morphology, as do mice with low 
ATG16L1 protein levels (Cadwell, Liu et al. 2008), while in murine macrophages 
ATG16L1 seems to regulate IL-1β secretion and inhibit intestinal inflammation 
(Saitoh, Fujita et al. 2008). Another study published in Nature by Murthy et al, 
showed that upon cellular stress and in the presence of the Ala281Thr variant, 
caspase 3 gets activated and ATG16L1 protein becomes more sensitive to cleavage, 
which may lead to impaired autophagy and subsequently to CD onset (Murthy, Li et 
al. 2014). Moreover, IRGM gene, which is also involved in autophagy (Singh, Davis 
et al. 2006), has been associated with CD risk (Wellcome Trust Case Control 
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Consortium 2007, Parkes, Barrett et al. 2007). Genetic variants within or upstream of 
the IRGM locus are linked to CD susceptibility (Parkes, Barrett et al. 2007, 
McCarroll, Huett et al. 2008, Rufini, Ciccacci et al. 2015), suggesting that autophagy 
pathways may play a key role in the development of Crohn’s disease.  
More recent genetic studies have identified TNFSF15 as another gene of the innate 
immune system to be associated with CD susceptibility (Jostins, Ripke et al. 2012, 
Franke, McGovern et al. 2010). TNFSF15 encodes for a protein named TL1A, which 
is a member of the TNF superfamily. TL1A is produced by innate immune cells such 
as monocytes, macrophages and DCs upon microbial stimulation and it binds to 
death domain receptor 3 (DR3) expressed on T cells, leading to T cell activation and 
secretion of proinflammatory cytokines (Migone, Zhang et al. 2002, Prehn, Thomas 
et al. 2007, Shih, Kwan et al. 2009). A SNP within the TNFSF15 gene has been 
strongly associated with CD susceptibility among Japanese, as well as East Asians 
and Europeans with IBD (Jostins, Ripke et al. 2012, Franke, McGovern et al. 2010, 
Yamazaki, McGovern et al. 2005, Kakuta, Kinouchi et al. 2006, Picornell, Mei et al. 
2007, Thiebaut, Kotti et al. 2009, Tremelling, Berzuini et al. 2008, Yang, Lim et al. 
2008). Interestingly, different haplotypes of the gene seem to be associated with 
either risk or protection depending on ethnicity (Picornell, Mei et al. 2007). In 
accordance with its genetic contributions, several pre-clinical studies have shown a 
role for TL1A in IBD pathogenesis (Barrett, Zhang et al. 2012, Shih, Barrett et al. 
2011, Zheng, Zhang et al. 2013). Mice overexpressing TL1A develop spontaneous 
intestinal inflammation characterized by Th2 responses and high levels of IL-13 
(Meylan, Song et al. 2011, Taraban, Slebioda et al. 2011), supporting the hypothesis 
of TLIA being an important regulator of mucosal immunity.  
Components of the adaptive immune system have also been implicated with IBD 
susceptibility. Some of the strongest associations with increased CD risk found by 
GWAS are genetic variations within the gene coding for the IL-23R (Duerr, Taylor 
et al. 2006). IL-23R variants are also found in patients with UC, psoriasis and 
ankylosing spondylitis (Duerr, Taylor et al. 2006, Cargill, Schrodi et al. 2007, 
Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis 
Consortium (TASC) et al. 2007), supporting the notion of genetic overlap among 
these diseases. Most importantly, associations with CD susceptibility have been 
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reported for several genetic loci of the IL-23:IL-17A axis (Duerr, Taylor et al. 2006, 
Barrett, Hansoul et al. 2008), while protein levels of IL-23 and Th17-relevant 
cytokines are increased in the colonic mucosa of both CD and UC patients 
(Annunziato, Cosmi et al. 2007, Fujino, Andoh et al. 2003a, Saruta, Yu et al. 2007), 
highlighting the significance of this pathway in the pathogenesis of IBD.  In 
particular, several genes of the IL-23 signalling pathway including JAK2, STAT3 
and p40 have been associated with both forms of IBD (Barrett, Hansoul et al. 2008, 
Franke, Balschun et al. 2008b, Silverberg, Cho et al. 2009, Fernando, Stevens et al. 
2008).  
1.1.2 Environmental implications in IBD 
Despite the accumulating evidence from GWAS strongly associating several genetic 
variants with IBD susceptibility, familial, and in particular twin studies, as well as 
epidemiological data clearly point out the need of additional factors for disease 
development. Such factors include diet, smoking, changes in the microbiome 
composition, certain types of surgery and geography. Overall, the relations between 
genetic predisposition and environmental influences remain unclear, highlighting the 
need of further studies to unravel the complicated and multifactor aetiology of IBD 
pathogenesis.  
Dietary habits may affect IBD occurrence, although it is quite challenging to study 
those associations. Breast-feeding for longer than 6 months, high consumption of 
fibres and low sugar intake seems to reduce the possibility of IBD development 
(Hansen, Jess et al. 2011). In particular, fibre intake from fruits specifically appears 
to reduce CD risk to a greater extent compared to fibres form vegetables, and this 
association is stronger for small intestinal CD than colonic (Ananthakrishnan, Khalili 
et al. 2013, Amre, D'Souza et al. 2007). Daily consumption of vegetables and whole 
meal bread also reduce the odds for IBD occurrence (Jakobsen, Paerregaard et al. 
2013). Omega 3 fatty acids that were thought to be beneficial for inflammatory 
disorders appear to have no effect on maintenance of remission in CD (Turner, 
Zlotkin et al. 2009).  
Smoking is probably the best-studied environmental factor associated with IBD, and 
interestingly enough it seems to affect differently CD and UC risk. It increases the 
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risk of CD, whereas it protects against UC (Cosnes, Beaugerie et al. 2001, Lindberg, 
Tysk et al. 1988). Current smokers are more likely to develop CD than non-smokers 
(Mahid, Minor et al. 2006, Higuchi, Khalili et al. 2012), while CD patients that 
smoke are in greater risk of experience aggressive disease and need surgery (Cosnes, 
Carbonnel et al. 1996, Cosnes, Carbonnel et al. 1999, Cosnes 2004, Cosnes 2008). In 
contrast, ex-smokers have significantly increased risk of UC occurrence than non-
smokers (Higuchi, Khalili et al. 2012).  In people with already established UC, 
smoking is associated with milder disease, while smoking cessation is associated 
with flares (Beaugerie, Massot et al. 2001).  
Emerging data point to vitamin D being associated with IBD occurrence. IBD 
incidence is suggested to be higher in northern latitudes and areas that are less 
exposed to UV light (Ananthakrishnan, Khalili et al. 2012). Moreover, both CD and 
UC patient’s lower levels of vitamin D were associated with increased risk for 
surgery and IBD-related hospitalizations (Ananthakrishnan, Cagan et al. 2013).  
Another environmental factor that appears to be associated with IBD risk include 
appendectomy, which is associated with risk for UC but not CD (Andersson, Olaison 
et al. 2001).  
In an effort to understand the pathobiology of IBD, more than 60 animal modes of 
experimental inflammatory bowel disease have been described over the last decades. 
And in spite the fact that each and every one of them has its limitations (mostly in 
terms of resemblance to human disease), they helped us unravel several important 
aspects in the aetiology and pathophysiology of IBD including the involvement of 
the host’s microbiome, its genetic background, as well as the role of the innate and 
adaptive immune system.  In general, based on the induction of the disease these 
models can be divided into 5 different groups: (a) antigen-specific and bacterial 
models, (b) chemical/immunological and physical inducible models, (c) genetic 
models, (d) adoptive transfer models and (e) spontaneous models (Hoffmann, 
Pawlowski et al. 2002).  
1.1.2.1 Antigen-specific models 
This relatively small category includes among others the OVA TCR TG mouse 
model (Iqbal, Oliver et al. 2002), as well as Helicobacter hepaticus induced models 
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of experimental colitis. In the OVA TCR TG model, colitis is induced by transfer of 
either polarized Th1 or Th2 cells into Rag2 KO mice colonized with OVA-
expressing E. coli (Iqbal, Oliver et al. 2002).  Although disease severity is similar 
between Th1 and Th2 transfers, histological features differ (Iqbal, Oliver et al. 2002). 
Helicobacter hepaticus induces intestinal inflammation in Rag2 KO mice (von 
Freeden-Jeffry, Davidson et al. 1998). In this model, colitis is IL-7 dependent, as 
Rag2xIl7 double KO mice do not develop disease (von Freeden-Jeffry, Davidson et 
al. 1998). Helicobacter hepaticus also induces colitis in mice deficient in the p50 
chain of NF-κB and heterozygously deficient for the p65 chain (Erdman, Fox et al. 
2001).      
1.1.2.2 Inducible models 
This group consists of animal models where the disease is induced chemically, 
immunologically or physically, including the first ever described animal model of 
experimental colitis, where intestinal inflammation in rabbits is caused by an 
immune complex (Kirsner 1961). Physically, intestinal inflammation can be induced 
via irradiation of MHC class II deficient mice (Marguerat, MacDonald et al. 1999). 
Amongst the chemically induced models, including oxazole colitis (Boirivant, Fuss 
et al. 1998) and the indomethacin model (Yamada, Deitch et al. 1993), the most 
commonly used are the dextran sodium sulphate (DSS) model (Cooper, Murthy et al. 
1993) and the 2,4,6-trinitrobenzenesulfonic acid (TNBS) or dinitrobenzene sulfonic 
acid (DNBS) model (Morris, Beck et al. 1989).  
Oral administration of 3-10% DSS via drinking water can cause colitis to several 
species such as mice, rats and hamsters that resembles some features of human UC 
(Okayasu, Hatakeyama et al. 1990, Kitajima, Takuma et al. 1999). Disease seems to 
be driven by direct epithelial damage leading to fibrosis, goblet cell hypoplasia and 
crypt loss, and is presented by weight loss, diarrhoea, rectal bleeding, shrinking of 
the colon and neutrophil infiltration (Okayasu, Hatakeyama et al. 1990, Kitajima, 
Takuma et al. 1999, Melgar, Karlsson et al. 2005). SCID and Rag-/- mice that lack B 
and T cells are also susceptible to DSS colitis, suggesting that adaptive immunity has 
no contribution at least to the acute phase of the disease (Dieleman, Ridwan et al. 
1994, Krieglstein, Cerwinka et al. 2002). However, in chronic DSS colitis T cells 
that accumulate to the colon appear to be pathogenic (Dieleman, Palmen et al. 1998). 
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Whether or not microbiota play a role in DSS colitis is still unclear with several 
studies supporting either side. Although bacterial products and or probiotics can 
improve DSS colitis (Rachmilewitz, Katakura et al. 2004, Verdu, Bercik et al. 2000), 
germ-free mice seem to be equally or even more prone to disease (Bylund-Fellenius 
et al., Microbiol Ecol Health, 1994; Kitajima, Morimoto et al. 2001).  
DNBS/TNBS colitis is induced by intrarectal administration of DNBS/TNBS 
dissolved in ethanol (EtOH) that results in the generation of Ag-specific adoptive 
immune responses (Elson, Beagley et al. 1996). However, innate immune cells are 
also involved as DNBS/TNBS inflammation also occurs in mice lacking 
lymphocytes (Fiorucci, Mencarelli et al. 2002). DNBS/TNBS inflammation seems 
microbiota and strain dependent with distinct cytokine profiles (Th1, Th2, Th17) 
being described in different genetic backgrounds (Elson, Beagley et al. 1996, 
Neurath, Fuss et al. 1995a, Dohi, Fujihashi et al. 1999). DNBS/TNBS induced 
inflammation shares many similarities with CD pathology, including the persistent 
fibrosis observed in the chronic version of this model (Kiesler, Fuss et al. 2015, 
Fichtner-Feigl, Fuss et al. 2007). 
1.1.2.3 Genetic models 
This is the biggest and most growing category of IBD animal models including both 
transgenic and knock-out (KO) animal models. In general, genetic models can be 
further divided into 5 groups based on the pathway that is altered: (a) models with 
IL-2/IL-2R deficiencies, (b) models with IL-10 signalling deficiencies, (c) TCR or 
MHC class II deficient models, (d) TGFβ deficient models and (e) models with 
alterations in signal transduction molecules (A20, Gai2, STAT-3, STAT-4) 
(Hoffmann, Pawlowski et al. 2002).  
One of the best-characterized and commonly used genetic models is the IL-10 
deficient mouse.  In this model, disease is very much dependent on T cells 
(Davidson, Leach et al. 1996). IFNγ signalling is also important as administration of 
neutralizing antibodies against IFNγ in young IL-10 deficient mice abrogates 
intestinal inflammation (Berg, Davidson et al. 1996). The same results are observed 
with administration of recombinant IL-10 (Rennick, Fort et al. 1997). In adult IL-10 
deficient mice, colitis onset can be prevented by anti-IL-12 Ab administration 
(Davidson, Hudak et al. 1998). Intestinal microbiota also mediate inflammation in 
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IL-10 deficient mice (Rennick, Fort et al. 1997). Germ-free IL-10 deficient mice do 
not develop colitis unless introduced to specific bacterial flora (Sellon, Tonkonogy et 
al. 1998). Helicobacter hepaticus (HT) seems able to induce colitis in IL-10 deficient 
mice (Kullberg, Ward et al. 1998), although other studies support that it has no effect 
in disease induction (Dieleman, Arends et al. 2000). With regards to human disease, 
IL-10 deficient mice develop colon cancer similarly to CD and UC patients (Sturlan, 
Oberhuber et al. 2001), as well as osteoporosis like CD patients do (Sylvester, F et al. 
2002).  
1.1.2.4 Adoptive transfer models  
This group comprises all IBD animal models where disease is induced by adoptive 
transfer of naïve T cells into immunodeficient recipients (Rag1 KO, Rag2 KO, SCID 
mice). Adoptively transferred CD4+CD45RBhigh T cells into SCID mice lead to 
colitis (Powrie, Leach et al. 1993, Morrissey, Charrier et al. 1993), as do 
CD4+CD62L+ T cells (Mudter, Wirtz et al. 2002, Neurath, Weigmann et al. 2002). In 
general, all T helper (Th) cells can cause colitis if adoptively transferred to 
immunocompromised recipients (Claesson, Bregenholt et al. 1999).  Inflammation 
seems to be driven by Th1 responses as in vivo blocking of IFNγ, TNFα and IL-12 
but not IL-4 prevents disease development (Brimnes, Reimann et al. 2001, Powrie, 
Leach et al. 1994, Leach, Bean et al. 1996, Mackay, Browning et al. 1998), while 
dendritic cells (DCs) are also important mediators (Leithauser, Trobonjaca et al. 
2001, Malmstrom, Shipton et al. 2001). Interestingly, in this model(s) disease 
development can be prevented if CD4+CD45RBlow T cells are co-transferred with 
CD4+CD45RBhigh T cells (Powrie, Leach et al. 1993, Morrissey, Charrier et al. 1993, 
Groux, O'Garra et al. 1997), an effect that is mediated by IL-10 production 
(Asseman, Mauze et al. 1999a). Similarly, colitis induction is abrogated by in vivo 
administration of anti-TGFβ (Powrie, Carlino et al. 1996) or anti-IL-10R1 Abs 
(Asseman, Mauze et al. 1999b).  
As observed in other IBD animal models, disease induction here is also driven by the 
intestinal microbiota. If CD4+CD45RBhigh T cells are transferred to SCID recipients 
with impaired flora or to mice treated with antibiotics, disease is ameliorated 
(Aranda, Sydora et al. 1997). Moreover, polyclonal CD4+CD45RBhigh T cells 
become oligoclonal and Ag-reactive once transferred (Matsuda, Gapin et al. 2000). 
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Finally, pathology in these models share many similarities with that observed in UC 
patients (Leach, Bean et al. 1996).  
1.1.2.5 Spontaneous models 
Animals rarely develop spontaneous colitis. Murine models in this category include 
the SAMP1/Yit mice that under SPF conditions spontaneously develop intestinal 
inflammation with clinical features similar to CD (Matsumoto, Okabe et al. 1998), 
and the C3H/HeJ mice that can also develop colitis under certain housing conditions 
(Sundberg, Elson et al. 1994).  
Another model of spontaneous IBD that resembles human UC was firstly described 
by Garrett et al, in an article published in Cell, back in 2007. Tbet deficiency in the 
innate immune compartment leads to spontaneous colitis in the absence of adaptive 
immunity (Garrett, Lord et al. 2007). Tbx21-/- x Rag2-/- mice spontaneously develop 
severe colitis with features similar to those observed in UC patients, hence referred 
to as Tbx21-/- x Rag2-/- Ulcerative colitis (TRUC) mice (Garrett, Lord et al. 2007). 
Disease is presented as early as 4 weeks with continuous inflammation starting from 
the rectum and followed by the left colon, intestinal wall thickening and anal 
prolapse, while the remaining gastrointestinal tract appears normal (Garrett, Lord et 
al. 2007). Histologically, is characterized by mononuclear, polymorphonuclear cell 
infiltration, goblet cell depletion, epithelial injury, and crypt loss (Garrett, Lord et al. 
2007). TRUC disease is driven by TNFα overproducing colonic DCs (Garrett, Lord 
et al. 2007), and at the early stages it can be ameliorated by anti-TNFα neutralizing 
Abs; anti-TNFα treatment is ineffective on 12-week old or older mice (Garrett, Punit 
et al. 2009). Similarly to other IBD animal models, the intestinal microflora has a key 
role in mediating TRUC disease (Garrett, Lord et al. 2007), as germ-free TRUC mice 
do not develop colitis (Garrett, Gallini et al. 2010) and inflammation is resolved 
following treatment with antibiotics (Garrett, Lord et al. 2007, Garrett, Gallini et al. 
2010) or probiotics (Veiga, Gallini et al. 2010). Moreover, TRUC disease is 
communicable to Tbet sufficient mice (Garrett, Lord et al. 2007). 
Recent work in our lab by Powell et al shed more light into the immunopathology of 
TRUC disease. In particular, IL-17A producing IL-7R+ innate lymphoid cells (ILCs) 
were proven to be key mediators of chronic colitis in the TRUC model of IBD 
(Powell, Walker et al. 2012). In vivo administration of anti-CD90 neutralizing Abs 
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significantly reduced intestinal inflammation, and the same effects were observed 
with IL-17A blockade (Powell, Walker et al. 2012). IL-17A production by ILCs is 
induced by IL-23 and TNFα, which is excessively produced by CD103-CD11b+ 
colonic DCs (Powell, Walker et al. 2012). Moreover, IL-7R signalling is also crucial 
for TRUC pathology as in vivo inhibition of IL-7R signalling seems to ameliorate 
disease (Powell, Walker et al. 2012).  Most importantly, Powell et al identified 
Helicobacter typhlonius as the main microbiota component that triggers TRUC 
disease (Powell, Walker et al. 2012).  
More recently, an independent study by Ermann et al corroborated those findings, 
while identifying NOD2 as an important upstream regulator of IL-23/IL-1 induced 
IL-17A production by ILCs, and TNFα as a key inducer of neutrophil chemo-






















Table 1: Available animal models to study IBD. (Modified from Hoffmann JC et al., 












Antigen-specific Inducible Genetic Adoptive transfer Spontaneous
Chemical Transgenic
Peptidoglycan-polysaccharider Acetic acidr,d Cytochrome c TCR tgm CD4+CD45RBhigh/SCIDm C3H/HeJBirm
Carageenanm, gp, rb DNBS/ethanolm,r HGF tgm CD4+CD45RBhigh/RAG-2 kom Cotton-top tamarinp
Complete Freund's adjuvantr DSSh,m,r HLA B27 x β2-MG tgr CD4+CD62Lhigh/SCIDm Grower/finisherpgs
Helicobacter hepaticus (rag-2 ko)m Indomethacinr HSV tyrosinekinase tg/gancyclovirm CD4+CD62Lhigh/RAG-1 kom HistiocyticUCd
Helicobacter hepaticus (p50-/- x p65+/-)m Lactulosem HTF tgm CD4+CD45RBhighYit/SCIDm Samp1/Yitm
 Hsp60m Oxazolonem IL-7 tgm CD4+/SCIDm
Lymphogranuloma venereum proctitism Sulfhydryl blockersr N-Cadherin dominant neg. tgm CD4+ con A blasts/SCIDm
Ovalbumin in OVA TCR tg micem TNBS/ethanolr,m,rb STAT4 tg/TNP-KLHm CD4+ con A blasts/RAG-1 kom
Ovalbumin/transfercolitis/OVA tg micem TGFβ receptor-II dominant neg. tgm Bone marrow/CD3εTg26m
TNBS/transfer/TCR kom Immunological CD40L tgm HSP60-CD8 clone/TCRβ kom




Radiation (MHC II ko)m Gi-2α kom
Gpx 1 ko x Gpx 2 kom
IL-2 receptor-β  kom
IL-2 receptor-α  kom















Indicated are the category and the species (d=dog; gp+guinea pig; m=mouse; p=primate; pgs=piglets; r=rat; rb=rabbit). 
DSS=Dexxtran sulfonic acid; HGF= hepatocyte growth factor; HTF= human fucosyl transferase; mdr=multiple drug 
resistance gene; tg=transgenic; TGF=transforming growth factor
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1.2 Immunopathology of IBD 
Although the exact cause of IBD remains unclear, accumulating evidence suggest 
that it results from a dysregulated immune response against the normal intestinal 
microbiota in a genetically predisposed host. Recent genetic studies associating SNPs 
at genetic loci involved in host detection, processing and presentation of luminal 
bacteria with altered IBD risk highlight the importance of host-microbe interactions 
in IBD pathogenesis. Similarly, studies showing how changes in microbiota 
composition, due to environmental factors such as diet and treatment with antibiotics, 
affect IBD occurrence also support this hypothesis. Extensive studies focusing on 
microbe-host interactions and the multiple functions of the mucosal immune system 
in the gut have provided new insights into both etiology and pathobiology of IBD.  
1.2.1 The microbiome 
The human gastrointestinal tract with a luminal surface of around 300m2 provides 
home to more than 1013 microorganisms  (Gill, Pop et al. 2006). This enormous 
microbial population that can be quite diverse even among healthy individuals 
(Human Microbiome Project Consortium 2012), helps us get the most of our dietary 
intake by complementing our metabolic capacity (Backhed, Ley et al. 2005), and has 
a great impact on shaping our intestinal immune responses. A person’s intestinal 
microbiota is acquired at birth but changes during the first year of life, while it 
remains quite stable throughout adulthood, although its composition may alter 
slightly in response to environmental factors or during disease (Eckburg, Relman 
2007, Turnbaugh, Hamady et al. 2009, Wu, Estrada et al. 2005). Several studies have 
now mapped the “normal” human gut microbiome, which is shared among most 
healthy individuals. The two dominant phyla are Bacteroidetes and Firmicutes, 
whereas Actinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia are also 
found in some people (Eckburg, Bik et al. 2005), as well as Methanogenic archaea, 
eukaryotes and viruses (Reyes, Haynes et al. 2010). However, the specific species of 
those phyla and their relative proportions differ notably among individuals.  
Patients with IBD have altered microbiota composition (Frank, St Amand et al. 2007, 
Ott, Musfeldt et al. 2004). Twins with UC were found to have less Bacteroides and 
more Actinobacteria and Proteobacteria compared to their healthy twin siblings 
(Lepage, Hasler et al. 2011). E. coli has also been found to be increased in people 
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with UC, while is also found in patients with CD (Chassaing, Darfeuille-Michaud 
2011). On the other hand, patients with CD appear to have less bacterial numbers of 
the phylum Firmicutes than healthy individuals (Kang, Denman et al. 2010, 
Manichanh, Rigottier-Gois et al. 2006). Moreover, altered bacterial composition has 
also been observed between CD patients, whose disease affects the ileum and colon 
(Willing, Dicksved et al. 2010). Taken together these data support the concept of 
microbiota having an important role in IBD pathobiology by providing the initial 
stimulus for an inflammatory immune response.  
1.2.2 The intestinal epithelium 
The epithelial cells of the gastrointestinal tract provide a physical barrier that 
separates the microbiota normally residing in the lumen, from the immune cells of 
the lamina propria, ensuring homeostasis. Only a small portion of bacteria is able to 
translocate to allow “normal” bacterial sampling by cells of the innate immune 
system (Slack, Hapfelmeier et al. 2009). Defects in the intestinal barrier leading to 
increased permeability and subsequently to persistent immune activation may lead to 
IBD (Sartor 2006). The intestinal epithelium consists of five functionally distinct cell 
types that derive from a common stem cell: 1) Absorptive enterocytes, 2) Mucus 
producing goblet cells, 3) hormone producing enderoendocrine cells, 4) M cells and 
5) antimicrobial and growth factor producing Paneth cells (van der Flier, Clevers 
2009).  
Goblet cells produce and secrete glycosylated mucins forming the mucosa (just 
above the epithelium), which comprises the first line of defence against the microbes 
in the lumen (Johansson, Ambort et al. 2011). The colon has a dual mucus layer 
restricting bacterial adhesion to the epithelium (Johansson, Larsson et al. 2011); 
whereas the small intestinal has a looser single layer of mucus allowing penetration 
of food substances (Sonnenburg, Xu et al. 2005). Paneth cells are located at the 
bottom of the crypts and are known for producing antimicrobial peptides (AMPs) 
and other inflammatory mediators (Bevins, Salzman 2011). Several genetic variants 
that are associated with IBD risk including those within the NOD2 locus affect 
Paneth cell function (Lala, Ogura et al. 2003), while goblet cell and mucus depletion 
are characteristics of UC (Jass, Walsh 2001, Danese, Fiocchi 2011), suggesting a role 
of the epithelium in IBD pathogenesis.    
35 
 
Figure 1: Innate immune responses in the gut. The intestinal epithelium forms a physical 
anatomical barrier that separates the lumenal contents from the rest of our body. It consists of several 
types of epithelial cells including antimicrobial peptide-producing Paneth cells, and mucin-secreting 
Goblet cells that form a mucus layer protecting the epithelium from direct contact with bacterial 
antigens. Right beneath the epithelium lays a thin layer of connective tissue known as lamina propria, 
enriched with innate immune cells such as macrophages, DCs, neutrophils and ILCs. In steady state, a 
limited translocation of commensal bacteria from the lumen to the LP is allowed, where mononuclear 
phagocytes sample bacterial antigens through TLRs and NLRs without initiating an inflammatory 










































1.2.3 The intestinal immune system  
A complex network of interactions exists among the microbiome, the epithelium and 
the immune cells that reside along the walls of the gastrointestinal tract. The 
intestinal immune system has been assigned with the difficult task of discriminating 
between commensal, harmless bacteria and invading pathogens that translocate 
across the epithelial monolayer, while is trained to maintain tolerance against the first 
and initiate protective immune responses against the later securing intestinal 
homeostasis. Breakdown of this fine balance between the host and its intestinal 
microbiota can lead to intestinal inflammation and subsequently to development of 
IBD.  
1.2.3.1 Mononuclear phagocytes (MPs) 
The intestinal mononuclear phagocyte (MP) system consists of two functionally 
distinct cell types: Mϕs (the main phagocytes) and DCs (the professional antigen- 
presenting cells), both of which play a central role in antigen sampling and T cell 
priming. Despite their apparent functional differences, these cells have a similar 
phenotype, which makes it difficult to differentiate them based on their surface 
markers, leaving their subtype identification somewhat controversial.  
§ Intestinal Mϕs  
In contrast to other tissues, intestinal Mϕs are constantly replenished by blood 
circulating monocytes (Tamoutounour, Henri et al. 2012, Bain, Scott et al. 2013, 
Rivollier, He et al. 2012, Bain, Bravo-Blas et al. 2014). In particular, Ly6Chi 
monocytes continuously arrive to the intestines in a CCR2-dependent manner (Bain, 
Bravo-Blas et al. 2014), where they start to down- regulate Ly6C while they start to 
up-regulate MHC II, CD64 and F4/80 through a process known as the monocyte 
waterfall (Tamoutounour, Henri et al. 2012). Ultimately, they give rise to resident 
Mϕs that also express high levels of the chemokine receptor CX3CR1 
(Tamoutounour, Henri et al. 2012, Bain, Scott et al. 2013) and can be identified as 
Ly6C-CD11c-MHCII+CD11b+CD64+
 
cells. They can be found throughout the 
gastrointestinal tract, mostly close to the epithelium (Hume, Perry et al. 1984), 
however their numbers tend to increase in the colon (in comparison with the small 
intestine) reaching their zenith towards the distal end (Nagashima, Maeda et al. 1996, 
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Denning, Norris et al. 2011). A subpopulation of CX3CR1 expressing Mϕs is located 
close to the epithelium that reaches the intestinal lumen to sample antigens (Niess, 
Adler 2010). Mice lacking CX3CR1 have less Mϕs in the lamina propria, high 
translocation of commensal bacteria to the MLN, and develop severe colitis, which 
can be ameliorated by IL-17A blockade or adoptive transfer of CX3CR1 sufficient 
Mϕs (Medina-Contreras, Geem et al. 2011). 
In steady state mucosa, macrophages exhibit an anti-inflammatory phenotype by 
producing IL-10 and low levels of TNFα (Bain, Scott et al. 2013), showing poor 
response to TLR ligands (Tamoutounour, Henri et al. 2012, Bain, Scott et al. 2013) 
and lacking respiratory burst activity (Rugtveit, Haraldsen et al. 1995) or nitric oxide 
production (Roberts, Riley et al. 2001). However, intestinal Mϕs are highly 
phagocytic (Smith, Smythies et al. 2011, Smythies, Sellers et al. 2005, N'Diaye, 
Branda et al. 2009). Their postulated roles include maintenance of epithelial 
turnover/integrity and tissue remodeling (Muller, Kaiser et al. 2012, Rani, Smulian et 
al. 2011, Pull, Doherty et al. 2005). They have also been implicated in the 
differentiation and maintenance of the FoxP3+
 
Treg pool (Hadis, Wahl et al. 2011, 
Murai, Turovskaya et al. 2009) and T effector cell lineages (Shaw, Kamada et al. 
2012). Similarly, in humans, intestinal Mϕs lack CD14 expression and under normal 
conditions exhibit anti-inflammatory properties, whilst remaining highly phagocytic 
(Smythies, Sellers et al. 2005, Smith, Smythies et al. 2001). However, in CD 
patients, an additional Mϕ population is present that expresses CD14 as well as other 
Mϕ and DC markers such as CD33, CD68, CD205 and CD209 and produces high 
levels of pro-inflammatory cytokines including TNFα, IL-6 and IL-23 (Kamada, 
Hisamatsu et al. 2008). These Mϕs seem to regulate IFNγ, but not IL-17A 
production by LPMCs (Kamada, Hisamatsu et al. 2008).    
During intestinal inflammation, instead of giving rise to anti-inflammatory Mϕs, 
newly recruited Ly6Chi monocytes give rise to CX3CR1int
 
expressing pro- 
inflammatory Mϕs (Bain, Scott et al. 2013, Zigmond, Varol et al. 2012, Weber, 
Saurer et al. 2011). Many independent studies using experimental models of colitis 
based on DSS or naïve T cell transfer, suggest that in this context, Ly6Chi
 
monocytes 
and their derivatives are highly pathogenic (Zigmond, Varol et al. 2012, Platt, Bain et 
al. 2010, Varol, Vallon-Eberhard et al. 2009). 
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§ Intestinal DCs  
Intestinal DCs are generally identified as MHCIIhiCD11chiCD64-F4/80- cells that can 
subsequently be separated into four functionally distinct subsets based on their 
expression of CD103 and CD11b. CD103+CD11b+ DCs comprise the majority of 
CD103+ DCs in the small intestine LP, but are rare in the colonic LP and their 
development depends on Flt3 (as of most classical DCs) (Bogunovic, Ginhoux et al. 
2009), GM-CSF (Greter, Helft et al. 2012), Notch-2 (Lewis, Caton et al. 2011) and 
IRF4 (Schlitzer, McGovern et al. 2013, Persson, Uronen-Hansson et al. 2013). In 
steady state, these cells represent the main compartment of CD103+ DCs that induces 
tolerance, and although their absence doesn’t affect FoxP3+ generation it decreases 
the number of Th17 cells (Lewis, Caton et al. 2011, Persson, Uronen-Hansson et al. 
2013, Welty, Staley et al. 2013). However, upon TLR5 activation CD103+CD11b+ 
DCs can prime T cells suggesting that these cells can switch from an anti-
inflammatory (tolerogenic) phenotype to a pro-inflammatory (immunogenic) one 
(Kinnebrew, Buffie et al. 2012, Uematsu, Fujimoto et al. 2008).  
CD103+CD11b-
 
DCs, whose development depends on Flt3, Batf3 and IRF8, share 
ontogeny as well as function with splenic CD8α+
 
DCs (Edelson, KC et al. 2010). 
They are able to cross- present antigen priming CD8+
 
T cells (Cerovic, Houston et al. 
2013, Fujimoto, Karuppuchamy et al. 2011), while they produce ALDH in MLN 
suggesting that they may play a role in FoxP3+
 
Treg induction (Cerovic, Jenkins et 
al. 2009). During inflammatory conditions, CD103+ DCs in MLN respond to TLR 




T cells (Cerovic, Houston 
et al. 2013, Cerovic, Jenkins et al. 2009). 
CD103-CD11b+
 
DCs are difficult to distinguish from intestinal Mϕs as they share 
phenotypic characteristics including intermediate expression levels of CX3CR1. 
Their progenitors and functions are poorly understood, although they are not Ly6Chi
 




DCs are found in small intestine and colonic LP as well as in MLN (Bain, 
Scott et al. 2013, Cerovic, Houston et al. 2013) and are capable of priming T cells 
(Cerovic, Houston et al. 2013). Lastly, CD103-CD11b- DCs are the minority of 
intestinal DCs and rare in the colonic LP. Their development may depend on Flt3 as 
39 
they proliferate after Flt3 administration, whereas they can induce IL-17 production 
by CD4+
 
T cells in vitro (Cerovic, Houston et al. 2013). 
Under inflammatory conditions (e.g. in experimental models of colitis) DCs 
accumulate in the gut (Uhlig, McKenzie et al. 2006), as well as in the mucosa of 
patients with IBD (Hart, Al-Hassi et al. 2005). In TRUC mice that develop 
spontaneous colitis TNFα producing CD103-CD11b+ DCs promote intestinal 
inflammation (Powell, Walker et al. 2012). A DC subset that expresses E-cadherin 
also promotes intestinal inflammation in experimental models of colitis via IL-6 and 
IL-23 production (Siddiqui, Laffont et al. 2010).  
1.2.3.2 Lymphocytes 
Adaptive immune cells, and in particular exaggerated T cell responses have also been 
associated with IBD pathogenesis. Initially, it was thought that CD is a Th1 mediated 
disease as T cells isolated from the mucosa of CD patients produce high amounts of 
IFNγ and IL-2 (Breese, Braegger et al. 1993, Noguchi, Hiwatashi et al. 1995), while 
UC is characterized by a Th2 immune response with UC patients producing more IL-
5 and IL-13 than individuals with CD (Fuss, Neurath et al. 1996, Fuss, Heller et al. 
2004, Heller, Florian et al. 2005). However, the fact that higher levels of IFNγ and 
IL-13 are found in the supernatants of cultures of biopsies obtained from UC patients 
when compared to those isolated from patients with CD (Rovedatti, Kudo et al. 2009, 
Vainer, Nielsen et al. 2000), challenge this paradigm. In addition, more recent studies 
implicate Th17 in IBD pathology, and in particular with CD, which is also consistent 
with all the GWAS that associate SNPs in the IL-23:IL-17A axis with increased IBD 
risk.  
Neutralizing antibodies against IL-12, a cytokine known for inducing Th1 
differentiation, have been shown to ameliorate disease in models of experimental 
colitis (Neurath, Fuss et al. 1995b). Accordingly in humans, anti-IL-12p40 antibodies 
(known as ustekinumab and briakinumab) seem to be effective in CD patients that do 
not respond to anti-TNF treatment (Sandborn, Gasink et al. 2012, Mannon, Fuss et 
al. 2004), suggesting a role for IL-12 in IBD pathology. However, IL-23, which 
shares the p40 chain with IL-12, is also blocked by the above drugs complicating the 
exact mechanisms of their action.  
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Th17 cells are known to be induced by IL-6 and TGFβ, expand by IL-23, and they 
produce high amounts of IL-17A, IL-17F, IL-21 and IL-22 (Dong, Nurieva 2003, 
Dong 2008, Zhou, Ivanov et al. 2007). Their differentiation depends on the 
transcription factor RORγt (Ivanov, McKenzie et al. 2006, Yang, Pappu et al. 2008), 
and they can be divided into two subsets based on their function with the IL-
17A/IFNγ coproducing generally considered as the “pathogenic” Th17 
subpopulation. IBD patients have increased IL-17A mRNA levels, as well as 
increased numbers of Th17 and Th1/Th17 cells in the lamina propria (Rovedatti, 
Kudo et al. 2009, Fujino, Andoh et al. 2003b, Sugihara, Kobori et al. 2010). 
Moreover, IL-17RA KO mice were protected from disease in a TNBS model of 
experimental colitis (Zhang, Zheng et al. 2006), also supporting a pathogenic role for 
IL-17A in IBD. In contrast, several studies have shown data suggesting a protective 
role for IL-17 in IBD pathogenesis. In a DSS model of colitis, IL-17A was found to 
be protective against mucosal inflammation, while IL-17F was shown to exacerbate 
disease (Moseley, Haudenschild et al. 2003, O'Connor, Kamanaka et al. 2009, Sarra, 
Pallone et al. 2010). Furthermore, blockade of IL-17A exacerbated disease in a DSS 
model of colitis (Ogawa, Andoh et al. 2004). Taken together these data leave unclear 
the implications of IL-17 in the pathobiology of IBD, while leaving open the 
possibility that genetic and/or other environmental factors affect the action of this 










1.3 Innate lymphoid cells 
Beside the well-known lymphocytes and the classic innate immune cells such as 
macrophages and DCs, a new family of innate immune cells is emerging as key 
players in IBD. Recently discovered innate lymphoid cells, also known as ILCs, 
comprise phenotypically and functionally distinct, non-cytotoxic cells of the innate 
immune system (Spits, Di Santo 2011, Spits, Artis et al. 2013, Eberl 2012). The ILC 
superfamily also includes the well-described natural killer (NK) cells, as well as the 
lymphoid tissue inducer (LTi) cells (Spits, Artis et al. 2013). All ILCs are 
characterized by a lymphoid-like morphology as given away by their name, and the 
lack of antigen specific receptors, therefore exhibiting no antigen specificity (Spits, 
Di Santo 2011, Spits, Artis et al. 2013, Eberl 2012). In addition, although ILCs 
express IL-2Rα (CD25) and IL-7R (CD127), they don’t express any surface markers 
that identify other immune subsets, instead they are defined by the lack thereof as 
Lineage negative (Lin-) cells (Spits, Di Santo 2011, Spits, Artis et al. 2013, Eberl, 
Marmon et al. 2004, Mebius, Rennert et al. 1997, Moro, Yamada et al. 2010a, Neill, 
Wong et al. 2010, Price, Liang et al. 2010).  ILCs are distributed throughout the 
body, in lymphoid as well as non-lymphoid tissues, and they can directly interact 
with numerous different cell types haematopoietic and non, being involved in several 
biological processes including the regulation of intestinal homeostasis (Spits, Di 
Santo 2011, Spits, Artis et al. 2013, Eberl 2012).   
1.3.1 ILC development & heterogeneity  
In contrast to T and B cells, the development of ILCs is yet to be fully characterized. 
Recent studies showed that ILC precursors (often referred to as α-lymphoid 
precursors) also derive from the common lymphoid progenitor (CLP), express the 
integrin α4β7 and the chemokine receptor CXCR6, and may give rise to conventional 
NK cells, as well to all ILC subsets (Klose, Flach et al. 2014, Cherrier, Sawa et al. 
2012, Possot, Schmutz et al. 2011). Downstream of αLPs are two known precursors 
both expressing the transcriptional repressor Id2, which give rise to conventional NK 
cells and ILCs (Klose, Flach et al. 2014, Cherrier, Sawa et al. 2012, Constantinides, 
McDonald et al. 2014). Mice deficient in Id2 have neither NK cells nor ILCs (Moro, 
Yamada et al. 2010a, Cherrier, Sawa et al. 2012, Monticelli, Sonnenberg et al. 2011a, 
Hoyler, Klose et al. 2012a, Yokota, Mansouri et al. 1999). The Id2+ ILC precursor 
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gives rise to all ILCs and LTi cells, but not to conventional NK cells (Klose, Flach et 
al. 2014). Next in line is the Id2+ ILC precursor that expresses both Id2 and the 
transcriptional factor promyeloid leukaemia zinc finger (PLZF), and can only give 
rise to all ILC subsets but not to LTi cells (Constantinides, McDonald et al. 2014). 
Additional transcriptional factors that seem to affect early differentiation of NK cells 
and ILCs are TOX and NFIL3 (Constantinides, McDonald et al. 2014, Fuchs, Vermi 
et al. 2013, Aliahmad, de la Torre et al. 2010, Geiger, Abt et al. 2014, Seillet, Rankin 
et al. 2014, Yu, Wang et al. 2014), and the basic-helix-loop-helix transcriptional 
factor E47, which is reported to block the development of NK and LTi cells (Boos, 
Yokota et al. 2007), hence favouring ILC development.  
Similarly to all T cell populations, ILC subsets are defined based on their need for 
transcriptional factors during development, the distinct combinations of cytokines 
they produce as well as their effector functions. Two important transcriptional factors 
that seem to drive the development of all ILCs that express the IL-7R (also known as 
CD127) are CTF-1 and GATA-3.  
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Figure 2: ILC development. A common lymphoid progenitor gives rise to an early ILC progenitor 
(EILP) in bone marrow and fetal liver. EILP can give rise to all ILC lineages, LTi cells and NK cells, 
but not to T or B cells. Downstream of EILP is the IL-15R-expressing NK precursor that gives rise to 
mature NK cells, as well as the common-helper like ILC precursor (CHILP) that is characterized by 
the expression of c-Kit, IL-7Rα, α4β7 and the transcription factors Id2, Tox and Nfil3. CHILP can 
further develop to LTi cells, or to PLZF-expressing precursor that gives rise to ILC1s, ILC2s and 















































1.3.1.1 Group 1 ILCs (ILC1s and NK cells) 
The group 1 ILCs comprises the well-known NK cells and the non-cytotoxic Lin- 
ILC1s (Spits, Artis et al. 2013). NK cell development depends on the transcriptional 
factors T-bet and Eomes (Gordon, Chaix et al. 2012); whereas the development of 
ILC1s appears to be associated with a down-regulation of the transcriptional factor 
RORγt and an up-regulation of T-bet (Vonarbourg, Mortha et al. 2010a, Bernink, 
Peters et al. 2013b). Both NK cells and ILC1s are activated by the cytokines IL-12, 
IL-15 and IL-18 (Klose, Flach et al. 2014, Fuchs, Vermi et al. 2013, Bernink, Peters 
et al. 2013b) and produce high levels of IFNγ (Klose, Flach et al. 2014, Fuchs, Vermi 
et al. 2013, Vonarbourg, Mortha et al. 2010a, Bernink, Peters et al. 2013b). 
Alongside IFNγ, ILC1s are also known to produce TNFα (Klose, Flach et al. 2014). 
Several independent studies focused on ILC1s, have highlighted the importance of 
these cells in immunity against intracellular bacteria and parasites (Klose, Flach et al. 
2014, Fuchs, Vermi et al. 2013, Vonarbourg, Mortha et al. 2010a, Bernink, Peters et 
al. 2013b). 
1.3.1.2 ILC2s 
In contrast to group 1 ILCs, ILC2s depend on the transcriptional factor GATA-3 for 
their development and maintenance (Hoyler, Klose et al. 2012b, Mjosberg, Bernink 
et al. 2012), while they also require IL-7 (Moro, Yamada et al. 2010b). Like Th2 
cells, ILC2s respond to type 2 cytokines such as IL-2 (Mirchandani, Besnard et al. 
2014, Oliphant, Hwang et al. 2014), IL-4 (Kim, Wang et al. 2014, Motomura, Morita 
et al. 2014), IL-25 and IL-33 (Neill, Wong et al. 2010, Price, Liang et al. 2010, 
Monticelli, Sonnenberg et al. 2011a, Moro, Yamada et al. 2010b, McHedlidze, 
Waldner et al. 2013, Imai, Yasuda et al. 2013, Saenz, Siracusa et al. 2013, Salimi, 
Barlow et al. 2013). Several studies have also shown that ILC2s get activated by IL-9 
(Wilhelm, Hirota et al. 2011, Turner, Morrison et al. 2013), thymic stromal 
lymphopoietin (TSLP) (Mjosberg, Bernink et al. 2012, Kim, Siracusa et al. 2013) 
and TL1A (Meylan, Hawley et al. 2014, Yu, Pappu et al. 2014). Upon activation, 
ILC2s are shown to produce type 2 cytokines to mediate their functions like IL-4, IL-
5, IL-9 and IL-13 (Neill, Wong et al. 2010, Price, Liang et al. 2010, Monticelli, 
Sonnenberg et al. 2011a, Moro, Yamada et al. 2010b, Wilhelm, Hirota et al. 2011, 
Mjosberg, Trifari et al. 2011).  ILC2s have been shown to have an important role in 
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several physiological and pathological processes including tissue repair, helminth 
immunity allergies and asthma (Neill, Wong et al. 2010, Price, Liang et al. 2010, 
Monticelli, Sonnenberg et al. 2011a, Moro, Yamada et al. 2010b, Wilhelm, Hirota et 
al. 2011, Mjosberg, Trifari et al. 2011, Bartemes, Kephart et al. 2014, Moffatt, Gut et 
al. 2010). In addition, recent studies have implicated ILC2s in metabolism and 
metabolic diseases (Molofsky, Nussbaum et al. 2013, Hams, Locksley et al. 2013, 
Miller, Asquith et al. 2010, Nussbaum, Van Dyken et al. 2013).  
1.3.1.3 Group 3 ILCs (ILC3s and LTi cells) 
Group 3 ILCs is probably the most diverse category of ILCs (both in human and 
mouse) and includes LTi cells and ILC3s (Spits, Artis et al. 2013). Murine ILC3s can 
be further divided into CCR6 expressing ILC3s and CCR6- ILC3s. The later (CCR6- 
ILC3s) includes two distinct ILC3 subpopulations that can be distinguished by their 
expression of natural cytotoxicity receptors (NCRs) or the lack thereof into NCR+ 
ILC3s and NCR- ILC3s, respectively, whereas CCR6 expressing ILC3s are 
essentially the CD4+ as well as CD4- LTi cells. In humans, the majority of ILC3s 
expresses CCR6, which can be further divided into two populations depending on 
whether or not they express the NCR NKp44 (Cella, Fuchs et al. 2009, Cupedo, 
Crellin et al. 2009, Satoh-Takayama, Vosshenrich et al. 2008b). Depending on the 
environmental stimulus, ILC3s can produce IL-17A, IL-17F, IL-22, TNFα and 
granulocyte macrophage colony-stimulating factor (GM-CSF) (Cella, Fuchs et al. 
2009, Cupedo, Crellin et al. 2009, Satoh-Takayama, Vosshenrich et al. 2008b, 
Sonnenberg, Monticelli et al. 2011, Buonocore, Ahern et al. 2010), while they 
respond to IL-1β and IL-23 (Cella, Otero et al. 2010, Mortha, Chudnovskiy et al. 
2014). In particular, LTi cells can produce IL-17A and IL-22 (Takatori, Kanno et al. 
2009), as can do the NCR- ILC3s (Satoh-Takayama, Vosshenrich et al. 2008b, 
Sonnenberg, Monticelli et al. 2011), whereas NCR+ ILC3s produce only IL-22 
(Spits, Di Santo 2011, Cella, Fuchs et al. 2009, Satoh-Takayama, Lesjean-Pottier et 
al. 2010, Vonarbourg, Mortha et al. 2010b).  
Similarly to Th17 cells, all ILC3s require for their development the transcriptional 
factor RORγt (Eberl, Marmon et al. 2004, Satoh-Takayama, Vosshenrich et al. 
2008a, Sun, Unutmaz et al. 2000), whereas their survival and effector functions 
depend on the transcriptional factor aryl hydrocarbon receptor (AHR) (Kiss, 
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Vonarbourg et al. 2011, Lee, Cella et al. 2011). Notably, recent evidence point to 
ILC3 plasticity and to T-bet as another transcriptional factor that can influence ILC3 
fate (Klose, Flach et al. 2014, Klose, Kiss et al. 2013, Rankin, Groom et al. 2013). In 
particular, in the presence of cytokines such as IL-12 and IL-18, ILC3s can become 
IFNγ producing ILC1s by down-regulating RORγt whilst up-regulating T-bet 
(Vonarbourg, Mortha et al. 2010b, Klose, Kiss et al. 2013), a phenomenon that has 
also been observed in humans (Cella, Otero et al. 2010, Bernink, Peters et al. 2013a).   
So far several studies have described a role for ILC3s in antibacterial immunity, 
chronic inflammation and tissue repair (Cella, Fuchs et al. 2009, Cupedo, Crellin et 
al. 2009, Satoh-Takayama, Vosshenrich et al. 2008b, Sonnenberg, Monticelli et al. 
2011, Buonocore, Ahern et al. 2010). In the lung, ILC3s appear to provide protection 
against foreign pathogens such as the bacteria Streptocucus pneumoniae (Van Maele, 
Carnoy et al. 2014) and Mycobacterium tuberculosis (Pitt, Stavropoulos et al. 2012), 
as well as against the fungus Candida albicans (Gladiator, Wangler et al. 2013). 
ILC3s have also been associated with the inflammatory skin disease psoriasis 
vulgaris (Pantelyushin, Haak et al. 2012). NCR+ ILC3s are present in the blood and 
skin of patients with psoriasis but absent in healthy individuals whose blood and skin 
contained only NCR- ILC3s instead (Villanova, Flutter et al. 2014). A potential role 
for ILC3s has also been described in multiple sclerosis (Perry, Han et al. 2012), 
although whether they are protective or pathogenic remains unclear. Moreover, 
emerging data point to an important role for ILC3s in cancer (Shields, Kourtis et al. 
2010), and in particular on their involvement in promoting colorectal cancer 
(Langowski, Zhang et al. 2006, Chan, Jain et al. 2014, Huber, Gagliani et al. 2012a, 
Kirchberger, Royston et al. 2013).  
1.3.2 ILC3s in IBD 
Accumulating evidence also suggests group 3 ILCs as key mediators of intestinal 
inflammation. ILC3s that develop and accumulate to the gastrointestinal tract and 
gut-associated lymphoid tissues in a microbiota-independent manner (Monticelli, 
Sonnenberg et al. 2011a, Lee, Cella et al. 2011, Sawa, Cherrier et al. 2010, 
Sonnenberg, Monticelli et al. 2012), secure intestinal homeostasis by regulating host-
microbiota interactions. Sonnenberg et al in a land mark study showed that ILC3s 
have an important role in anatomically containing the commensal flora (Sonnenberg, 
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Monticelli et al. 2012). Loss of ILC3s in the intestine resulted in lower levels of IL-
22 and reduced production of antimicrobial peptides by intestinal epithelial cells 
leading to peripheral dissemination of Alcaligenes bacteria and systemic 
inflammation (Sonnenberg, Monticelli et al. 2012). Notably, IL-22 administration 
was able to prevent systemic inflammation in this setting (Sonnenberg, Monticelli et 
al. 2012). Besides helping containing commensal bacteria within their natural 
environment (lumen), ILC3s promote intestinal homeostasis by regulating host’s 
adaptive immune responses against its microbiota. Hepworth et al provided the first 
evidence of ILCs directly regulating adaptive immunity by showing that loss of 
RORγt expressing ILCs (group 3 ILCs) resulted in enhanced antigen-specific Th17 
responses against commensal bacteria (Hepworth, Monticelli et al. 2013). 
Interestingly, RORγt+ ILC functions were independent of the IBD relevant cytokines 
IL-17A, IL-22 and IL-23 (Hepworth, Monticelli et al. 2013). Instead, it was shown 
that ILC3s express MHC class II and therefore can process and present antigen to 
CD4+ T cells, hence limiting pathological responses to commensal bacteria 
(Hepworth, Monticelli et al. 2013). Supporting the antigen-presenting capacity of 
intestinal ILC3s, an independent study showed that splenic ILC3s also express MHC 
class II, and co-stimulatory molecules and can prime T cells in vitro (von Burg, 
Chappaz et al. 2014). Shedding more light into ILC3-T cell interactions at the 
intestinal barrier, Korn et al showed that loss of CD4 T cells leads to increased ILC 
numbers in the intestinal lamina propria, as well as high production of IL-22 and 
AMPs (Korn, Thomas et al. 2014), further supporting the cross talk of ILC3s with T 
cells.  In the gut, ILC3s also appear to interact with B cells (the other major cell type 
of adaptive immunity), as well as several innate immune cells such as macrophages 
and DCs in order to maintain intestinal homeostasis. Kruglov et al showed that 
RORγt expressing ILCs regulate both T cell dependent and independent IgA 
induction by production of soluble lymphotoxin α (sLTα3) and membrane-bound 
lymphotoxin β (LTα1β2), respectively (Kruglov, Grivennikov et al. 2013). 
Moreover, granulocyte-macrophage colony-stimulating factor (GM-CSF) producing 
ILC3s were shown to affect phagocyte functions resulting in decreased regulatory T 
cell numbers, and therefore to impaired oral tolerance (Mortha, Chudnovskiy et al. 
2014). Taken all together, these studies strongly suggest that ILC3s have a crucial 
role in promoting and maintaining intestinal homeostasis. 
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Taking these findings a step further, someone could hypothesize that ILC3s may also 
have an important role during intestinal inflammation that could subsequently lead to 
the development of IBD. Indeed, several independent studies have shown evidence 
implicating ILC3s with intestinal inflammation and IBD pathogenesis. Satoh-
Takayama et al showed that loss of NKp46+ RORγt expressing, IL-22 producing 
innate immune cells was associated with increased susceptibility to Citrobacter 
rodentium colitis (Satoh-Takayama, Vosshenrich et al. 2008b), implicating for the 
first time what were later named NCR+ ILC3s with intestinal inflammation. Other 
independent groups have also shown that IL-22 producing RORγt+ ILC3s exhibit 
protective functions in different murine models of IBD (Zheng, Valdez et al. 2008, 
Sawa, Lochner et al. 2011, Cox, Kljavin et al. 2012). On the other hand, Buonocore 
et al showed that RORγt expressing innate immune cells promote Helicobacter 
hepaticus induced, innate driven colitis via IL-23-mediated IL-17A and IFNγ 
production (Buonocore, Ahern et al. 2010), directly implicating ILC3s in the 
development of IBD.  In accordance with that notion, IL-23 responsive ILC3s are 
increased in the inflamed intestine of CD, but not UC patients, compared to healthy 
individuals (Geremia, Arancibia-Carcamo et al. 2011). Complementing these studies, 
previous work in our lab by Powell et al have also identified ILC3s as key mediators 
of intestinal inflammation in mouse models of experimental colitis as well as in 













Figure 3: ILC3s & gut homeostasis. ILC3s are enriched at mucosal surfaces, and in particular in the 
lamina propria of the intestines. There, mononuclear phagocytes such as macrophages and DCs 
activate ILC3s via IL-1β, IL-23 and TL1A production. In turn, ILC3s secrete high amounts of IL-17A, 
IL-22 and GM-CSF to mediate their functions. IL-22 that acts primarily on the epithelium, promotes 
epithelial integrity and proliferation, induces antimicrobial peptide production by Paneth cells and 
mucin secretion by Goblet cells. IL-17A, which is also know for promoting epithelial integrity 
induces neutrophil recruitment. ILC3s regulate gut homeostasis by inducing oral tolerance through 
GM-CSF production, and by inhibiting antigen-specific T cell responses against commensal bacteria 































1.4 Interleukin 22 
Growing evidence suggest interleukin 22 (IL-22), one of the signature ILC3 
cytokines, as a key effector cytokine in the gastrointestinal track. In the gut, IL-22 
has been shown to promote host’s defence against pathogens, tissue regeneration, 
and to secure and maintain the integrity of the intestinal epithelial barrier. IL-22 was 
firstly identified by Dumoutier et al in IL-9 treated lymphoma cells as a T cell 
inducible factor related to IL-10 superfamily, hence originally named IL-10 related T 
cell derived inducible factor (IL-TIF) (Dumoutier, Louahed et al. 2000). Most cells 
of the innate and adaptive immune system are able to produce IL-22 including 
macrophages, DCs, neutrophils, mast cells, ILCs, NKT cells, conventional as well as 
γδ T cells (Cella, Fuchs et al. 2009, Cella, Otero et al. 2010, Lee, Cella et al. 2011, 
Korn, Thomas et al. 2014, Colonna 2009, Hanash, Dudakov et al. 2012, Lee, Yang et 
al. 2015, Mann, Bernardo et al. 2014, Sonnenberg, Fouser et al. 2011, Zindl, Lai et 
al. 2013), while fibroblasts provide a non-haematopoietic cellular source of IL-22 
(Ikeuchi, Kuroiwa et al. 2005). In contrast to all other cytokines, IL-22 is the only 
cytokine that mediate her functions by acting almost exclusively on non-
haematopoietic cells such as epithelial and stromal cells (Wolk, Kunz et al. 2004). In 
general, IL-23 and IL-1β are the main known inducers of IL-22 production 
(Kastelein, Hunter et al. 2007, Lee, Kumagai et al. 2013), whereas TGFβ and IL-25 
appear to be negative regulators of IL-22 (Weiss, Wolk et al. 2004, Wolk, Witte et al. 
2007, Zheng, Danilenko et al. 2007).  
1.4.1 IL-22 signaling pathway 
The IL-22 receptor (IL-22R) is a cell surface receptor comprising a heterodimer 
complex of IL-22R1, which is unique for IL-22 and IL-10R2 that is shared with the 
receptor for IL-10 (Li, Tomkinson et al. 2004). At first, IL-22 binds to IL-22R1 
subunit causing a transformation that allows subsequently binding to the IL-10R2 
subunit initiating the downstream signaling (Li, Tomkinson et al. 2004). Similarly to 
IL-10 signaling pathway, following IL-22 binding to its receptor, Janus kinase (JAK) 
and tyrosine kinase 2 (Tyk2) are activated and trigger the phosphorylation of signal 
transducer and activator of transcription 3 (STAT3) (Lejeune, Dumoutier et al. 2002, 
Naher, Kiyoshima et al. 2012, Jones, Logsdon et al. 2008). However, IL-22 can also 
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activated other kinases including p38, MEK/ERK and JNK, as well as trigger STAT1 
and STAT5 phosphorylation (Lejeune, Dumoutier et al. 2002, Jones, Logsdon et al. 
2008).   
IL-22 also binds with high affinity to a soluble IL-22 receptor known as IL-22BP 
(Ciccia, Guggino et al. 2015). IL-22BP forms stable complexes with IL-22, 
essentially blocking it’s binding to IL-22R1 and its signaling activation (de Moura, 
Watanabe et al. 2009). IL-22BP can be found in different tissues such as placenta, 
lung, skin and the gastrointestinal tract and is constitutively produced by colonic DCs 
(Huber, Gagliani et al. 2012b). IL-22BP is also expressed by macrophages, 
eosinophils, as well as epithelial cells, and has already been linked with 
inflammatory conditions (Weiss, Wolk et al. 2004, Dumoutier, Lejeune et al. 2001, 
Wei, Ho et al. 2003, Martin, Beriou et al. 2016, Yang, Gao et al. 2014).  
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Figure 4: IL-22 signaling pathway. IL-22 binds to a heterodimer recepteror found in the cell 
membrane of several non-hematopoietic cells. Initially, a monomer of IL-22 binds to IL-22R1 causing 
a structural change that allows the complex to subsequently bind to IL-10R2 triggering the IL-22 
signaling cascade. Upon activation, tyrosine and serine of STAT3 are phosphorylated through Jak1 
and Tyk2 activation, although IL-22 can also activate kinase p38, MEK/ERK and JNK leading to 
STAT1 and STAT5 phosphorylation. In addition, IL-22 can bind with high affinity to a soluble 
receptor IL-22BP negatively regulating its actions. Ultimately, IL-22 signaling triggers the expression 



















1.4.2 Biologic effects of IL-22 
In general, IL-22 has different functions depending on the target tissue. At barrier 
surfaces such as skin, lungs and the gastrointestinal tract, IL-22 is well known for its 
role in host defence against pathogens, whereas in other organs such as liver and 
pancreas IL-22 promotes cell survival and proliferation. In a mouse model of 
pancreatitis, IL-22 deficiency was associated with increased tissue damage and 
fibrosis (Feng, Park et al. 2012).  In the liver, following hepatitis infection or tissue 
resection, IL-22 has been shown to promote tissue regeneration (Radaeva, Sun et al. 
2004, Ki, Park et al. 2010, Brand, Dambacher et al. 2007). In the gut, IL-22 that is 
mainly produced by ILC3s seems to have a protective role against intestinal 
infections (Zheng, Valdez et al. 2008, Monticelli, Sonnenberg et al. 2011b), while its 
inhibition in murine models of IBD is associated with increased inflammation 
(Zenewicz, Yancopoulos et al. 2008, Sugimoto, Ogawa et al. 2008).    Similarly to its 
actions in the gastrointestinal tract, several independent studies have shown a 
protective role for IL-22 in the lung, where IL-22 deficiency is associated with 
increased bacterial invasion (Aujla, Chan et al. 2008, Dhiman, Venkatasubramanian 
et al. 2014). However, despite its well-documented beneficial effects, IL-22 appears 
to be detrimental in other pathological conditions such as psoriasis (Wolk, Witte et 
al. 2009, Wolk, Haugen et al. 2009) and cancer. Increased IL-22 levels are associated 
with pathology in several types of cancer including lung, liver, and pancreatic 
cancers (Di Lullo, Marcatti et al. 2015, Nardinocchi, Sonego et al. 2015). In 
colorectal cancer, elevated IL-22 production leads to greater tumour burden and 
reduced survival (Huang, Cao et al. 2015, Koltsova, Grivennikov 2014, Kryczek, Lin 
et al. 2014). In conclusion, IL-22 seems to have both beneficial and detrimental 
effects depending on the tissue and/or the environmental context. Further 
investigation is needed to identify how these pathways can be regulated and/or 







Figure 5: Beneficial (in black) & detrimental (in red) actions of IL-22 in the tissue. (Adapted 
from Dudakov, Hanash et al. 2015). IL-22 acts on epithelial cells and some fibroblasts in several 
different tissues. In the kidneys, liver, lung, skin, synovium, and thymus it promotes proliferation, 
tissue regeneration and wound healing, while in barrier surfaces including the lungs, intestines and the 
skin, IL-22 induces antimicrobial peptide production and secretion of defensins. However, IL-22 has 
also been implicated in several types of cancer such as breast, cervical, colorectal, pancreatic, liver, 
skin and thyroid cancer, as well as in other inflammatory conditions like GvHD.   
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Lung: bronchial epithelial cells, fibroblasts
Promotes proliferation of epithelial cells
Regeneration from tissue damage
Thymus: thymic epithelial cells (TECs)
Promotes TEC proliferation and survival
Endogenous regeneration of thymopoiesis 
after acute thymic damage
Liver: hepatocytes, liver 




liver stem and progenitor cells
Pancreas: acinar cells,
islet α-cells and β-cells
High constitutive expression of IL-22R
Induces Reg3β, Reg3γ, Bcl-2, Bcl-XL
Kidney: tubular epithelial cells
Promotes tissue regeneration in a 
TLR4-dependent fashion
Polymorphisms of IL-22R lead to 
nephropathy in children
GVHD: GI tract, liver, skin, thymus
IL-22-producing ILCs depleted and 
epithelial tissues targeted during GVHD  
Donor IL-22 could contribute to
GVHD pathology
Host IL-22 could contribute to tissue 
regeneration from GVHD damage
Cancer: skin, thyroid, lung, 





Promotes proliferation of fibroblasts
Induces expression of CCL2 and RANKL
Gut: stem and progenitor cells, 
epithelial cells, myofibroblasts
Targets stem and progenitor cells 
and more mature epithelial cells
Induces S100 proteins, Reg3β, 
Reg3γ, Bcl-2, Bcl-XL, defensins
Skin: keratinocytes, 
dermal fibroblasts
Promotes proliferation of 
keratinocytes and dermal 
fibroblasts
Induces CXCL1, -2, -5, and -8;
defensins; S100 molecules
Figure 3
Target tissues and physiological effects of IL-22. A role for IL-22 has been described in numerous tissues, including gut, liver, lung, skin,
thymus, kidney, heart, pancreas, and synovial tissue. IL-22R is expressed on epithelial cells and some fibroblasts in those tissues. IL-22
can promote their cellular proliferation, resistance to apoptosis, and wound healing. In barrier organs such as gut, lung, and skin, IL-22
also promotes the production of antimicrobial molecules such as S100, Reg3β, and Reg3γ, as well as defensins, thereby aiding in host
defense and barrier function. IL-22 is important for promoting tissue regeneration after injury in several organs. However, studies have
also indicated that IL-22 is associated with malignancies of the skin, thyroid, breast, stomach, pancreas, liver, cervix, and colon as well
as with other inflammatory pathology including psoriasis. In bone marrow transplantation, ILC-derived IL-22 is important for tissue
regeneration after injury caused by alloreactive T cells; however, there is also some evidence that IL-22 produced by donor T cells can
contribute to inflammation and graft-versus-host disease (GVHD) pathology. Red text refers to tissue; blue text refers to pathologies.
interplay in inflammation are in oral mucosa, where IL-1β and IL-22 cooperate in inducing
CCL20 expression by human gingival fibroblasts, leading to recruitment of Th17 cells and pe-
riodonta disease (244); in a model of psoriasis, where a combination of IL-22, IL-17A, IL-1α,
oncostatin M, and TNFα synergistically increased chemokine and antimicrobial-peptide expres-
sion (245); in the lungs, where IL-22 reduced bleomycin-related lung toxicity in IL-17-deficient
mice but promoted ai way inflammation if IL-17 was present (246); in chronic hepatitis, where IL-
22-related pathology was dependent on the recruitment of Th17 cells (247); and in an anti-CD40
administration model of colitis, where IL-22 was reported to exacerbate colon inflammation that










































































































































































Aims and hypothesis 
Hypothesis 
Several independent studies including previous work in this lab have implicated 
ILC3s with IBD pathogenesis. However, the majority of those studies focus on the 
role of the NCR+ subset of group 3 ILCs, and their effects in the small intestine 
leaving the remaining ILC3 populations and their role in colonic inflammation 
somewhat understudied. Therefore, this thesis tests the hypothesis that NCR- ILC3s 
are also important drivers of colonic inflammation and their effector pathways could 
also be explored for the generation of novel IBD therapies.  
 
Aims 
This thesis aims to identify how NCR- ILC3s regulate colonic inflammation by: 
1. Defining the transcriptional changes on these cells during colonic 
inflammation using mouse models of experimental IBD 
2. Identifying their molecular mediators and cellular targets  





Materials & Methods 
2.1 Mice and animal husbandry 
Balb/c Tbx21-/-Rag2-/- double KO (TRUC) mice have been described previously 
(Powell et al., 2015; Powell et al., 2012). Tbx21-/-Rag2-/-Il22-/- (TRUCIl22-/-) triple 
KO mice were generated by backcrossing Balb/c Tbx21-/-Rag2-/- double KO (TRUC) 
mice with Balb/c Il22-/- mice that were provided by Pfizer. Lgr5-eGFP reporter mice 
were provided by Professor Fiona Watt, King’s College London. RORc-eGFP 
reporter mice were provided by Professor Gerard Eberl, Institute Pasteur, Paris and 
have been described previously (Lochner et al., 2008). RORc-eGFP reporter mice 
were backcrossed with Rag1-/- mice to generate Rag1-/-RORc-eGFP mice. WT 
C57Bl/6 mice were purchased from Charles River Laboratories. Il10-/- mice were 
provided by Professor Werner Muller, Faculty of Life Sciences, University of 
Manchester. Mice were housed in specific pathogen free (SPF) conditions. All mice 
were handled according to local (KCL) and national guidelines, and all our 
experimental protocols were reviewed and approved by our local ethics review 
committee. All animal experiments were conducted in accredited facilities in 
accordance with the UK Animals (Scientific Procedures) Act 1986 (Home Office 
license number PPL 70/7869).      
2.2 Genotyping 
Genomic DNA was extracted by digesting ear or tail biopsies in 250µl of lysis buffer 
(5mM EDTA, 100mM Tris-HCl pH 8.5, 0.2% SDS, 200mM NaCl, 1mg/ml 
proteinase K) at 56oC o/n. Inactivation of proteinase K was achieved by incubating 
digested samples at 75oC for 15min. Digested samples containing the genomic DNA 
were diluted 1:3 in nuclease-free H2O and were used further for genotypic analysis.  
Each PCR reaction consisted of 1µl of genomic DNA, 12.5µl Mango Mix 2x 
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(Bioline Ltd., London, UK), 9.5µl nuclease-free H2O and 1µl of each PCR primer 
(forward and reverse). 12µl of each PCR product were loaded on 1.5% or 2% agarose 
gel premixed with GelRed Nucleic Acid Gel Stain (Biotium) to visualise DNA bands 
following UV illumination (Unipro Gold). All primers and programs used for 
genotyping purposes are listed in tables 2 and 3, respectively.  
 
Table 2: List of primers used for genotyping 













































Table 3: List of PCR programs used for genotyping 




































































































































2.3 Animal models of experimental colitis 
2.3.1 DSS 
3% DSS (MW 36,00-50,000, MP Biomedicals, LLC) was administered orally in 
drinking water for 5 or 6 days to C57Bl6 mice and animals were culled at day 7 or 8 
respectively. Food consumption and water intake were measured (and recorded) 
daily throughout the period of DSS administration to ensure that any differences due 
to variations on DSS dosage are accounted for. Mice were monitored daily and 
scored for weight loss, rectal bleeding and faeces consistency. Disease activity index 
was calculated as the sum of the above scores divided by 3 according to the table 
below {{478 Cooper,H.S. 1993;}}. All animals were daily thoroughly observed for 
general signs of distress or adverse symptoms and any mice presented with these 
features were humanely culled on welfare grounds.  
Table 4: Scoring of disease activity index (DAI). (Adapted from Cooper HS 
et al., 1993). 
Score Weight loss Stool consistency Rectal bleeding 
0 None Normal Normal 
1 1 - 5 %   
2 5 - 10 % Loose stools  
3 10 - 20 %   
4 > 20 % Diarrhoea Gross bleeding 
2.3.2 DNBS 
200µl of 3mg DNBS (Sigma-Aldrich) resolved in 50% EtOH were administered 
rectally while mice were under isoflurane anaesthesia. Mice were monitored daily for 
weight loss, general signs of distress and adverse disease symptoms. Any mice 
presented with these features were humanely culled on welfare grounds; otherwise 
mice were culled 3 days post administration for further analysis. DNBS 
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administration was performed by Dr Nicholas Powell with the kind help of Stuart 
Newman (BSU staff).  
2.3.3 TCT 
0.5 or 2 x106 naïve CD4+ T cells (defined as live CD4+CD25-CD44loCD62Lhi cells) 
were FACS sorted from spleens of 8-week-old C57Bl6 WT female or male donor 
mice, and injected (in 200µl of sterile PBS) intraperitoneally into 8-10 week old 
C57Bl6 Rag1-/- recipients. Purity checks were performed at the end of every sort and 
cells were always found more than 97% pure. Recipient mice were monitored twice 
per week for weight loss, general signs of distress and adverse symptoms. Any mice 
presented with these features were humanely culled on welfare grounds; otherwise 
mice were culled 4 to 6 weeks post adoptive transfer for further analysis.  
2.3.4 Il10-/-  
Il10-/- mice were introduced to HT and TRUC microbiota by oral gavage, which was 
kindly performed by Dr Emilie Stolarzcyk. Mice were monitored twice per week for 
weight loss, general signs of distress and adverse symptoms. Any mice presented 
with these features were humanely culled on welfare grounds; otherwise mice were 
culled 4 weeks post gavage for further analysis.  
2.3.5 TRUC 
TRUC mice are descendants of the TRUC colony generated at Harvard {{201 
Garrett,W.S. 2007;}}, while TRnUC mice were generated at KCL by backcrossing 
commercially available Balb/c Tbx21-/- mice with Balb/c Rag2-/- mice as described 
previously {{122 Powell,N. 2012;}}. TRUCIl22-/- mice were generated at KCL by 
backcrossing TRnUC mice with Il22-/- mice that were obtained from Pfizer. Due to 
the transmitability of TRUC disease TRUC mice were bred and housed at a different 
isolator at all times.   
2.4 in vivo treatment of mice 
Neutralizing anti-IL-22 mAb (clone IL22-01) and recombinant IL-22 (rIL-22) were 
developed and provided by Pfizer. 200µg of IL22-01 (per mouse) were administered 
ip. every 3 to 4 days. 100µg of rIL-22 (per mouse) were administered ip. at days 0, 4, 
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8 and 12, while mice were culled at day 14. 150µg of anti-CXCL1 (clone 124014, 
R&D Systems) were administered ip every 3 to 4 days.  Anti-CXCR2 (clone 242216, 
R&D Systems) was administered ip.  at a dose of 100µg per mouse at days 0, 3, 7, 10 
and 14, while mice were culled at day 15. Tunicamycin (1µg per mouse) was 
dissolved in 0.1% DMSO and was administered rectally to TRUCIl22-/- mice at day 0 
and 5. Control mice were administered 0.1% DMSO alone. 4-phenylbutyric acid (4-
PBA) (Sigma Aldrich) was administered orally (in drinking water) to TRUC mice at 
a final concentration of 20mM for 6 weeks. Ip. injections were kindly performed by 
Dr Nicholas Powell and Dr Luke Roberts. Tunicamycin  (Sigma Aldrich) 
administration was performed by Dr Nicholas Powell with the kind help of Stuart 
Newman (BSU staff) for the administration of inhaled anaesthesia. 
2.5 Tissue collection and single cell preparation 
Mice were euthanized by either cervical dislocation or by a rising concentration of 
carbon dioxide gas, and then dissected in a laminar flow cabinet under aseptic 
conditions. Once dissected, spleens and MLNs were placed into ice-cold complete 
cell culture media, while colons were first flashed with ice-cold PBS to remove 
faeces and then transferred into fresh ice-cold PBS. Single cell suspensions from 
spleen and MLN were prepared by mechanical disruption of the tissue using nylon 
mesh. To remove any red blood cells, cells isolated from spleen (but not MLN) were 
resuspended in 2ml ACK lysis buffer (0.15M NH4Cl, 1mM KHCO3, 0.1mM 
Na2EDTA, pH=7.2-7.4) and incubated at RT for 2min. All cell washes were 
performed using complete cell culture media or ice cold PBS and centrifugation at 
1800rpm, 4oC for 5min, unless stated otherwise. Cell counts were measured 
manually using Trypan Blue staining (1:2 dilution) to distinguish live from dead 
cells.  
2.6 Isolation of colonic LP leukocytes (cLPMCs) 
Colons were opened longitudinally, cleaned thoroughly with ice-cold PBS and cut 
into 1-2mm pieces and washed with 10ml 5mM EDTA, 1mM Hepes in HBSS 
(Gibco) in a shaking water bath (300rpm) at 37oC for 20min. Tissue was then 
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vortexed vigorously for 10sec and passed through a 100µM cell strainer and 
collected in C-tubes (Miltenyi) in complete RPMI (Gibco) containing 10% fetal calf 
serum, 0.25mg/ml Collagenase D (Roche), 1.5mg/ml Dispase II (Roche) and 
0.01µg/ml DNase (Roche) and put in a shaking water bath (300rpm) at 37oC for 
40min. Before and after the 40min incubation C-tubes were vigorously shaken for 
30sec. Solutions were then passed through 100µM cell strainers and washed with 
ice-cold PBS. Cells were resuspended in 10ml of the 40% fraction of a 40:80 Percoll 
(GE Healthcare) gradient and carefully placed on top of 5ml of the 80% fraction in 
15ml tubes. Percoll gradient separation was performed by 20min centrifugation at 
2600rpm at room temperature without break. LP cells were collected from the 
interphase of the gradient and washed with ice-cold PBS. Cells were resuspended in 
1ml PBS, counted and immediately used for further experiments.        
2.7  Immunomagnetic based cell separation 
Enrichment of CD4+ T cells from the spleen was achieved by positive selection using 
magnetic cell purification. Unfractionated single cells were firstly introduced to ACK 
lysis buffer to remove red blood cells (as described above) and then washed in ice-
cold PBS by 10min centrifugation at 1800rpm, 4oC. Cells were resuspended in 
MACS buffer (PBS, 2% FCS, 1mM EDTA) and incubated with anti-CD4 magnetic 
beads for 20min on ice according to manufacture’s instructions.  Cells were washed 
of excess beads with MACS buffer by 5min centrifugation at 1800rpm, 4oC and 
resuspended in 500ul of MACS buffer before passing through MACS LS magnetic 
columns attached to a quadroMACS magnet.  Columns were washed 3 times with 
3ml MACS buffer before positively selected CD4+ T cells were eluted with 1ml 
PBS. Cells were washed with complete cell culture media and stored on ice pending 
further analysis. All reagents and equipment were supplied by MIltenyi Biotec 
Gmbh, Bergisch Gladbach, Germany.   
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2.8 Flow cytometry 
2.8.1 Cell surface and intracellular/intranuclear stainings  
Single cell suspensions from spleens, MLNs and colonic tissue were washed with ice 
cold PBS and centrifugation at 1800rpm, 4oC for 5min prior to all staining. Cells 
were then resuspended in 200µl PBS containing Fc block (aCD32/CD16, 
eBioscience) at 1:100 dilution and incubated on ice for 10min. Antibodies against all 
surface markers were added at appropriate dilutions as well as LIVE/DEAD Fixable 
Dead Cell Stain (Invitrogen) used in 1:1000. Samples were mixed by vortex and 
incubated for another 20min on ice in the dark. After the incubation, cells were 
washed with ice cold PBS and centrifugation at 1800rpm, 4oC for 5min and then 
fixed with 400µl of 4% PFA and incubated at RT for 15min in the dark. After 
fixation, cells were washed again with ice cold PSB, resuspended in 150-200µl PBS 
and stored at 4oC in the dark awaiting sample acquisition. For 
intracellular/intranuclear staining, after the incubation with antibodies against cell 
surface markers, cells were washed and resuspended in 1ml Cytofix/Cytoperm 
(eBioscience) following o/n incubation at 4oC to accomplish cell/nuclear 
permeability. Cells were then washed with freshly made Perm buffer (eBioscience), 
and stained with mAbs against intracellular/intranuclear markers diluted 1:200 in 
Perm buffer  (containing Fc block at 1:200) for 45min on ice in the dark.  After the 
ICC staining, cells were washed with perm buffer and resuspended in 150-200µl PBS 
and stored at 4oC in the dark awaiting sample acquisition. All monoclonal antibodies, 










Table 5: List of mAb used for FACS 
Antigen Fluorochrome Clone Source 
CD11b FITC M1/70 BD 
CD127 APC eBioRDR5 eBioscience 
CD127 BUV737 SB/199 BD 
CD25 APC PC61.5 eBioscience 
CD27 BV605 LG.3A10 BD 
CD3 BUV395 145-2C11 BD 
CD4 BV786 RM4-5 BD 
CD4 FITC GK1.5 eBioscience 
CD44 PE IM7 eBioscience 
CD45 Pac. orange MCD4530 Invitrogen 
CD45 V500 30-F11 BD 
CD62L eFlour®450 MEL-14 Biolegend 
epCAM eFlour®450 G8.8 eBioscience 
Gr-1 PE RB6-8C5 eBioscience 
Gr-1 APC-Cy7 RB6-8C5 eBioscience 
iCOS APC C398.4A eBioscience 
IL-17R APC PAJ-17R eBioscience 
IL-22R PE 496514 
 
R&D 
KLRG1 PerCP- eFlour®710 2F1 eBioscience 
NKp46 PE-Cy7 29A1.4 eBioscience 
RORγt PE B2D eBioscience 
RORγt BV786 Q31-378 BD 
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2.8.2 Sample acquisition and analysis 
All samples were acquired on a BD LSRFortessa™ (BD Biosciences) at the 
Biomedical Research Council (BRC) Flow Core (15th Floor, Tower Wing, Guy’s 
Hospital). Data were analysed using FlowJo software (Treestar).  
2.8.3 Cell sorting 
To obtain a pure population of naïve CD4+ T cells from the spleen, splenic single cell 
suspensions were first treated with ACK buffer for red blood cell lysis, enriched for 
CD4+ cells using immunomagnetic based cell separation and then stained with mAbs 
against CD4, CD25, CD44 and CD62L and LIVE/DEAD Fixable Dead Cell Stain 
(Invitrogen, UK) as described above. Naïve CD4+ T cells were defined as live 
CD4+CD25-CD44loCD62Lhi cells. Purity checks were performed after every sort and 
purity was always found to be above 97%. To obtain pure populations of colonic 
ILC2s and NCR- ILC3s, cLPMCs were stained with mAbs against CD45, CD90, 
CD127, KLRG1 and NKp46 and Live/Dead dye as described above. ILC2s and 
NCR- ILC3s were defined as live CD45+CD90+CD127+KLRG1+NKp46- and 
CD45+CD90+CD127+KLRG1-NKp46- cells respectively unless stated otherwise. 
Intestinal epithelial stem cells were sorted from murine colonoids that were 
generated from Lgr5-eGFP reporter mice as single live epCAM+(Lgr5)-eGFP+ cells. 
Regulatory T cells (Tregs) were sorted from the spleen of FoxP3-eGFP reporter mice 
as live CD4+CD25+(FoxP3)-eGFP+ cells. Tregs from spleens of WT and Il10-/- mice 
were sorted as live CD4+CD25+CD62Lhi cells. All sorts were performed on BD Aria 
I, BD Aria II or BD Aria Fusion (BD Biosciences) at the BRC Flow Core (15th Floor, 
Tower Wing, Guy’s Hospital) by experienced members of staff.  
2.9 Cell cultures 
FACS purified NCR- ILC3s isolated from the colon of TRUC or TRUCIl22-/- mice 
were always cultured for 24h in complete RPMI (Gibco) containing 10% FCS in the 
presence or absence of 10ng/ml IL-23 and 10ng/ml IL-1β unless stated otherwise. 
For the co-culture experiments NCR- ILC3s isolated from the colon of TRUC or 
TRUCIl22-/- mice were activated for 48h with 20ng/ml IL-2, 50ng/ml IL-7, 10ng/ml 
IL-23 and 10ng/ml IL-1β prior to being co-cultured with colonoids. 
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2.10 Colonoid cultures 
All colonoids that were used for experiments described in this thesis were developed 
and maintained by our collaborator Dr Anastasia Tsakmaki. Mouse colonic crypts 
were isolated, cultured, and grown into organoids as described previously {{479 
Sato,T. 2011;}}. Mouse crypts were cultured in growth medium containing advanced 
Dulbecco’s modified Eagle’s medium/F12, penicillin/streptomycin (100 units/mL), 
10mM HEPES, 2mM Glutamax, supplements N2 (1x) and B27 (1x), 50ng/mL 
mouse epidermal growth factor (all obtained from Life Technologies), 1mM N-
acetylcysteine (Sigma-Aldrich), 50% v/v Wnt3a conditioned medium, 10% v/v R-
spondin-1 conditioned medium, 10% v/v Noggin conditioned medium and 3µM 
CHIR99021 (Cambridge Biosciences). Medium was changed every 2 days. 
Differentiation towards a mature epithelium was achieved by withdrawal of Wnt3a 
for 3 days. During the last 24h in differentiation medium colonoids were treated with 
10ng/ml IL-22 or with 50ng/ml IL-17A. For the co-culture experiments, NCR- ILC3s 
that were isolated from the colon of TRUC and TRUCIl22-/-, FACS purified and 
activated as described above, were then resuspended in differentiation medium and 
co-cultured with colonoids at an ILC/crypt ratio of 25:1. After 24 hours ILCs were 
removed, colonoids were harvested from matrigel, washed with PBS and processed 
for RNA extraction and downstream analysis. 
2.11 Cell lines 
Mode K cell line was obtained from Dr Dominique Kaiserlian (INSERM) {{480 
Vidal,K. 1993;}}. Cells were cultured in complete DMEM (Gibco) containing 10% 
FCS and were split 1:4 when confluent. Once confluent cells were lift up using 
0.05% trypsin-EDTA (Gibco), spin down at 1800rpm for 5 min, and then cells were 
either frozen down in 1ml 90% FCS-10% DMSO or plated in 6-well plates at 
2x106/well in 3ml/well complete DMEM (Gibco) containing 10% FCS for further 
experiments.  To measure CXCL1 and CXCL5 production followed by IL-22 
treatment, Mode K cells were cultured with 10ng/ml IL-22 in the presence or 
absence of selective pathway inhibitors together with vehicle control (DMSO 0.1%). 
The inhibitors tested were NSC74859 85µM (STAT3 inhibitor, Tocris Bioscience), 
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SB203580 10µM (p38 inhibitor, Sigma-Aldrich), LY294002 10µM (PI3K inhibitor, 
Sigma-Aldrich), SP600125 10µM (JNK inhibitor, Sigma-Aldrich), BAY11-7082 
2µM (NF-κB inhibitor, Tocris Bioscience), TC-S7006 5µM (MAP3K8 inhibitor, 
Tocris Bioscience) and PD98059 1µM (MEK1 inhibitor, Tocris Bioscience).  
2.12 ELISA 
Cytokine concentrations in supernatants (S/Ns) of either stimulated cell cultures or 
explant cultures were measured by ELISA. At the endpoint, S/Ns were harvested and 
stored at -20oC pending further analysis. IL-22 and IL-17A ELISA kits were 
purchased from eBioscience and ELISAs were performed according to the 
manufacturer’s protocols. Cytokine concentrations were determined within the linear 
phase of a standard curve made with known cytokine concentrations provided by the 
supplier.    
2.13 RNA extraction 
Whole tissue colonic fragments or FACS purified cells were lysed in 1ml TRIsure 
(Bioline) and stored at -80oC pending further processing. Samples were left to thaw 
at RT and homogenized by vortex for 10sec. To extract the RNA, 200µl of 
chloroform were added to each sample followed by 10sec vortex and 15min 
incubation at RT. Samples were centrifuged at max speed for 15min at 4oC and the 
clear S/N phase (containing the RNA) was transferred to new 1.5ml eppendorf tubes 
and then mixed with equal volume of isopropanol. Samples were vortex and then left 
at RT for 10min, followed by 8min centrifugation at max speed at 4oC. RNA pellets 
were rinsed with 0.5ml of 75% EtOH and left to airdry at RT. Depending on pellet 
size; RNA was dissolved in 10-100µl of RNase/DNase free H2O and stored at -80oC 
awaiting further analysis.  
2.14 cDNA synthesis (reverse transcription) 
RNA samples were left to thaw on ice and the amount of RNA per sample was 
measured with NanoDrop. 11µl of RNA sample (always containing the same amount 
of RNA across all samples of the same experiment) that was always less that 4µg 
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RNA, were mixed with 1µl oligo dT and incubated at 65oC for 5min. At the end of 
the incubation, RNA samples were mixed with 8µl of reverse transcription mix 
containing 4µl Buffer 5x, 1µl RNase Inhibitor (RI) at 20U/µl, 2µl dNTPs and 1µl 
Reverse Transcriptase (RT).  Reverse transcription was then accomplished by 
incubating RNA samples at 42oC for 1h followed by 65oC for 5min and then 4oC 
forever. cDNA samples (20µl) were stored at -20oC until further use.     
2.15 RT-qPCR 
Total RNA was extracted from colonoids using RNeasy mini kit  (Qiagen) and 
RNase-free DNase set (Qiagen) and reverse transcribed using a high-capacity cDNA 
reverse transcription kit (Life technologies) according to manufacturer's instructions. 
Quantitative PCR was performed using QuantiTect primers  (Qiagen) and Quantitect 
SybrGreen MasterMix (Qiagen) on a LightCycler 480 (Roche). Sequences for mouse 
sXbp1 splicing primers were obtained from Kaser et al. {{432 Kaser,A. 2008;}}. 
Samples were analysed in triplicates and relative expression of mRNAs was 
determined after normalisation against the housekeeping gene Beta-2-Microglobulin 
(B2M). 
2.16 Microarrays and data analysis 
2.16.1 Sample collection and preparation  
ILC2s and NCR- ILC3s were isolated from colon and sorted using a BD FACS Aria 
III cell sorter (BD Biosciences) following LIVE/DEAD Fixable Dead Cell Stain 
(Invitrogen) and labelled with antibodies conjugated to fluorochromes, CD45, CD90, 
CD127, KLRG1, and NKp46. RNA from sorted cells and from colonic tissue 
fragments (distal region) was extracted using TRIsure (Bioline) as described above.  
Contaminating DNA was removed with the RNase-Free DNase Set (Qiagen) 
according to the manufacturer’s protocol. cDNA was synthetized using Ovation 
PicoSL WTA System V2 according to the manufacture’s protocol (Nugen, USA) and 
labelled using Encore BiotinIL module according to the manufacture’s protocol 
(Nugen, USA). RNA and cDNA quantity and quality were assessed using the Agilent 
RNA 6000 Nano Kit or Agilent RNA 6000 Pico Kit (depending on the amount of 
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RNA) according to the manufacture’s protocol (Agilent Technologies, USA). 
Labelled cDNA were hybridised on a MouseWG-6 v2.0 Expression BeadChip 
(Illumina, USA).  
2.17 Data analysis 
All raw data  [from experiments described in this thesis, as well as those obtained 
from the Gene Expression Omnibus (GEO) repository (Accession number 
GSE59071) {{254 Vanhove,W. 2015;}}] were analysed using Partek® Genomic 
Suite Software and GraphPad PRISM® version 7 software. 
2.18 Histology 
Whole colons or 1cm tissue fragments from the distal end (1cm away from the anus) 
were removed and fixed in 10% PFA (CellPath). Tissue processing, cutting as well 
as haematoxylin and eosin (H&E) staining of 5um sections (1-3 per sample) were 
performed at the Pathology Core of Blizard Institute (Barts and the London). All 
histology slides were blindly scored for colitis by Professor Tom T MacDonald 
(QMUL) based on signs of mononuclear infiltrate (0-3), polymorphonuclear infiltrate 
(0-3), epithelial hyperplasia (0-3) and epithelial injury (0-3). All histology pictures 
were acquired with Eclipse Ti-E Live Cell Imaging System 2 microscope at the 
Nikon Centre (KCL) using 40x magnitude. Data were analysed at the Nikon Centre 
(KCL) using NIS Elements AR software.  
2.19 Statistical analysis 
All graphs were generated and analysed using GraphPad Prism 7 software. Data 
represent mean or mean with SD unless stated otherwise. Statistical analysis was 
performed using non-parametric Mann-Whitney test or one-way ANOVA unless 
stated otherwise. Statistical significance was indicated using * for p values less than 





Results: IL-22 producing NCR- ILC3s are an 
important ILC subset in colonic inflammation 
ILCs are enriched at barrier surfaces and especially in the gut, where they act as 
effector cells enhancing host immunity against viruses, bacteria and parasites, whilst 
promoting wound healing and tissue regeneration. In particular, ILC3s are known to 
have an important role in host defence against bacterial infections (Satoh-Takayama, 
Vosshenrich et al. 2008, Sonnenberg, Fouser et al. 2011), which is at least partly 
dependent on IL-22 mediated induction of antimicrobial peptide responses (Zheng, 
Valdez et al. 2008). Group 3 ILCs are also involved in the anatomical containment of 
lymphoid tissue-resident commensal bacteria (Sonnenberg, Monticelli et al. 2012), as 
well as in the regulation of specific T cell responses against those bacteria 
(Hepworth, Monticelli et al. 2013). During the resolution stage of inflammation, 
ILC3s show involvement in tissue repair by promoting proliferation of Lgr5+ stem 
cells (Lindemans, Calafiore et al. 2015). 
On the other end of the spectrum, many studies have shown ILC3s to promote 
intestinal inflammation via IFNγ (Fuchs, Vermi et al. 2013, Buonocore, Ahern et al. 
2010) and IL-17 production (Buonocore, Ahern et al. 2010, Powell, Walker et al. 
2012). Moreover, cytokine producing ILCs are expanded in the gut of CD and UC 
patients, the two main forms of IBD (Geremia, Arancibia-Carcamo et al. 2011, 
Powell, Lo et al. 2015), whereas they are shown to have an important role in 
preclinical models of IBD (Buonocore, Ahern et al. 2010, Powell, Walker et al. 2012, 
Powell, Lo et al. 2015). Taken together, ILCs and/or their cytokine mediators may 
constitute new therapeutic strategies to treat IBD.  
Despite the profound effector functions of group 3 ILCs in the intestinal barrier, most 
studies focus on NCR+ ILC3s, while NCR- ILC3s and their functional role in vivo 
remains poorly understood. Furthermore, the majority of studies focus on the small 
intestine leaving the colonic ILC subsets and their functions under-investigated. By 
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investigating the role of NCR- ILC3s in colitis, this thesis aims to provide new 
insights into the role of NCR- ILC3s in colonic inflammation. 
3.1 NCR- ILC3s are the predominant colonic ILC3 subset 
in health and disease  
To begin to understand the role of NCR- ILC3s in colonic inflammation, the 
frequency of these cells in the colonic LP was investigated in steady state as well as 
in several models of experimental colitis. To do so, mononuclear cells were isolated 
from the colonic LP of Rorc-eGFP reported mice (Lochner, Peduto et al. 2008), 
stained with fluorochrome-conjugated antibodies against cell surface markers and 
analysed by flow cytometry. RORγt expressing ILC3s and NCR- ILC3s were 
identified using the gating strategy shown in Figure 6. In steady state, KLRG1+ 
ILC2s and RORγt+ ILC3s were the dominant ILC subsets in the colon (Figure 6). 
Within group 3 ILCs, NCR- ILC3s were the most common subset accounting for 
more than 70% of the ILC3 population (Figure 8). Similarly to healthy colon, after 
induction of colitis in Rorc-eGFP mice using DSS and DNBS as described in Figure 
7, NCR- ILC3s were the main ILC3 subset in the colonic LP, although a slight 
decrease on the percentage of these cells was also observed (Figure 8). The 
frequency of NCR- ILC3s was then examined in the T cell transfer model of colitis 
(Powrie, Leach et al. 1993) by generating Rag1-/-Rorc-eGFP mice, to which 2x106 
million of naïve (CD25-CD44loCD62Lhi) CD4+ T cells were adoptively transferred 
ip. as described in Figure 7. Again, NCR- ILC3s were the most abundant ILC3 
population in the colonic LP (Figure 8). Finally, to investigate the frequency of 
ILC3s in the Il10-/- model of chronic colitis, a different multi-colour Ab panel for 
flow cytometry was developed to allow use of the same gating strategy (Figure 6) for 
ILC3 identification but with intracellular staining for the transcriptional factor 
RORγt. NCR- ILC3s were yet again the most abundant ILC3 subset, although an 
expansion of these cells was also observed (Figure 8). Taken together these data 
suggest that in steady state as well as during intestinal inflammation the majority of 
ILC3s in the colonic LP is NCR- ILC3s, although it is not clear whether NCR- ILC3 
numbers are actually affected upon intestinal inflammation.  
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Figure 6: Gating strategy used to identify NCR- ILC3s in colonic LP. Flow plots representative of 
the gating strategy used to identify ILC2s and NCR- ILC3s in all experiments described in this thesis. 
In all experiments, where RORc-eGFP or Rag1-/-RORc-eGFP mice where used, RORγt+ ILC3s were 
identified based on GFP expression. In all other experiments, where mice didn’t contain the RORc-
eGFP transgene (Il10-/-, Rag2-/-, TRUC mice) a fluorochrome-conjugated Ab that binds RORγt was 














































Figure 7: Protocols for induction of experimental colitis in vivo. A. 3% DSS in drinking water was 
administered to 8-12 week old RORc-eGFP mice for 5 days. Mice where switched to normal water at 
day 5 and culled at day 7 for further analysis. B. 3µg DNBS in 200µl 50% EtOH were administered 
rectally to 8-12 week old RORc-eGFP mice under isoflurane anaesthesia. Animals were culled 3 days 
later for further analysis. C. 2x106 FACS purified naïve CD4+ T cells from spleens of 8-week-old 
female WT mice were injected ip. to 8-12 week-old Rag1-/-RORc-eGFP male and female recipients in 
200µl sterile PBS at day 0. Mice were culled 30 days later for further analysis. D. 8-12 week old Il10-/- 
mice were gavaged orally with intestinal microbiota harvested from TRUC mice at day 0 and culled at 
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Figure 8: NCR- ILC3s are the dominant group 3 ILC subset in colonic LP in both health and 
disease.  Experimental colitis was induced in genetically modified mice as shown in Figure 7, and 
mononuclear cells were isolated from the colonic LP of healthy (control) and diseased mice to identify 
by flow cytometry the percentages of NCR- ILC3s in health and disease, respectively. A.  Histogram 
plots showing percentage of NCR- ILC3s in colonic LP in steady state and during intestinal 
inflammation using DSS, DNBS, TCT and Il10-/- model of experimental colitis, respectively. Cells 
were gated as single live CD45+CD3-IL-7R+KLRG1-RORγt+NKp46- cells. Data representative of a 
single experiment with n=5 (Baseline), n=7 (DSS), n=8 (DNBS), n=6 (TCT) and n=6 (Il10-/-). Data 
were analysed using FlowJo software (Treestar). B. Pie charts showing percentages (mean +/- SD) of 
NCR- and NCR+ ILC3s in colonic LP in steady state, DSS, DNBS, TCT and Il10-/- model of 
experimental colitis, respectively. Data representative of a single experiment with n=5 (Baseline), n=7 
(DSS), n=8 (DNBS), n=6 (TCT) and n=6 (Il10-/-). Statistical analysis was performed using FlowJo 
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3.2 The majority of CD4 expressing group 3 ILCs are 
NCR- ILC3s 
Since NCR- ILC3s may also express CD4, the frequency of CD4 expressing group 3 
ILCs in the colonic LP was also investigated. Mononuclear cells were isolated from 
the LP of Rorc-eGFP reporter mice, stained with fluorochrome-conjugated 
antibodies against known ILC cell surface markers and analysed by flow cytometry.  
RORγt expressing ILC3s were identified using the gating strategy shown in Figure 6. 
In steady state, less than 30% of ILC3s express CD4 in the colon, the majority of 
which (~95%) are NCR- ILC3s (Figure 9). Similarly to steady state, CD4 expressing 
ILC3s accounted for less than 30% of the ILC3 population in all models of 




















Figure 9: Less than 30% of colonic LP ILC3s express CD4 in steady state. Mononuclear cells 
were isolated from the colonic LP of healthy mice to identify by flow cytometry the percentage of 
CD4+ ILC3s. A.  Histogram plots showing percentages of CD4+ ILC3s and NCR-CD4+ ILC3s in 
colonic LP in steady state. ILC3s were gated as single live CD45+CD3-IL-7R+KLRG1-RORγt+ cells. 
Data representative of a single experiment with n=5. Data were analysed using FlowJo software 
(Treestar). B. Pie charts showing percentages (mean +/- SD) of CD4+ ILC3s and NCR-CD4+ ILC3s in 
colonic LP in steady state respectively. Data representative of a single experiment with n=5. Analysis 
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3.3 NCR- ILC3s are the dominant ILC3 subset in ILC 
mediated colitis 
To selectively investigate the role of NCR- ILC3s in chronic colonic inflammation 
without the influence of other immune cells implicated in the pathology of IBD, 
Tbx21-/-Rag2-/- Ulcerative Colitis (TRUC) mice were studied. This experimental 
model of chronic colitis resembles many aspects of human UC and offers a unique 
opportunity to selectively study NCR- ILC3s and their role in colitis. Due to Rag2 
deficiency B and T lymphocytes are absent, whereas ILC1s and NCR+ ILC3s are 
impaired since their development depends on the transcription factor T-bet (Powell, 
Walker et al. 2012, Powell, Lo et al. 2015, Sciume, Hirahara et al. 2012, Klose, Flach 
et al. 2014). As shown in Figure 10, the percentage of ILC1s is less than one third of 
the percentage of ILC1s observed in TRUC mice (10.2% and 37.1%, respectively). 
Similarly, the percentage of NCR+ ILC3s is also reduced in the colonic LP of TRUC 
mice compared to control Rag2-/- mice (Figure 10). However, without enumeration 
data, it is impossible to draw any conclusions regarding the absolute numbers of 
these cells in TRUC mice compared to control Rag2-/- mice. TRUC mice develop 
chronic colitis and previous studies have already established a central role for NCR- 
ILC3s in this disease (Powell, Walker et al. 2012, Powell, Lo et al. 2015, Ermann, 













Figure 10: Reduced percentages of ILC1s and NCR+ ILC3s in TRUC mice. cLPMCs were 
isolated from the colon of TRUC and Rag2-/- (control) mice to identify all ILC subpopulations by 
FACS. A. Flow dot plots showing the percentages of the different ILC subsets (as defined by their 
expression of RORγt and NKp46 in the colonic LP of Rag2-/- and TRUC 8-12 week old mice, 
respectively. Data representative of a single experiment with n=4. Analysing was performed using 
FlowJo software (Treestar). B. Pie charts depicting percentages (mean) of NCR- ILC3s, NCR+ ILC3s, 
ILC1s and ILC2s in the colon of Rag2-/- and TRUC mice respectively. Data representative of a single 
experiment with n=4. Data were analysed using FlowJo software (Treestar) and GraphPad PRISM® 
version 7 software.  
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3.4 IL-22 responsive genes are highly expressed in TRUC 
disease 
To further characterize NCR- ILC3 mediated chronic colitis, transcriptional changes 
in the colon of TRUC mice were studied using microarray analysis. 1cm long 
fragments were obtained from the distal colon (~1cm away from the anal verge) of 8-
12 week old Rag2-/- and TRUC mice. Tissue was homogenized, RNA was extracted, 
reverse transcribed, amplified and labelled for subsequent microarray analysis 
(MouseWG-6 v2.0 Expression BeadChip, Illumina). As expected, colonic tissue 
from TRUC mice showed a distinct transcriptional profile compared to the colonic 
tissue obtained from Rag2-/- mice as depicted by principal component analysis in 
Figure 11A. In total, seven hundred and eighty nine genes were differentially 
expressed (+/- 1.5 fold) in the colon of TRUC mice in comparison with the colon of 
Rag2-/- mice (Figure 11B). Gene set enrichment analysis (GSEA) on these genes 
performed by Dr Behdad Afzali revealed an enrichment of transcripts known to be 
regulated by IL-22 such as Reg3b (32.2 fold increase) and Reg3g (9.1 fold increase) 
















Figure 11: Transcriptional analysis of colonic tissue from TRUC vs. Rag2-/- (control) mice. 1cm 
long fragments of distal colon were harvested from 8-12 week old TRUC and Rag2-/-  (control) mice 
and whole genome expression studies were performed using Illumina gene expression arrays. A. PCA 
of gene expression on distal colon of TRUC vs. Rag2-/- mice. Numbers along axes indicate relative 
scaling of the principal variables. Each sphere represents one mouse. Data representative of a single 
experiment with 3 biological replicates. Analysis was performed using Partek® software. B. Heat map 
and cluster dendogram showing deferentially (+/- 1.5 fold) expressed genes on TRUC vs. Rag2-/- 
(control) mice. Data representative of a single experiment with 3 biological replicates. Analysis was 
performed using Partek® software. C. Volcano plot (fold change plotted against statistical 
significance of change) depicting transcriptional changes in colon of TRUC vs. Rag2-/- (control) mice. 
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To interrogate the possibility of IL-22 driving an important transcriptional program 
in NCR- ILC3 mediated colitis, the expression pattern of IL-22 responsive genes was 
analysed in the colon of TRUC mice. IL-22R is known to be expressed in non-
haematopoietic cell lineages such as epithelial and stromal cells (Wolk, Kunz et al. 
2004). To characterize the expression profile of IL-22 receptor (IL-22R) in the colon, 
unfractionated cells were isolated from the colon of 8-12 week old WT mice, and 
stained with fluorochrome-conjugated Abs to allow epithelial/immune cell separation 
by flow cytometry. As shown in Figure 12, only epithelial cells (CD45-EpCAM+) but 
not immune cells (CD45+EpCAM-) express IL-22R in the murine colon. Therefore, 
an in vitro culture system of colonic epithelial organoids was established by Dr 
Anastasia Tsakmaki and Dr Gavin Bewick. Colonic crypt stem cells from WT mice 
were harvested and cultured to form three dimensional organ buds that retain the 
phenotypic and functional characteristics of intact primary colonic epithelial cells 

















Figure 12: IL-22R expression is confined to colonic epithelial cells. Unfractionated cells were 
isolated from the colon of 8-12 week old WT mice and their expression of IL-22R was analysed by 
FACS.  Flow dot plots (gated on single cells) showing gating strategy to define epithelial and immune 
cells in colonic LP of 8-12 week old WT mice and their IL-22R expression (histogram overlays). Data 































Then, to define a profile of IL-22 responsive genes expressed in the colonic 
epithelium, colonoids were treated by Dr Anastasia Tsakmaki with or without 
10ng/ml of murine recombinant IL-22 for a period of 24h. Transcriptional changes 
triggered by IL-22 treatment were identified by microarray analysis (Mouse Gene 2.0 
ST array, Affymetrix). IL-22 treatment resulted in marked transcriptional changes in 
colonoids. In total, four hundred fifty one genes were significantly (P<0.002) 
differentially expressed (+/- 1.5 fold) in IL-22 treated colonoids compared to 
untreated ones (data not shown). Notably, amongst these genes were known IL-22 
responsive genes such as Reg3b (187 fold increase, P<1.96 x10-6), Reg3g (9.12 fold 
increase, P<3x10-6), S100a8 (P<9x10-7), S100a9 (11.6 fold increase, P<2x10-4), Fut2 
(2 fold increase, P<6x10-6) and Saa3 (2.3 fold increase, P<0.002), as shown in Figure 
13. Moreover, GSEA performed by Dr Behdad Afzali revealed that IL-22 responsive 
genes in colonic epithelial cells (as identified in IL-22 treated colonoids) were 
significantly enriched in the colon of TRUC mice (P<0.0001) (Figure 14A). 
Furthermore, as shown in Figure 14B, the expression of the IL-22 responsive genes 
found in colonoids significantly correlated with the expression level of these 
transcripts in the colon of TRUC mice (r2=0.66, P<0.0001) (Analysis done by Dr 
Nicholas Powell). In particular, a comparison between the 30 most highly 
upregulated genes in TRUC mice and the top 30 upregulated genes in IL-22 treated 
colonoid revealed one third overlap (10 genes were shared), while a comparison 
between the 10 most highly upregulated genes in TRUC mice and the top 10 
upregulated genes in IL-22 treated colonoid showed a 40% overlap (Figure 15) 











Figure 13: Top 30 of IL-22 responsive genes. Mouse colonoids (generated as described in Chapter 
2) were stimulated with or without 10ng/ml IL-22 for 24h. To identify all differentially expressed 
genes whole transcriptomic analysis was performed using Mouse Gene 2.0 ST array, Affymetrix.   IL-
22 responsive genes were defined as genes upregulated in IL-22 treated colonoids when compared to 
untreated  (control) colonoids. Graph showing fold change of the top 30 upregulated genes in IL-22 
treated colonoids. Data representative of a single experiment with 3 technical replicates. Analysis was 





























































































































Figure 14: NCR- ILC3 mediated colonic inflammation is characterised by a striking IL-22 
responsive transcriptional profile. A. GSEA of IL-22 responsive genes in the colon of TRUC and 
Rag2-/- mice. IL-22 responsive genes were identified by microarray analysis as significantly (p<0.05) 
differentially expressed genes (+/-2 fold change) in colonic epithelial cells (colonoids) treated for 24h 
with or without 10ng/ml IL-22 (n=3) using the Mouse Gene 2.0 ST array (Affymetrix). This IL-22 
responsive gene set was used to perform a GSEA in a whole genome expression array dataset of genes 
expressed in the distal colon of Rag2-/- (n=3) and TRUC (n=3) mice (MouseWG-6 v2.0 Expression 
BeadChip, Illumina). B. Correlation of the expression of the top 50 most highly upregulated IL-22 
responsive genes in colonoids with their expression in the colon of TRUC mice. IL-22 responsive 
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genes were defined by whole genome microarray analysis of colonoids treated for 24h with or without 
20ng/ml IL-22 (n=3). The expression of IL-22 responsive genes was then correlated with the 
expression of these genes in whole segments from distal colon of TRUC mice when compared to 


















Figure 15: Shared expression of the top 30 (1, 3) and top 10 (2, 4) most highly upregulated genes 
in the colon of TRUC mice and IL-22 treated colonoids, respectively. 1cm long fragments of distal 
colon were harvested from 8-12 week old TRUC and Rag2-/- (control) mice and whole genome 
expression studies were performed using microarrays (MouseWG-6 v2.0 Expression BeadChip, 
Illumina). Highly upregulated genes in TRUC colon were defined as significantly (p<0.05) 
upregulated genes (+/- 1.5 fold) in TRUC vs. Rag2-/- (control colon) by microarray analysis. Colonic 
epithelial cells (colonoids) were treated for 24h with or without 10ng/ml IL-22 (n=3) and whole 
genome expression analysis was performed using Mouse Gene 2.0 ST array (Affymetrix). IL-22 
responsive genes were identified as significantly (p<0.05) upregulated (+/- 1.5 fold change) in IL-22 
treated vs. untreated (control) colonoids. Graph showing the top 30 (1, 3) and top 10 (2, 4) most 































































































3.5 NCR- ILC3s are prominent producers of IL-22 
In accordance with the dominant IL-22 responsive signature in NCR- ILC3 mediated 
colitis, previous work in the lab has shown that mononuclear cells isolated from the 
colonic LP (cLPMCs) of TRUC mice produced significantly more IL-22 and IL-17A 
compared to cLPMCs from Rag2-/- mice, and in absolute terms the IL-22 levels were 
substantially higher than the IL-17A ones. Taken together, these data point to a 
potential role for IL-22 in TRUC disease. Since neutrophils (Zindl, Lai et al. 2013) 
and other myeloid cells (Pickert, Neufert et al. 2009) also produce IL-22, the source 
of IL-22 in the colon of TRUC mice was investigated. Previous work in the lab using 
FACS analysis on cLPMCs isolated from TRUC mice showed that immune (CD45+) 
cells that produce IL-22 in the colon of TRUC mice express CD90, a known ILC 
marker, whereas a substantial proportion of these cells also produce IL-17A, 
suggesting that ILCs are the main cellular source of IL-22 in TRUC disease.  
To confirm that NCR- ILC3s and not ILC2s, the other major ILC subset in TRUC 
mice, were indeed the producers of IL-22 in TRUC disease, NCR- ILC3s and ILC2s 
were FACS sorted from the colonic LP of TRUC mice for subsequent whole 
transcriptome analysis by microarrays. As expected NCR- ILC3s and ILC2s from the 
colonic LP of TRUC mice showed distinct gene expression profiles (Figure 16A) 
that were similar to their corresponding small intestinal counterparts (Robinette, 
Fuchs et al. 2015). In total, four hundred and seventy genes were differentially 
expressed (+/- 1.5 fold, P<0.05) between NCR- ILC3s and ILC2s (Figure 16B), 
including ILC2 (Gata3, Il5, il13) and ILC3 (il22, il17a, Il23r) relevant genes, 
respectively (Figure 18C), with the il22 gene being both the most highly upregulated 
and most significantly differentially expressed gene in NCR- ILC3s (13.6 fold 
increase, P<0.005). Moreover, stimulation with both IL-1β and IL-23 induced 
differential expression of 324 genes (+/- 1.5 fold, P<0.05) on FACS purified NCR- 
ILC3s, with il22 being both the most highly upregulated and most significantly 
differentially expressed gene in activated NCR- ILC3s (Figure 17A). To corroborate 
these findings on protein level, FACS sorted NCR- ILC3s fro the colon of TRUC 
mice were stimulated with or without IL-1β and IL-23 for 24h, and IL-22 levels in 
the supernatant (S/N) were measured by ELISA. As shown in Figure 17B, although 
colonic NCR- ILC3s spontaneously produce IL-22, IL-1β and IL-23 stimulation 
90 
significantly increased IL-22 production by these cells. Taken together, these data 
show that IL-22 drives a dominant transcriptional program in NCR- ILC3 mediated 


























Figure 16: ILC2s and NCR- ILC3s show distinct gene expression profiles in the colon of TRUC 
mice. ILC2s and NCR- ILC3s were FACS purified from the colonic LP of 8-12 week old TRUC mice 
and whole genome expression studies were performed using Illumina gene expression arrays. A. PCA 
of gene expression on distal colon of ILC2s vs. NCR- ILC3s. Numbers along axes indicate relative 
scaling of the principal variables. Each sphere represents one technical replicate. Data representative 
of a single experiment with 3 technical replicates. Analysis was performed using Partek® software. B. 
Heat map and cluster dendogram showing deferentially (+/- 2 fold) expressed genes on ILC2s vs. 
NCR- ILC3s purified from the colonic LP of TRUC mice. Data representative of a single experiment 
with 3 technical replicates. Analysis was performed using Partek® software. C. Volcano plot (fold 
change plotted against statistical significance of change) depicting transcriptional changes between 
ILC2s and NCR- ILC3s purified from the colonic LP of TRUC mice. Data representative of a single 
experiment with 3 technical replicates. Analysis was performed using Partek® software. 
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Figure 17: NCR- ILC3s are prominent producers of IL-22 in the TRUC model of experimental 
colitis. NCR- ILC3s were FACS sorted from the colon of TRUC mice and stimulated for 24h with or 
without 20ng/ml IL-23 or 10ng/ml IL-1β. Cells were the lysed, RNA was extracted and transcriptome 
analysis was performed using Illumina gene expression arrays. A. Volcano plot (fold change plotted 
against statistical significance of change) showing transcriptional differences on FACS purified NCR- 
ILC3s stimulated  (24h) with or without IL-23 and IL-1β (n=3 in each group). Data representative of a 
single experiment with 3 technical replicates. Analysis was performed using Partek® software. B. IL-
22 production (mean with SD) in S/Ns of FACS sorted NCR- ILC3s from the colon of 8-12 week old 
TRUC mice. Cells were stimulated for 24h with (n=3) or without IL-23 and IL-1β (n=2) and IL-22 
production was measured by ELISA. Data polled from 2 independent experiments. Statistical analysis 
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3.6 IL-22 drives inflammation in TRUC mice 
The striking IL-22 transcriptional signature observed in TRUC disease strongly 
suggests a functional role for this cytokine in NCR- ILC3 mediated chronic colitis.  
To interrogate this possibility, and taking into account recent data highlighting the 
importance of IL-22 in restoring intestinal epithelial homeostasis (Lindemans, 
Calafiore et al. 2015), Tbx21-/-Rag2-/-Il22-/- (TRUCIl22-/-) triple knock out (KO) mice 
were generated. Surprisingly, in contrast to TRUC mice that develop disease 
characterized by colitis, increased colonic weight and splenomegaly, TRUCIl22-/- 
mice did not develop spontaneous colitis (data not shown). As shown by Powell et al. 
in 2012, the intestinal microbiota composition plays a central role in TRUC disease, 
so TRUCIl22-/- mice were orally gavaged with intestinal microbiota harvested from 
TRUC mice to access whether exposure to “colitogenic” microbiota would impact 
disease susceptibility. Even then, TRUCIl22-/- mice remained disease free. 
TRUCIl22-/- mice exhibited 0 histological score as defined by H&E staining (Figure 
18A and 18B) and had significantly smaller spleens and colons, compared to TRUC 
mice (Figure 18C). In addition, TRUCIl22-/- mice had significantly less immune 
infiltration in secondary lymphoid tissues such as spleen and MLN, as well as in the 















Figure 18: IL-22 is pathogenic in TRUC disease. TRUC and TRUCIl22-/- mice were orally gavaged 
with intestinal microbiota at day 0 and culled 6 weeks later at day 42. Spleen and colon masses were 
recorded, tissue fragments were obtained from the distal colon for histological analysis, and single 
cells suspensions were prepared from spleens, MLNs and colons to measure immune infiltrate. A. 
H&E staining on sections from the distal colon of TRUC and TRUCIl22-/- mice. B. Histology score 
(mean with SD) of TRUC and TRUCIl22-/- mice. Data pooled from two independent experiments with 
n=5 and n=6 respectively. Statistical analysis was performed using GraphPad PRISM® version 7 
software (Mann-Whitney two-tailed test). C. Spleen and colon weights (line depicts mean) of TRUC 
vs. TRUCIl22-/- mice. Each square represents one mouse. Data pooled from two independent 
experiments with n=5 and n=6 respectively. Statistical analysis was performed using GraphPad 
PRISM® version 7 software (Mann-Whitney two-tailed test). D. Total cell counts in spleen, MLN and 
colon (mean with SD) of TRUC and TRUCIl22-/- mice, respectively. Data pooled from two 
independent experiments with n=5 and n=6 respectively. Statistical analysis was performed using 







































































































































To address whether blocking of IL-22 in vivo could ameliorate disease in TRUC 
mice, aIL-22 neutralizing Abs were administered intraperitoneally (ip.) to TRUC 
mice every three to four days, and mice were culled at day 27 (Figure 19A) for 
subsequent analysis. As shown in Figure 19B and 19C, in vivo blockade of IL-22 
attenuated TRUC disease, with treated mice exhibiting zero histological score. 
Moreover, aIL-22 treated mice had significantly smaller organ masses compare to 
TRUC mice treated with isotype control antibodies (Figure 19D).   
In accordance with IL-22 having a key role in NCR- ILC3 mediated chronic colitis, 
in vivo administration of recombinant IL-22 to TRUCIl22-/- mice induced disease to 
otherwise protected TRUCIl22-/- mice (Figure 20). TRUCIl22-/- mice treated for a 
period of 14 days as shown in Figure 20A, had significantly higher histological score 
than TRUCIl22-/- mice treated with PBS (Figure 20B and 20C). Furthermore, 
TRUCIl22-/- mice had significantly larger colon masses compared to PBS treated 
mice, although no difference in the spleen sizes was observed (Figure 20D). Taken 















Figure 19: IL-22 blockade attenuates TRUC disease. TRUC mice were administered ip. with 
200µg aIL-22 or isotype antibody (control) and seven days later were culled for downstream analysis. 
Spleen and colon masses were recorded and tissue fragments were obtained from the distal colon for 
histological analysis. A. Experimental protocol for in vivo administration of aIL-22 or isotype control 
Ab in TRUC mice. B. H&E staining of distal colon of TRUC mice treated with isotype control and 
aIL-22 respectively. Data representative of a single experiment. C. Histology score (mean with SD) of 
TRUC mice treated with isotype control and aIL-22 respectively. Data representative of a single 
experiment. Statistical analysis was performed using GraphPad PRISM® version 7 software (Mann-
Whitney two-tailed test). D. Spleen and colon weights (line depicts mean) of isotype treated vs. aIL-
22 treated TRUC mice. Each square represents one mouse. Data representative of a single experiment. 
Statistical analysis was performed using GraphPad PRISM® version 7 software (Mann-Whitney one-
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Figure 20: rIL-22 induces disease in TRUCIl22-/- mice. TRUCIl22-/- mice were administered ip. 
with 100µg rIL-22 or PBS (control) at days 0, 4, 8 and 12, and were culled at day 14 for downstream 
analysis. Spleen and colon masses were recorded and tissue fragments were obtained from the distal 
colon for histological analysis. A. Experimental protocol for in vivo administration of rIL-22 or PBS 
(control) in TRUCIl22-/- mice. B. H&E staining on sections from the distal colon of TRUCIl22-/- mice 
treated with PBS and rIL-22 respectively. Data representative of a single experiment. C. Histology 
score (mean with SD) of TRUCIl22-/- mice treated with PBS and rIL-22 respectively. Data 
representative of a single experiment. Statistical analysis was performed using GraphPad PRISM® 
version 7 software (Mann-Whitney two-tailed test). D. Spleen and colon weights (line depicts mean) 
of PBS vs. rIL-22 treated TRUCIl22-/- mice. Each square represents one mouse. Data representative of 
a single experiment. Statistical analysis was performed using GraphPad PRISM® version 7 software 
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In the first results chapter, it is shown that NCR- ILC3s is the most abundant ILC3 
subset in the colonic LP in steady state, as well as during intestinal inflammation. 
Several independent studies have described an important role for ILC3s in host 
immunity to foreign pathogens and commensal bacteria in the gut (Sonnenberg, 
Monticelli et al. 2012, Hepworth, Monticelli et al. 2013), but only a minority of those 
were focused on NCR- ILC3s (Buonocore, Ahern et al. 2010, Powell, Walker et al. 
2012). Here, it is shown that NCR- ILC3s are the majority of ILC3s in the murine 
colon, and their large proportion amongst ILC3s is maintained upon induction of 
intestinal inflammation using several mouse models of experimental IBD, such as 
DSS and DNBS induced colitis, T cell transfer induced colitis, and Il10-/- mice. 
Moreover, further analysis showed that only a small percentage of ILC3s (around 
30%) expresses the surface marker CD4, and that the vast majority (>95%) of those 
cells are NCR- ILC3s. However, it’s worth mentioning here that although these 
experiments showed clearly that NCR- ILC3s are the major ILC3 subpopulation in 
the murine colon both in health and disease, they were only performed once with 
4<n<8, and thus, they need to be repeated in order to confirm these preliminary 
findings. Moreover, as there are no enumeration data in these experiments it is 
difficult to draw any meaningful conclusions about the absolute numbers of NCR- 
ILC3s in the colonic LP and how (if at all) are affected during intestinal 
inflammation. 
As described previously, the TRUC mouse is an ideal model to study NCR- ILC3s 
due to the lack of adaptive immunity caused by Rag2 deficiency, as well as the 
impaired percentages of ILC1s and NCR+ ILC3s, the development of which depends 
on the transcription factor T-bet (Powell, Walker et al. 2012, Powell, Lo et al. 2015, 
Sciume, Hirahara et al. 2012, Klose, Flach et al. 2014). To be expected, NCR- ILC3s 
were also found to be the most abundant ILC3 subset in the colon of TRUC mice. In 
this chapter, it was shown that the percentages of both ILC1s and NCR+ ILC3s were 
reduced in the colonic LP of TRUC mice compared to Rag2-/- control mice. Again, 
since the role of T-bet in the development of ILC1s and NCR+ ILC3s is well 
characterized (Powell, Walker et al. 2012, Powell, Lo et al. 2015, Sciume, Hirahara 
et al. 2012, Klose, Flach et al. 2014), this experiment was only performed once with 
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n=4 and without obtaining any enumeration data. Thus, repeating this experiment, 
including absolute numbers of all ILC subsets found in the colonic LP of TRUC 
mice, would be extremely informative for the work described in this thesis. 
Previous work in the lab and other independent groups have already established a 
role for ILC3s in TRUC disease (Powell, Walker et al. 2012, Powell, Lo et al. 2015, 
Ermann, Staton et al. 2014), therefore TRUC mice were exploited to scrutinize the 
role of NCR- ILC3s in chronic colonic inflammation, which is the aim of this thesis. 
Transcriptome analysis in whole tissue from the colon of TRUC and Rag2-/- control 
mice revealed a distinct IL-22 transcriptional signature in TRUC disease. Transcripts 
known to be regulated by IL-22 such as those encoding for antimicrobial peptides 
(Reg3b, Reg3g) were increased in the colon of TRUC mice, corroborating the well-
characterized role of IL-22 in host’s defence against bacterial pathogens 
(Sonnenberg, Monticelli et al. 2012, Hepworth, Monticelli et al. 2013). Since IL-22 
acts solely on the intestinal epithelium and not on other immune cells in the gut 
(Wolk, Kunz et al. 2004), mouse colonoids were developed by our collaborator Dr 
Anastasia Tsakmaki in order to define the transcriptional changes enforced by IL-22 
in colonic epithelial cells. IL-22 stimulation induced notable transcriptional changes 
in murine colonoids, and as revealed by GSEA kindly performed by Dr Behdad 
Afzali these transcripts were enriched in the TRUC colon. Interestingly, the 
expression of these transcripts in IL-22 treated colonoids was positively correlated 
with their expression in the TRUC colon as shown by Dr Nick’s Powell analysis. 
Taken together these findings indicate for the first time that IL-22 may have a role in 
TRUC disease.  
Indeed, cLPMCs isolated form the colon of TRUC mice produced significantly more 
IL-22 than those isolated from the colon of Rag2-/- control mice. Moreover, previous 
work in the lab by FACS analysis on cLPMCs from TRUC mice revealed that the 
vast majority of IL-22 found in the colon of these mice came from cells expressing 
CD90, a known ILC marker, suggesting that ILCs are the main producers of IL-22 in 
the colonic LP in TRUC disease. Transcriptome analysis on FACS purified 
unstimulated ILC2s and NCR- ILC3s from the colon of TRUC mice, showed Il22 as 
the most highly upregulated, as well as most significantly expressed gene found on 
NCR- ILC3s. IL-23 and IL-1β are known inducers of IL-22 production (Kastelein, 
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Hunter et al. 2007, Lee, Kumagai et al. 2013), transcriptome analysis on FACS 
sorted unstimulated and IL-23 and IL-1β stimulated NCR- ILC3s from the colonic LP 
of TRUC mice showed significantly increased expression of Il22 in treated NCR- 
ILC3s. These findings were also corroborated in protein level, as it was shown that 
FACS sorted NCR- ILC3s from TRUC mice produced significantly more IL-22 upon 
24h stimulation with IL-23 and IL-1β. These findings support further the hypothesis 
that IL-22 may be an important effector cytokine in TRUC disease.  
Indeed, in this chapter it was shown for the first time that IL-22 drives inflammation 
in TRUC disease. Genetic depletion of IL-22 in TRUC mice protected them from 
colitis. In accordance with these findings, in vivo blockade of IL-22 by 
administration of neutralizing antibodies to TRUC mice significantly attenuated 
colonic inflammation, whereas in vivo administration of recombinant IL-22 to 
TRUCIl22-/- mice induced colitis in otherwise protected TRUCIl22-/- mice. Taken 
together these data challenge our current understanding of the actions of IL-22 in the 
gut, where is mainly viewed as a promoter of tissue regeneration and repair 
(Lindemans, Calafiore et al. 2015). Several independent studies have shown a 
protective role for IL-22 during acute epithelial injury caused by chemical insults 
such as DSS (Sugimoto, Ogawa et al. 2008) or methotrexate, a known chemotherapy 
agent (Aparicio-Domingo, Romera-Hernandez et al. 2015). In addition, IL-22 is 
known to be protective against self-limiting colonic infections as those caused by 
Citrobacter rodentium (Sanos, Bui et al. 2009, Satoh-Takayama, Vosshenrich et al. 
2008). The results described in this chapter, somehow contradict our current views 
on IL-22 and its beneficial actions in the intestinal mucosa, pointing for the first time 
to a pro-inflammatory role for this cytokine. However, these findings were observed 
using TRUC mice, a model of chronic colitis where by definition tissue injury is on-
going and inflammation doesn’t reach a resolution phase, suggestion that the action 
of IL-22 might be context dependent. Furthermore, the absence of adaptive immunity 
in this system, may have also contributed to the pro-inflammatory actions of IL-22 
described in this chapter. Thus, whether IL-22 is beneficial or detrimental during 
chronic inflammation in an immune competent organism is yet to be clear. 
Finally, Powell et al have already established a key role for ILC3s in TRUC disease, 
which is at least partially mediated by IL-17A production (Powell, Walker et al. 
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2012). The results described in chapter 3 of this thesis implicate for the first time IL-
22 (another cytokine that is co-produced along with IL-17A by NCR- ILC3s) in 
TRUC pathogenesis suggesting for the first time that IL-22 may have a pro-
inflammatory role during chronic colitis and that NCR- ILC3s might use more than 




Results: IL-22 may drive inflammation in TRUC 
disease through ER stress induction in colonic 
epithelial cells 
In the previous chapter it was shown that NCR- ILC3s drive colitis in TRUC mice 
through the production of IL-22 providing new insights into TRUC pathogenesis, 
although how exactly IL-22 regulate disease in these mice remains unclear.  
Therefore, this chapter aims to shed some light into how IL-22 regulates intestinal 
inflammation in the TRUC model of chronic colitis.  
Emerging data now link endoplasmic reticulum (ER) stress with IBD pathogenesis 
(Kaser, Lee et al. 2008, Bertolotti, Wang et al. 2001, Zhang, Chen et al. 2015, Li, 
Zhang et al. 2017, Das, Png et al. 2013). Intestinal epithelial cells such as Paneth 
cells and Goblet cells are highly secretory cells, and thus prone to ER stress (Kaser, 
Lee et al. 2008, McGuckin, Eri et al. 2010, Todd, Lee et al. 2008). ER stress 
generally occurs when either unfolded or misfolded proteins accumulate in the ER 
(Kaser, Martinez-Naves et al. 2010, Kaser, Adolph et al. 2013).  To avoid or 
minimize ER stress, an important cellular process is generated known as unfolded 
protein response (UPR) (Todd, Lee et al. 2008), which is particularly crucial to cells 
in the gastrointestinal tract (Kaser, Lee et al. 2008, McGuckin, Eri et al. 2010). As 
several independent studies have shown associations between IBD susceptibility and 
components of the UPR (Kaser, Lee et al. 2008, Shkoda, Ruiz et al. 2007, Deuring, 
de Haar et al. 2012), the hypothesis that IL-22 may drive colitis in TRUC mice 
through ER stress induction in colonic epithelial cells was tested in this chapter.  
4.1 IL-22 induced the expression of known ER stress genes 
in colonic epithelial cells 
Initially, to identify any specific pathways that IL-22 may imprint on the colonic 
epithelium, the pool of genes that were upregulated in IL-22 treated colonoids 
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compared to untreated ones were further interrogated. Strikingly, IL-22 treatment 
significantly increased the number of transcripts encoding for ER stress genes in 
mouse colonoids (Figure 21), which is in accordance with studies implicating ER 
stress in IBD pathogenesis (Kaser, Lee et al. 2008, Bertolotti, Wang et al. 2001, 
Zhang, Chen et al. 2015, Li, Zhang et al. 2017, Das, Png et al. 2013). 
Therefore, in order to test the hypothesis of IL-22 inducing ER stress in colonic 
epithelial cells, mouse colonoids were treated with Tunicamycin-a known ER stress 
inducer (Das, Png et al. 2013)- by our collaborator Dr Anastasia Tsakmaki and as 
expected, Tunicamycin significantly induced the transcription of several ER stress 
genes including Grp78 and sXbp1 (p<0.0001 and p<0.001 respectively) in mouse 
colonoids (Figure 22), which were also induced following stimulation with IL-22 
(Figure 21), suggesting that IL-22 may induce ER stress in colonic epithelial cells. 
However, its worth mentioning here that induction of some known ER stress by IL-
22 in colonic epithelial cells is not necessarily indicative of ER stress presence in 
these cells, and thus further experiments are needed to interrogate the possibility of 











Figure 21: ER stress gene expression in IL-22 treated colonoids. Mouse colonoids were stimulated 
for 24h with or without 10ng/ml IL-22 for transcriptome analysis by microarrays (Mouse Gene 2.0 ST 
array, Affymetrix). Graph showing fold change in gene expression of known ER stress genes defined 
by microarray analysis. Blue bars represent significantly differentially expressed transcripts. Data 
representative of a single experiment with 3 technical replicates. Statistical analysis was performed 






















































































Figure 22: ER stress gene expression in Tunicamycin treated colonoids. Mouse colonoids were 
stimulated for 24h with or without Tunicamycin for transcriptome analysis by microarrays (Mouse 
Gene 2.0 ST array, Affymetrix). Graph showing fold change in gene expression of known ER stress 
genes defined by microarray analysis. Highlighted bars represent significantly upregulated genes. 
Data representative of a single experiment with 3 technical replicates. Statistical analysis was 

































































4.2 ER stress genes were significantly upregulated in the 
colon of TRUC mice 
Subsequently, to formally investigate whether IL-22 drives colitis in TRUC mice 
through IL-22 mediated induction of ER stress in the colonic epithelium, gene 
expression microarray data on whole colonic tissue from TRUC and Rag2-/- control 
mice were further interrogated focusing on ER stress pathways. Interestingly, 
transcripts encoding known ER stress genes such as Grp78, sXbp1 and Atf6 were 
significantly upregulated in TRUC colon (Figure 23), supporting the hypothesis that 
IL-22 might drive TRUC disease through induction of ER stress in colonic epithelial 
cells.  However, as mentioned before, additional experiments are required to confirm 



















Figure 23: ER stress gene expression in the colon of TRUC mice. 1cm long fragments of distal 
colon were harvested from 8-12 week old TRUC and Rag2-/- (control) mice and whole transcriptome 
analysis was performed using microarrays (MouseWG-6 v2.0 Expression BeadChip, Illumina). Graph 
showing fold change of known ER stress genes upregulated in the colon of TRUC vs. Rag2-/- mice as 
defined by microarray analysis. Highlighted bars represent significantly upregulated genes. Data 
representative of a single experiment with 3 biological replicates. Statistical analysis was performed 














































4.3 IL-22 produced by NCR- ILC3s induced expression of 
ER stress genes in colonic epithelial cells 
Accordingly, to formally test the hypothesis of NCR- ILC3s driving TRUC disease 
via IL-22 mediated induction of ER stress, NCR- ILC3s were FACS sorted as 
described in chapter 2 from the colon of TRUC and TRUCIl22-/- mice respectively, 
activated through 48h stimulation with IL-2, IL-7, plus IL-23 and IL-1β, two known 
positive regulators of IL-22 (Kastelein, Hunter et al. 2007, Lee, Kumagai et al. 
2013), followed by a 24h co-culture with colonoids as shown in Figure 24A. At the 
end of the 24h stimulation, mRNA levels of Grp78, sXbp1 and Grp94 were measured 
by RT-qPCR by Dr Anastasia Tsakmaki. As depicted in Figure 24B, Grp78, sXbp1 
and Grp94 expression were significantly reduced in colonoids that were co-cultured 
with IL-22 deficient NCR- ILC3s compared to the levels in colonoids co-cultured 
with IL-22 sufficient NCR- ILC3s. Taken together, this data further support the 
hypothesis that NCR- ILC3s may drive inflammation in TRUC mice through IL-22 
















Figure 24: IL-22 sufficient NCR- ILC3s upregulated ER stress genes in colonic epithelial cells. 
A. NCR- ILC3s were FACS purified from the colon of TRUC and TRUCIl22-/- mice, stimulated for 
48h with 20ng/ml IL-2, 50ng/ml IL-7, 10ng/ml IL-1β and 10ng/ml IL-23, and then co-cultured for 24h 
with mouse colonoids. Transcripts of known ER stress genes were quantified by RT-qPCR. B. Grp78, 
sXbp1 and Grp94 expression in mouse colonoids co-cultured for 24h with NCR- ILC3s FACS purified 
from the colon of TRUC and TRUCIl22-/- mice, respectively. Data representative of a single 
experiment with 3 technical replicates. Statistical analysis was performed using GraphPad PRISM® 
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4.4 Inhibition of ER stress with 4-PBA attenuated TRUC 
disease 
To formally address the impact of IL-22 induced ER stress in TRUC disease, TRUC 
mice were orally administered with the known ER stress inhibitor 4-phenylbutryic 
acid (4-PBA) (He, Zou et al. 2017) for a period of 6 weeks as shown in Figure 25A. 
Throughout the course of this experiment mice were regularly checked for weight 
loss and general signs of distress by Dr Nick Powell. Interestingly, as shown in 
Figure 25B and 25C, in vivo administration of the ER stress inhibitor 4-PBA 
significantly ameliorated the histological severity of TRUC disease. Moreover, 
TRUC mice treated with 4-PBA had significantly lighter colons compared to control 
mice treated with water, but no difference in their spleen weights as depicted in 
Figure 25D. Taken together these data suggest a direct link between ER stress and 

















Figure 25: In vivo administration of 4-PBA attenuates TRUC disease. A. 20mM 4-PBA in 
drinking water was administered to TRUC mice for a period of 6 weeks. B. H&E staining on sections 
from the distal colon of TRUC mice treated with 20mM 4-PBA or H2O (controls), respectively. C. 
Histology score (mean with SD) of TRUC mice treated with 20mM 4-PBA or H2O (controls), 
respectively. Data representative of a single experiment with n=8. Statistical analysis was performed 
using GraphPad PRISM® version 7 software (Mann-Whitney one-tailed test, *p<0.05, **P<0.005, 
***p<0.0001). D. Spleen and colon weights (line depicts mean) of TRUC mice treated with 20mM 4-
PBA or H2O (controls), respectively. Each square/triangle represents one mouse. Data representative 
of a single experiment with n=8. Statistical analysis was performed using GraphPad PRISM® version 
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4.5 Induction of ER stress with Tunicamycin induced 
colitis in otherwise protected TRUCIl22-/- mice 
Driven by these data, the possibility that restoration of ER stress might rescue the 
colitis phenotype in otherwise healthy TRUCIl22-/- mice was considered. Therefore, 
the hypothesis that experimental induction of ER stress using Tunicamycin will have 
an impact on colitis development in TRUCIl22-/- mice was tested. For this purpose, 
TRUCIl22-/- mice were intrarectally administered with Tunicamycin by Dr Nick 
Powell following the experimental protocol shown in Figure 26A. Mice were 
frequently monitored for weights loss and general signs of distress. As depicted in 
Figures 26B and 26C, in vivo administration of the ER stress inducer Tunicamycin 
resulted in the development of colitis in TRUCIl22-/- mice, which did not occur in 
control mice administered the vehicle control. In addition, colon weights were also 
significantly increased in TRUCIl22-/- mice treated with Tunicamycin in comparison 
with control mice (Figure 26D).  Taken all together these data show for the first time 
















Figure 26: In vivo administration of Tunicamycin induces colitis in TRUCIl22-/- mice. A. 1µg of 
Tunicamycin dissolved in 0.1% DMSO (or just 0.1% DMSO) was administered ir. to TRUCIl22-/- 
mice at day 0 and day 5, and mice were culled at day 7 for downstream analysis. B. H&E staining on 
sections from the distal colon of TRUCIl22-/- mice treated with or without Tunicamycin, respectively. 
C. Histology score (mean with SD) of TRUCIl22-/- mice treated with or without Tunicamycin 
respectively. Data representative of a single experiment with n=9 (Tunicamycin) and n=8 (0.1% 
DMSO). Statistical analysis was performed using GraphPad PRISM® version 7 software (Mann-
Whitney one-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Colon weights (line depicts mean) of 
TRUCIl22-/- mice treated with or without Tunicamycin, respectively. Each square/triangle represents 
one mouse. Data representative of a single experiment with n=9 (Tunicamycin) and n=8 (0.1% 
DMSO). Statistical analysis was performed using GraphPad PRISM® version 7 software (Mann-
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4.6 IL-22 and IL-17A synergistically induced expression of 
ER stress genes in colonic epithelial cells 
Since previous work by Dr Nick Powell in our lab has already established a 
pathogenic role for IL-17A in TRUC disease, and as IL-17A is produced in 
combination with IL-22 by colonic NCR- ILC3s, the hypothesis of IL-17A 
synergizing with IL-22 to induce ER stress was tested. Therefore, and in order to 
examine whether the effects of IL-22 and potentially IL-17A were the same across 
the fully differentiated epithelium and the epithelial stem cells, mouse colonoids 
from Lgr5-eGFP reporter mice were generated by our collaborator Dr Anastasia 
Tsakmaki. As Lgr5 is a known marker for epithelial stem cells, using mouse 
colonoids generated Lgr5-eGFP reporter mice would allow us to test whether IL-22 
and potentially IL-17A act solely on the differentiated epithelium to induce ER stress 
or on the pluripotent epithelial stem (GFP+) cells as well.  Following 24h stimulation 
with or without IL-22 and IL-17A, single cells suspensions were prepared from the 
colonoids and Lgr5-eGFP+ and Lgr5-eGFP+ cells were FACS sorted based on eGFP 
expression as shown in Figure 27A. To confirm purity, Lrg5 expression on the two 
populations was also measured by RT-qPCR as shown in Figure 27B by Dr 














Figure 27: Gating strategy used to FACS purify colonic epithelial cells from mouse colonoids. 
Mouse colonoids were generated as described previously using Lgr5-eGFP mice. Single cell 
suspensions were prepared and cells were stained with surface markers to allow FACS purification of 
epithelial (EpCAM+) cells. Epithelial stem cells (EpCaM+Lgr5+) were identified as GFP+ cells.  A. 
Flow plots showing gating strategy used to FACS sort epithelial cells and epithelial stem cells from 
mouse colonoids. Data representative of two independent experiments with n=3. Data were analysed 
using FlowJo software (Treestar). B. Lgr5 expression measured by RT-qPCR on epithelial cells and 
epithelial stem cells sorted from mouse colonoids. Data representative of two independent 
experiments with n=3. Statistical analysis was performed using GraphPad PRISM® version 7 































A     



















Moreover, FACS analysis was also performed on the sorted populations to examine 
whether or not there are any differences in the expression of IL-22R and IL-17R 
between colonic epithelial and colonic epithelial stem cells. As shown in Figure 28, it 
seems that epithelial stem cells express higher levels of both IL-22R and IL-17R than 
epithelial cells, suggesting that IL-22 and possibly IL-17A may have a greater impact 
on epithelial stem cells than on the fully differentiated epithelium.  
Finally, as shown in Figure 29, IL-22 and IL-17A stimulation significantly increased 
the expression of both Grp78 and sXbp1 in both colonic epithelial and colonic 
epithelial stem cells, although the induction in the Lgr5+ population was greater. 
Together these data suggest that IL-17A synergizes with IL-22 to induce ER stress in 
colonic epithelial cells, and in particular in the colonic stem cells supporting even 



















Figure 28: IL-22R and IL-17R expression on colonic epithelial (GFP-) and colonic stem cells 
(GFP+). Mouse colonoids were generated as described previously using Lgr5-eGFP mice. Single cell 
suspensions were prepared and cells were stained with surface markers to allow FACS purification of 
epithelial (EpCAM+) cells. Epithelial stem cells (EpCaM+Lgr5+) were identified as GFP+ cells.  
Histogram overlays showing IL-22R and IL-17R expression respectively on epithelial (GFP-) and 
epithelial stem (GFP+) cells from mouse colonoids. Data representative of two independent 























Figure 29: Grp78 and sXbp1 expression on colonic epithelial (GFP-) and colonic stem cells 
(GFP+). Mouse colonoids were generated as described previously using Lgr5-eGFP mice and 
stimulated for 24h with our without 10ng/ml IL-22 and 50ng/ml IL-17A. Single cell suspensions were 
prepared and cells were stained with surface markers to allow FACS purification of epithelial 
(EpCAM+) cells. Epithelial stem cells (EpCaM+Lgr5+) were identified as GFP+ cells. Graphs showing 
Grp78 and sXbp1 expression (mean with SD) on epithelial cells (GFP-) and epithelial stem cells 
(GFP+) FACS sorted from mouse colonoids treated with or without 10ng/ml IL-22 and 50ng/ml IL-
17A. Data representative of two independent experiments with n=3. Statistical analysis was performed 





















































































4.7 Impact of regulatory T-cells on IL-22 induced epithelial 
ER stress  
The final question tested in this chapter, was whether this profound effect of IL-22 
on the colonic epithelium could be in any way regulated. Although the data 
generated in this section are preliminary, and further work is needed to verify or 
challenge the results generated, they have been included in this thesis as interesting 
preliminary findings. In order to generate a more physiological setting [since TRUC 
mice do not have regulatory T cells (Tregs)], Tregs from the spleen of FoxP3-eGFP 
reporter mice were FACS sorted as shown in Figure 30A, mixed with aCD3 beads 
and added to colonoid cultures for a period of 24h in the presence or absence of the 
ER stress inducing IL-22. To determine whether any of the changes observed might 
be dependent on the immunosuppressive cytokine IL-10, which has been shown 
previously to alleviate ER stress (Shkoda, Ruiz et al. 2007), neutralizing anti-IL-10 
mAbs were also used in some conditions. Interestingly, as depicted in Figure 30B, 








Figure 30: Regulatory T cells significantly reduce IL-22 induced ER stress in colonic epithelial 
cells.  Mouse colonoids were generated as described previously. FoxP3+ Tregs were FACS purified 
from the spleen of FoxP3-eGFP reporter mice, mixed with aCD3 beads in 1:2 ratio and co-cultured 
for 24h with mouse colonoids in the presence or absence of 10ng/ml IL-22. A. Gating strategy used to 
FACS sort regulatory T cells from the spleen of FoxP3-eGFP reporter mice. Data were analysed using 
FlowJo software (Treestar). B. Grp78 and sXbp1 expression (mean with SD) in colonoids co-cultured 
with Tregs for 24h in the presence or absence of IL-22 with or without aIL-10. Data representative of 
a single experiment with 6 technical replicates. Statistical analysis was performed using GraphPad 
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To confirm this surprising finding, another co-culture experiment was performed 
with Tregs FACS sorted from the spleens of WT and Il10-/- mice as shown in Figure 
31A. However, although at a glance it may seem that indeed Tregs can supress ER 
stress induction by IL-22 in an IL-10 independent manner, in this experiment IL-22 
alone failed to significantly increase ER stress in the treated colonoids as shown in 
Figure 31B making these data un-interpretable.  
The same problem was encountered when colonoids were treated for 24h with IL-22 
in the presence or absence of IL-10 (Figure 32), magnifying the need for further 
experiments in order to establish whether or not Tregs supress IL-22 induced ER 







Figure 31: Regulatory T cells seem to reduce IL-22 induced ER stress in colonic epithelial cells.  
Mouse colonoids were generated as described previously. Tregs were FACS purified from the spleen 
of WT and Il10-/- mice, mixed with aCD3 beads in 1:2 ratio and co-cultured for 24h with mouse 
colonoids in the presence or absence of 10ng/ml IL-22. A. Gating strategy used to FACS sort 
regulatory T cells from the spleen of WT and Il10-/- mice. Data were analysed using FlowJo software 
(Treestar). B. Grp78 and sXbp1 expression (mean with SD) in colonoids co-cultured with WT or   
Il10-/- Tregs for 24h in the presence or absence of IL-22. Data representative of a single experiment 
with 6 technical replicates. Statistical analysis was performed using GraphPad PRISM® version 7 
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Figure 32: Effect of IL-10 on IL-22 induced ER stress in colonic epithelial cells.  Mouse colonoids 
were generated as described previously and stimulated for 24h with or without 10ng/ml IL-22 in the 
presence or absence of IL-10. Graphs showing Grp78 and sXbp1 expression (mean with SD) in 
colonoids stimulated for 24h with or without IL-22 in the presence or absence of IL-10. Data 
representative of a single experiment with 3 technical replicates. Statistical analysis was performed 





































































In chapter 3 it was shown that IL-22 producing NCR- ILC3s drive disease in TRUC 
mice. The data shown in this chapter (4) suggest that IL-22 producing NCR- ILC3s 
might contribute to colonic inflammation in TRUC disease through induction of ER 
stress in colonic epithelial cells, supporting further the link between ER stress and 
IBD pathogenesis.  
IL-22 stimulation induced transcriptional changes on colonic epithelial cells that 
were similar to those observed by Tunicamycin- a powerful ER stress inducer (Das, 
Png et al. 2013). Transcripts for known ER stress genes such as Grp78 and sXbp1 
were also found increased in the colon of TRUC mice compared to the healthy colon 
of Rag2-/- control mice. These findings were also confirmed by RT-qPCR kindly 
performed by Dr Anastasia Tsakmaki, suggesting that ER stress may be involved in 
TRUC pathology. A better, un-bias approach to define whether ER stress could 
potentially be associated with TRUC disease would be to perform pathway analysis 
on the gene sets generated by whole transcriptome analysis on the colon of TRUC vs. 
Rag2-/- control mice. Interestingly, pathway analysis on genes induced on colonic 
epithelial cells following IL-22 stimulation showed that indeed ER stress and 
apoptosis related genes were upregulated in colonic epithelial cells by IL-22. 
Additional GSEA could reveal exactly how much the ER stress pathway is enriched 
in the colon of TRUC mice. However, induction of known ER stress genes by IL-22 
is not necessarily indicative of ER stress presence in these cells. Further experiments 
including additional and possibly better read-outs for ER stress are needed to 
corroborate these findings and firmly link ER stress to TRUC pathology.     
A co-culture experiment of FACS purified NCR- ILC3s isolated from TRUC and 
TRUCIl22-/- mice with murine colonoids revealed that only IL-22 sufficient NCR- 
ILC3s were able to significantly induced the expression of the ER stress genes 
Grp78, sXbp1 and Grp94 in colonic epithelial cells. These findings further support 
the notion of IL-22 producing NCR- ILC3s being the key inducers of ER stress in 
colonic epithelial cells. Both Grp78 and sXbp1 transcripts have been found increased 
in the small intestine and colon of patients with CD and UC compared to healthy 
individuals (Kaser, Lee et al. 2008, Shkoda, Ruiz et al. 2007, Deuring, de Haar et al. 
2012) highlighting the importance of these molecules in the development of 
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intestinal inflammation. Moreover, mice in which Xbp1 is genetically disrupted and 
thus are unable to control ER stress have been shown to be more susceptible to 
intestinal inflammation (Kaser, Lee et al. 2008).  
In accordance with ER stress being involved in TRUC pathology, in this chapter it 
was also shown that in vivo administration of the known ER stress inhibitor 4-PBA 
(He, Zou et al. 2017) attenuated TRUC disease. TRUC mice treated with 4-PBA had 
significantly lighter colons and lower histological scores. Moreover, in vivo 
administration of the ER stress inducer Tunicamycin was able to induce colitis to 
otherwise healthy TRUCIl22-/- mice. Although these experiments were only 
performed once and need to be repeated, they showed for the first time a clear 
involvement of ER stress in the pathology of TRUC disease. These findings support 
further the current notion of ER stress being involved in IBD pathogenesis. 
Furthermore, additional work in the lab revealed that in vivo blockade of IL-22 not 
only attenuated TRUC disease, but also reduced the expression of known ER stress 
genes in the colon of TRUC mice (data not shown). Similarly, in vivo administration 
of recombinant IL-22 to TRUCIl22-/- mice not only induced colonic inflammation, 
but also increased the expression of known ER stress genes in the colon of these 
mice as well (data not shown).  Taken together these data show for the first time a 
direct link between ER stress and TRUC disease, and suggest that NCR- ILC3s may 
contribute to colonic inflammation in TRUC mice through IL-22 mediated induction 
of ER stress in colonic epithelial cells.   
In contrast to NCR+ ILC3s that almost exclusively produce IL-22, NCR- ILC3s also 
secrete IL-17A, a cytokine that has already been found to be a key regulator of 
intestinal inflammation in TRUC mice (Powell, Walker et al. 2012, Powell, Lo et al. 
2015). Interestingly, additional work in the lab showed that IL-17A magnified the 
induction of ER stress genes observed in IL-22 stimulated colonic epithelial cells 
(data not shown). Moreover, in this chapter it was shown that IL-22 and IL-17A were 
able to synergistically induce the expression of known ER stress genes in both 
colonic epithelial and epithelial stem cells, and notably, this effect was more 
profound in the later. Taking into account that NCR- ILC3s constitute the majority of 
ILC3s in the colonic LP, as well as their ability to produce pro-inflammatory 
cytokines such as IL-17A and IFNγ, the data presented so far suggest additional 
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ways with which these cells might regulate immunopathology in TRUC mice. 
Moreover, these findings support the hypothesis of IL-22 having diverse and context-
dependent actions in the gut mucosa, where in the presence of other pro-
inflammatory signals (e.g. IL-17A) during chronic inflammation IL-22 signaling may 
promote inflammatory responses rather than tissue repair and regeneration.  
At the final section of chapter 4, the hypothesis that regulatory T cells (Tregs) might 
regulate IL-22 mediated induction of ER stress in colonic epithelial cells was also 
tested. Preliminary findings suggested that likely Tregs could regulate ER stress 
induction in colonic epithelial cells in an IL-10 independent way, since Tregs were 
able to significantly reduce the expression of ER stress genes Grp79 and sXbp1 in 
colonic epithelial cells, while neutralizing antibody against IL-10 was able to reverse 
this effect. Notably, these findings contradict already published studies describing 
IL-10 as a potential ER stress inhibitor (Shkoda, Ruiz et al. 2007). However, in 
follow-up experiments that were performed to validate and confirm these findings 
IL-22 itself failed to induce the expression of the known ER stress genes Grp79 and 
sXbp1 in colonic epithelial cells, making these data un-interpretable. Therefore, 
further studies are necessary to scrutinize whether IL-22 mediated induction of ER 
stress in colonic epithelial cells could be regulated by Tregs, and if so the underlying 
mechanisms.  
In summary, the data described in this chapter provide new insights into TRUC 
pathogenesis by revealing a clear and direct link between ER stress and TRUC 
disease. Moreover, taken all together these findings form the hypothesis of NCR- 
ILC3s being at least partly the drivers of ER stress induced inflammation in colonic 
epithelial cells through the production of pro-inflammatory cytokines IL-22 and IL-
17A, which seem to act both in the fully differentiated epithelium, as well as the 
colonic epithelial stem cells. The results described in the first two chapters of this 
thesis, support further the notion of NCR- ILC3s being the key drivers of intestinal 
inflammation in TRUC mice, whilst pointing to a pro-inflammatory role of IL-22 in 
the context of chronic inflammation challenging the current belief of its protective 
functions during intestinal infections (Sanos, Bui et al. 2009, Satoh-Takayama, 
Vosshenrich et al. 2008) or chemically induced epithelial injury (Sugimoto, Ogawa 
et al. 2008). However, this is largely based on transcriptomic data and in vitro 
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experimental settings, and therefore further studies are necessary to formally address 
the involvement of NCR- ILC3s and their effector cytokine IL-22 in ER stress 
induction in the colonic epithelium. Furthermore, as already discussed above 
additional experiments are also required to establish the presence of ER stress in the 
colonic epithelium, as increased expression of some known ER stress genes could 






Results: IL-22 drives neutrophil recruitment via 
induction of CXCL1 and CXCL5 production by 
colonic epithelial cells  
The data presented in chapter 4 of this thesis showed that ER stress is directly 
involved in the pathology of TRUC disease, whereas it was also suggested that NCR- 
ILC3s may drive colonic inflammation through IL-22 mediated induction of ER 
stress in the colonic epithelium. Since most cytokines are pleiotropic, the hypothesis 
that IL-22 might have additional effects on the colonic epithelium was tested in this 
chapter.  
Chemokines are small cytokines, which are well known for their important role in 
regulating leukocyte trafficking to barrier surfaces. In particular, in the gut mucosa it 
is thought that chemokines produced by epithelial cells induce the recruitment of 
immune cells such as monocytes, neutrophils and T cells, and thus contribute to or 
even regulate the inflammatory response (Zimmerman, Vongsa et al. 2008). In 
accordance with the above belief, several studies have shown elevated expression 
levels of pro-inflammatory chemokines in CD and UC patients (Reinecker, Loh et al. 
1995, Ina, Kusugami et al. 1997, Huang, Eckmann et al. 1996) suggesting a central 
role for chemokines and the epithelium in the pathogenesis of IBD. 
Neutrophil recruitment to the colonic LP is a well-established feature of TRUC 
disease (Powell, Walker et al. 2012, Ermann, Staton et al. 2014), thus the hypothesis 
of IL-22 being implicated in this process via induction of neutrophil chemo-
attractants was tested in this chapter.  
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5.1 Chemokine genes are upregulated in TRUC colon 
In order to identify any chemokines that regulate neutrophil trafficking to the colonic 
tissue, whole tissue fragments (0.5cm long) from the distal colon of TRUC and Rag2-
/- mice were processed for downstream micro array analysis. As shown in Figure 33, 
several chemokine genes were significantly upregulated in the colon of TRUC mice 
compared to control Rag2-/- mice, including a striking increase in the gene expression 
of Cxcl1 and Cxcl5. Interestingly, Cxcl1 and in particular Cxcl5 are two chemokines 






















Figure 33: Chemokine gene expression in TRUC mice. 1cm long fragments of distal colon were 
harvested from 8-12 week old TRUC and Rag2-/- (control) mice and whole transcriptome analysis was 
performed using microarrays (MouseWG-6 v2.0 Expression BeadChip, Illumina). Graph showing fold 
change of chemokine genes upregulated in the colon of TRUC vs. Rag2-/- mice as defined by 
microarray analysis. Highlighted bars represent significantly upregulated genes. Data representative of 
a single experiment with 3 biological replicates. Statistical analysis was performed using Partek® and 









































































5.2 IL-22 induces chemokine production in colonic 
epithelial cells 
To interrogate the possibility of IL-22 playing a role in neutrophil recruitment in 
TRUC disease via induction of CXCL1 and CXCL5 production by colonic epithelial 
cells, murine colonoids were generated and stimulated for 24h with 10ng/ml 
recombinant IL-22 by our collaborator Dr Anastasia Tsakmaki for further micro 
array analysis. As shown in Figure 34, many CXC (Figure 34A) and CC  (Figure 
34B) chemokine genes were significantly unregulated in the IL-22 treated colonoids 
compared to unstimulated ones. Most importantly, the same three chemokines (Ccl7, 
Cxcl1 and Cxcl5) that were found significantly upregulated in the TRUC colon, were 
indeed the most highly upregulated genes in the colonoids upon IL-22 stimulation.  
In order to validate the results from the gene array analysis, Dr Anastasia Tsakmaki 
stimulated again colonoids for 24h with or without 10ng/ml recombinant IL-22 for 
downstream RT-qPCR analysis. As shown in Figure 35, both Cxcl1 and Cxcl5 
expression were significantly upregulated in IL-22 treated colonoids compared to 
controls.   
These data were further corroborated in a protein level, as shown in Figure 36. The 
concentration of both CXCL1 and CXCL5 in the supernatants of IL-22 treated 
colonoids were significantly higher than those in unstimulated (control) colonoids, as 
measured by ELISA by Dr Luke Roberts (Figure 36), suggesting that IL-22 may 
further act on colonic epithelial cells instructing them to produce known neutrophil 










Figure 34: Chemokine gene expression in IL-22 treated colonoids. Mouse colonoids were 
stimulated for 24h with or without 10ng/ml IL-22 for transcriptome analysis by microarrays (Mouse 
Gene 2.0 ST array, Affymetrix). A. Graph showing fold change in gene expression of CXC 
chemokines. Data representative of a single experiment with 3 technical replicates. Blue bars 
represent significantly differentially expressed transcripts. Data representative of a single experiment 
with 3 technical replicates. Statistical analysis was performed using Partek® and GraphPad PRISM® 
version 7 software (ANOVA, *p<0.05, **P<0.005, ***p<0.0001). B. Graph showing fold change in 
gene expression of Ccl chemokines. Data representative of a single experiment with 3 technical 
Figure 34 
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replicates. Blue bars represent significantly differentially expressed transcripts. Data representative of 
a single experiment with 3 technical replicates. Statistical analysis was performed using Partek® and 


























Figure 35: IL-22 induces Cxcl1 and Cxcl5 expression in colonic epithelial cells. Mouse colonoids 
were stimulated for 24h with or without 10ng/ml IL-22 and Cxcl1 and Cxcl5 gene expression was 
measured by RT-qPCR. Graphs showing Cxcl1 and Cxcl5 gene expression in mouse colonoids treated 
with or without IL-22, respectively. Data pooled from two independent experiments with n=3. 
Statistical analysis was performed using GraphPad PRISM® version 7 software (Mann-Whitney, one-




































































Figure 36: IL-22 induces CXCL1 and CXCL5 production by colonic epithelial cells. Mouse 
colonoids were stimulated for 24h with or without 10ng/ml IL-22, and CXCL1 and CXCL5 levels in 
the culture S/Ns were measured by ELISA. Graphs showing the concentration of CXCL1 and CXCL5 
in S/Ns of colonoids stimulated with or without IL-22. Data representative of a single experiment with 
6 technical replicates. Statistical analysis was performed using GraphPad PRISM® version 7 software 



















































5.3 IL-22 producing NCR- ILC3s induce CXCL1 and 
CXCL5 production by colonic epithelial cells 
To formally investigate whether NCR- ILC3s regulate chemokine production by 
colonic epithelial cells in an IL-22 dependent manner, NCR- ILC3s were FACS 
sorted as described in Chapter 2 from the colon of TRUC and TRUCIl22-/- mice 
respectively, activated through 48h stimulation with the known positive regulators of 
IL-22, IL-23 and IL-1β, followed by a 24h co-culture with colonoids as shown in 
Figure 24A. At the end of the 24h stimulation, mRNA levels of Cxcl1 and Cxcl5 
were measured by RT-qPCR by Dr Anastasia Tsakmaki. As depicted in Figure 37, 
both Cxcl1 and Cxcl5 expression were significantly reduced in colonoids that were 
co-cultured with IL-22 deficient NCR- ILC3s compared to the levels in colonoids co-
cultured with IL-22 sufficient NCR- ILC3s. Taken together, this data suggest that 
NCR- ILC3s may play a role in the regulation of neutrophil recruitment to the gut 
through IL-22 mediated induction of CXCL1 and CXCL5 production by colonic 
















Figure 37: IL-22 sufficient NCR- ILC3s induce Cxcl1 and Cxcl5 expression in colonic epithelial 
cells.  NCR- ILC3s were FACS purified from the colon of TRUC and TRUCIl22-/- mice, stimulated 
for 48h with 20ng/ml IL-2, 50ng/ml IL-7, 10ng/ml IL-1β and 10ng/ml IL-23, and then co-cultured for 
24h with mouse colonoids. Cxcl1 and Cxcl5 transcripts were quantified by RT-qPCR. Graphs showing 
Cxcl1 and Cxcl5 expression in mouse colonoids co-cultured for 24h with NCR- ILC3s FACS purified 
from the colon of TRUC and TRUCIl22-/- mice, respectively. Data representative of a single 
experiment with 3 technical replicates. Statistical analysis was performed using GraphPad PRISM® 





























































5.4 IL-22 drives neutrophil recruitment in TRUC disease 
In order to test the hypothesis that in TRUC disease, IL-22 regulates neutrophil 
recruitment to the cLP by inducing CXCL1 and CXCL5 production by colonic 
epithelial cells, cLPMCs were isolated from the colon of TRUC and TRUCIl22-/- 
mice and the percentages of neutrophils infiltrating the lamina propria were 
measured by FACS analysis. As shown in Figures 38A and 38B, the percentage of 
neutrophils (defined as live CD45+CD11b+Gr-1hi cells) in the cLP of TRUCIl22-/- 
mice is significantly impaired compared to control TRUC mice. However, there were 
no differences in the absolute number of neutrophils in the colonic LP of TRUC and 
TRUCIl22-/- mice (Figure 38C). Similarly, no differences were found in the total 
cLPMCs between TRUC and TRUCIl22-/- mice (Figure 38D), thus a third repeat of 
this experiment would most likely help clarify whether genetic deletion of IL-22 is 
associated with impaired neutrophil recruitment to the gut in TRUC mice.  
Consistent with the hypothesis that IL-22 regulates neutrophil accumulation to the 
cLP of TRUC mice through induction of chemokine production by colonic epithelial 
cells, TRUCIl22-/- mice had significantly reduced percentages of neutrophils in their 
spleen when compared to control TRUC mice as shown in Figures 39A and 39B. 
Moreover, the total numbers of neutrophils were also impaired in the spleen of these 
mice compared to control TRUC mice (Figure 39C). However, there was no 
difference in the total splenocyte counts between TRUC and TRUCIl22-/- mice as 
shown in Figure 39D.  
Interestingly, in vivo blockade of IL-22 by ip. injections of a neutralizing mAb in 
TRUC mice, didn’t seem to affect the percentage of neutrophils in the cLP of TRUC 
mice compared to control mice that received the Isotype antibody (Figures 40A and 
40B). Yet, the absolute number of neutrophils, as well as the total cLPMCs in the 
cLP of TRUC mice treated with the aIL-22 mAb were found to be significantly 
decreased compared to control mice as shown in Figure 40C and 40D, respectively. 
This experiment supports the hypothesis of IL-22 regulating neutrophil accumulation 
to the cLP in TRUC disease, but given that it was only performed once, additional 
repeats are needed to prove this hypothesis.  
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In an attempt to further explore these findings, recombinant IL-22 was in vivo 
administered ip. to TRUCIl22-/- mice, and the neutrophils in colon and spleen of 
these mice were analysed by FACS as previously. As shown in Figures 41A and 
41B, the percentage of neutrophils in the cLP of TRUCIl22-/- mice that received rIL-
22 was significantly increased compared to control mice treated with PBS. In 
addition, as shown in Figures 41C and 41D, the absolute number of neutrophils as 
well as the total cLPMCs were also significantly increased in the cLP of rIL-22 
treated TRUCIl22-/- mice compared to PBS treated mice (controls) respectively, 
suggesting that indeed IL-22 may be a key regulator of neutrophil recruitment to the 
gut in TRUC disease.  
Surprisingly, in vivo administration of rIL-22 significantly reduced the percentage of 
neutrophils in the spleen of TRUCIl22-/- mice compared to PBS treated mice 
(controls) as shown in Figures 42A and 42B. However, there was no difference in the 
absolute number of neutrophils in the spleen of TRUCIl22-/- mice treated with rIL-22 
and PBS treated TRUCIl22-/- mice (Figure 42C). Similarly, as shown in Figure 42D, 
the total number of splenocytes didn’t seem to be affected by rIl-22 administration in 
TRUCIl22-/- mice either, suggesting that there may be different mechanisms that 
regulate neutrophil trafficking to the spleen. Taken all together, these findings 
suggest that IL-22 may play a role in neutrophil trafficking to the colon during 
chronic colitis in TRUC mice, possibly through induction of chemokine production 
such as CXCL1 and CXCL5 by colonic epithelial cells, although additional repeats 











Figure 38: Reduced percentage of neutrophils in the colonic lamina propria of TRUCIl22-/- mice. 
TRUC and TRUCIl22-/- mice were orally gavaged with intestinal microbiota at day 0 and culled 6 
weeks later at day 42. cLPMCs were isolated using Percoll gradient and stained with Abs against 
surface markers to analyse neutrophil infiltrate by FACS. A. Representative dot plots showing the 
percentage of neutrophils defined as CD11b+Gr-1hi cells in the cLP of TRUC and TRUCIl22-/- mice, 
respectively. Cells gated as single live CD45+ cells. Data representative of two independent 
experiments with n=5 and n=6, respectively. B. Graph showing the percentage of CD11b+Gr-1hi cells 
in the cLP of TRUC and TRUCIl22-/- mice. Data representative of two independent experiments with 
n=5 and n=6, respectively. Statistical analysis was performed using PRISM® version 7 software 
(Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). C. Graph showing the absolute 
number of CD11b+Gr-1hi cells in the cLP of TRUC and TRUCIl22-/- mice. Data representative of two 
independent experiments with n=5 and n=6, respectively. Statistical analysis was performed using 
PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. 
Graph showing the absolute number of cLPMCs in TRUC vs. TRUCIl22-/- mice. Data representative 
of two independent experiments with n=5 and n=6, respectively. Statistical analysis was performed 
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Figure 39: TRUCIl22-/- mice exhibit impaired neutrophil recruitment in the spleen. TRUC and 
TRUCIl22-/- mice were orally gavaged with intestinal microbiota at day 0 and culled 6 weeks later at 
day 42. Single cell suspensions were prepared from the spleens of TRUC and TRUCIl22-/- mice and 
stained with Abs against surface markers to analyse neutrophil infiltrate by FACS. A. Representative 
dot plots showing the percentage of neutrophils defined as CD11b+Gr-1hi cells in the spleen of TRUC 
and TRUCIl22-/- mice, respectively. Cells gated as single live cells. Data representative of two 
independent experiments with n=5 and n=6, respectively. B. Graph showing the percentage of 
CD11b+Gr-1hi cells in the spleen of TRUC and TRUCIl22-/- mice. Data representative of two 
independent experiments with n=5 and n=6, respectively. Statistical analysis was performed using 
PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). C. 
Graph showing the absolute number of CD11b+Gr-1hi cells in the spleen of TRUC and TRUCIl22-/- 
mice. Data representative of two independent experiments with n=5 and n=6, respectively. Statistical 
analysis was performed using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, 
**P<0.005, ***p<0.0001). D. Graph showing the absolute number of splenocytes in TRUC vs. 
TRUCIl22-/- mice. Data representative of two independent experiments with n=5 and n=6, 
respectively. Statistical analysis was performed using PRISM® version 7 software (Mann-Whitney 
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Figure 40: IL-22 blockade resulted in impaired neutrophil numbers in the cLP of TRUC mice. 
TRUC mice were administered ip. with 200µg aIL-22 or isotype antibody (control) and culled seven 
days later for downstream analysis. cLPMCs were isolated using Percoll gradient and stained with 
Abs against surface markers to analyse neutrophil infiltrate by FACS. A. Representative dot plots 
showing the percentage of neutrophils defined as CD11b+Gr-1hi cells in the cLP of TRUC mice 
treated with 200µg of aIL-22  (n=6) or isotype control Ab (n=8), respectively. Cells gated as single 
live CD45+ cells. Data representative of a single experiment. B. Graph showing the percentage of 
CD11b+Gr-1hi cells in the cLP of TRUC mice treated with 200µg of aIL-22  (n=6) or isotype control 
Ab (n=8), respectively. Data representative of a single experiment. Statistical analysis was performed 
using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, 
***p<0.0001). C. Graph showing the absolute number of CD11b+Gr-1hi cells in the cLP of TRUC 
mice treated with 200µg of aIL-22  (n=6) or isotype control Ab (n=8), respectively. Data 
representative of a single experiment. Statistical analysis was performed using PRISM® version 7 
software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Graph showing the 
absolute number of cLPMCs in the cLP of TRUC mice treated with 200µg of aIL-22  (n=6) or isotype 
control Ab (n=8), respectively.  Data representative of a single experiment. Statistical analysis was 
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Figure 41: Administration of recombinant IL-22 resulted in increased neutrophil recruitment in 
the cLP of TRUCIl22-/- mice. TRUCIl22-/- mice were administered ip. with 100µg rIL-22 or PBS 
(control) at days 0, 4, 8 and 12, and were culled at day 14 for downstream analysis. cLPMCs were 
isolated using Percoll gradient and stained with Abs against surface markers to analyse neutrophil 
infiltrate by FACS. A. Representative dot plots showing the percentage of neutrophils defined as 
CD11b+Gr-1hi cells in the cLP of TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or PBS (control) 
(n=7), respectively. Cells gated as single live CD45+ cells. Data representative of a single experiment. 
B. Graph showing the percentage of CD11b+Gr-1hi cells in the cLP of TRUCIl22-/- mice treated with 
100µg rIL-22 (n=5) or PBS (control) (n=7), respectively. Data representative of a single experiment. 
Statistical analysis was performed using PRISM® version 7 software (Mann-Whitney two-tailed test, 
*p<0.05, **P<0.005, ***p<0.0001). C. Graph showing the absolute number of CD11b+Gr-1hi cells in 
the cLP of TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or PBS (control) (n=7), respectively. 
Data representative of a single experiment. Statistical analysis was performed using PRISM® version 
7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Graph showing the 
absolute number of cLPMCs in TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or PBS (control) 
(n=7), respectively. Data representative of a single experiment. Statistical analysis was performed 
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Figure 42: Administration of recombinant IL-22 resulted in increased neutrophil percentages in 
the spleen of TRUCIl22-/- mice. TRUCIl22-/- mice were administered ip. with 100µg rIL-22 or PBS 
(control) at days 0, 4, 8 and 12, and were culled at day 14 for downstream analysis. Single cell 
suspensions were prepared from the spleens of TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or 
PBS (control) (n=7) and stained with Abs against surface markers to analyse neutrophil infiltrate by 
FACS. A. Representative dot plots showing the percentage of neutrophils defined as CD11b+Gr-1hi 
cells in the spleen of TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or PBS (control) (n=7), 
respectively. Cells gated as single live cells. Data representative of a single experiment. B. Graph 
showing the percentage of CD11b+Gr-1hi cells in the spleen of TRUCIl22-/- mice treated with 100µg 
rIL-22 (n=5) or PBS (control) (n=7), respectively. Data representative of a single experiment. 
Statistical analysis was performed using PRISM® version 7 software (Mann-Whitney two-tailed test, 
*p<0.05, **P<0.005, ***p<0.0001). C. Graph showing the absolute number of CD11b+Gr-1hi cells in 
the spleen of TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or PBS (control) (n=7), respectively. 
Data representative of a single experiment. Statistical analysis was performed using PRISM® version 
7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Graph showing the 
absolute number of splenocytes in TRUCIl22-/- mice treated with 100µg rIL-22 (n=5) or PBS (control) 
(n=7), respectively. Data representative of a single experiment. Statistical analysis was performed 
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5.5 In vivo blocking of CXCL1 didn’t seem to affect 
neutrophil recruitment to the colon of TRUC mice 
To formally address a potential involvement of the chemokine CXCL1 that was 
found to be induced in colonic epithelial cells upon IL-22 stimulation, in neutrophil 
accumulation to the cLP of TRUC mice, a neutralizing mAb against CXCL1 was in 
vivo administered to TRUC mice, and neutrophil recruitment to the colon of these 
mice was analysed by flow cytometry. As shown in Figures 43A and 43B, there was 
no difference in the percentage of neutrophils in the cLP of aCXCL1 treated TRUC 
mice compared to isotype treated (control) mice. Similarly, there were no differences 
in the total neutrophil counts or the total cLPMCs between aCXCL1 and isotype 
treated control mice (Figure 43C and 43D, respectively). Although these findings 
seem to suggest that CXCL1 is not needed for neutrophil recruitment to the colon of 
TRUC mice, this experiment was only performed once, hence additional repeats are 

















Figure 43: CXCL1 didn’t seem to affect neutrophil recruitment to the cLP of TRUC mice. 
TRUC mice were administered ip. with 150µg aCXCL1or isotype antibody (control) every 3 to 4 days 
and culled for downstream analysis. cLPMCs were isolated using Percoll gradient and stained with 
Abs against surface markers to analyse neutrophil infiltrate by FACS. A. Representative dot plots 
showing the percentage of neutrophils defined as CD11b+Gr-1hi cells in the cLP of TRUC mice 
treated with 150µg of aCXCL1 (n=5) or isotype control Ab (n=7), respectively. Cells gated as single 
live CD45+ cells. Data representative of a single experiment. B. Graph showing the percentage of 
CD11b+Gr-1hi cells in the cLP of TRUC mice treated with 150µg of aCXCL1 (n=5) or isotype control 
Ab (n=7), respectively. Data representative of a single experiment. Statistical analysis was performed 
using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, 
***p<0.0001). C. Graph showing the absolute number of CD11b+Gr-1hi cells in the cLP of TRUC 
mice treated with 150µ g of aCXCL1 (n=5) or isotype control Ab (n=7), respectively. Data 
representative of a single experiment. Statistical analysis was performed using PRISM® version 7 
software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Graph showing the 
absolute number of cLPMCs in TRUC mice treated with 150µ of aCXCL1 (n=5) or isotype control 
Ab (n=7), respectively. Data representative of a single experiment. Statistical analysis was performed 
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5.6 In vivo blocking of CXCR2 didn’t seem to affect 
neutrophil recruitment to the colon of TRUC mice 
Since IL-22 was found to induce both CXCL1 and CXCL5 production by colonic 
epithelial cells, the effect of in vivo blocking both of these two chemokines in 
neutrophil trafficking in TRUC mice was investigated. Indeed, the failure of CXCL1 
blockade alone could be accounted for by its redundancy in this system, with CXCL5 
being able to compensate to mediate neutrophil recruitment. Therefore, we sought to 
block both CXCL1 and CXCL5 by administering a blocking anti-CXCR2 mAb to 
TRUC mice, since both CXCL1 and CXCL5 use the CXCR2 receptor. As shown in 
Figures 44A and 44B, CXCR2 blockade didn’t affect the percentage of neutrophils in 
the cLP of TRUC mice. Similarly, the absolute number of neutrophils was also not 
affected in the cLP of aCXCR2 treated TRUC mice in comparison to isotype treated 
(control) mice (Figure 44C). In vivo blocking of CXCR2 in TRUC mice didn’t seem 
to affect the total cLPMCs either as shown in Figure 44D.  
Similarly, in vivo administration of CXCR2 didn’t affect neutrophil accumulation to 
the spleen of treated TRUC mice compared to control mice (Figure 45). As shown in 
Figures 45A and 45B, the percentage of neutrophils in the spleen of aCXCR2 treated 
TRUC mice is slightly increased if anything, compared to the one in control mice. 
The absolute neutrophil number, as well as the total splenocyte counts were also 
unaffected in aCXCR2 treated mice compared to isotype treated (control) mice as 
shown in Figures 45C and 45D, respectively. Again, additional repeats of these 










Figure 44: CXCR2 blockade didn’t seem to affect neutrophil recruitment to the cLP of TRUC 
mice. TRUC mice were administered ip. with 100µg aCXCR2 or isotype antibody (control) at day 0, 
3, 7, 10, 14 and culled at day 15 for downstream analysis. cLPMCs were isolated using Percoll 
gradient and stained with Abs against surface markers to analyse neutrophil infiltrate by FACS. A. 
Representative dot plots showing the percentage of neutrophils defined as CD11b+Gr-1hi cells in the 
cLP of TRUC mice treated with 100µg of aCXCR2 (n=3) or isotype control Ab (n=2), respectively. 
Cells gated as single live CD45+ cells. Data representative of a single experiment. B. Graph showing 
the percentage of CD11b+Gr-1hi cells in the cLP of TRUC mice treated with 100µg of aCXCL1 (n=3) 
or isotype control Ab (n=2), respectively. Data representative of a single experiment. Statistical 
analysis was performed using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, 
**P<0.005, ***p<0.0001).  C. Graph showing the absolute number of CD11b+Gr-1hi cells in the cLP 
of TRUC mice treated with 100µg of aCXCR2 (n=3) or isotype control Ab (n=2), respectively. Data 
representative of a single experiment. Statistical analysis was performed using PRISM® version 7 
software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Graph showing the 
absolute number of cLPMCs in TRUC mice treated with 100µg of aCXCR2 (n=3) or isotype control 
Ab (n=2), respectively. Data representative of a single experiment. Statistical analysis was performed 
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Figure 45: CXCR2 blockade didn’t seem to affect neutrophil recruitment to the spleen of TRUC 
mice. TRUC mice were administered ip. with 100µg aCXCR2 or isotype antibody (control) at day 0, 
3, 7, 10, 14 and culled at day 15 for downstream analysis. Single cell suspensions were prepared from 
the spleens of TRUC mice treated with 100µg aCXCR2 (n=4) or isotype control Ab (n=10) and 
stained with Abs against surface markers to analyse neutrophil infiltrate by FACS. A. Representative 
dot plots showing the percentage of neutrophils defined as CD11b+Gr-1hi cells in the spleen of TRUC 
mice treated with 100µg of aCXCR2 (n=4) or isotype control Ab (n=10), respectively. Cells gated as 
single live CD45+ cells. Data representative of a single experiment. B. Graph showing the percentage 
of CD11b+Gr-1hi cells in the spleen of TRUC mice treated with 100µg of aCXCR2 (n=4) or isotype 
control Ab (n=10), respectively. Data representative of a single experiment. Statistical analysis was 
performed using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, 
***p<0.0001). C. Graph showing the absolute number of CD11b+Gr-1hi cells in the spleen of TRUC 
mice treated with 100µg of aCXCR2 (n=4) or isotype control Ab (n=10), respectively. Data 
representative of a single experiment. Statistical analysis was performed using PRISM® version 7 
software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001). D. Graph showing the 
absolute number of splenocytes in TRUC mice treated with 100µg of aCXCR2 (n=4) or isotype 
control Ab (n=10), respectively. Data representative of a single experiment. Statistical analysis was 
performed using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, 
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5.7 IL-22 seems to induce CXCL5 production in a small 
intestinal epithelial cell line 
The data presented in this chapter collectively support the hypothesis that NCR- 
ILC3s and IL-22 are involved in the regulation of neutrophil recruitment to the colon 
in TRUC disease. This process could be mediated by the known neutrophil chemo-
attractants CXCL1 and CXCL5 that are produced by colonic epithelial cells in 
response to IL-22 stimulation. However, the mechanism of how IL-22 acts on the 
colonic epithelium to induce the production of the above chemokines is still 
unknown.  
In an attempt to identify the molecules involved in the downstream signalling of the 
IL-22R, a small intestinal epithelial cell line (Mode K) was obtained. Mode K were 
grown and expanded in culture, and once confluent they were stimulated for 24h 
with 10ng/ml of recombinant IL-22 with or without commercially purchased 
inhibitors for further analysis. Unfortunately, as shown in Figure 46A, IL-22 
stimulation failed to induce the expression of Cxcl5 in Mode K cells.  
Similarly, 24h stimulation with IL-22 didn’t induce CXCL5 production by Mode K 
cells Mode K cells (Figure 48B). As such, no conclusions could be drawn by the use 
of inhibitors that are known to block the IL-22 signaling pathway. Different settings 












Figure 46: Cxcl5 expression in Mode K cells. Mode K cells were cultured until confluent then 
transferred in 6-well plates at a concentration of 2x106cell/well and stimulated for 24h with 10ng/ml 
recombinant IL-22. mRNA and protein levels of CXCL5 were measured by RT-qPCR and ELISA, 
respectively. A. Cxcl5 expression in Mode K cells stimulated for 24h with or without 10ng/ml 
recombinant IL-22 measured by RT-qPCR. Data representative of two independent experiments with 
3 technical replicates. Statistical analysis was performed using PRISM® version 7 software (Mann-
Whitney two-tailed test, *p<0.05, **P<0.005, ***p<0.0001).   B. CXCL5 production by Mode K cells 
stimulated for 24h with 10ng/ml recombinant IL-22 in the presence or absence of several IL-22 
signaling pathway inhibitors. CXCL5 concentration in the S/Ns was measured by ELISA. Data 
representative of a single experiment with 3 technical replicates. Statistical analysis was performed 
using PRISM® version 7 software (Mann-Whitney two-tailed test, *p<0.05, **P<0.005, 
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5.8 Discussion 
In the previous two chapters (3 and 4) of this thesis, it was shown that IL-22 has a 
key role in TRUC disease, quite possibly through induction of ER stress in colonic 
epithelial cells. The data shown in this chapter suggest that IL-22 might also regulate 
neutrophil recruitment to the colonic LP by inducing the production of chemokines 
CXCL1 and CXCL5 by colonic epithelial cells.  
Neutrophil accumulation to the colonic LP is an important aspect of TRUC 
pathology (Powell, Walker et al. 2012, Ermann, Staton et al. 2014).  Transcripts 
encoding for several CXC and CCL chemokines were increased in the colon of 
TRUC mice compared to Rag2-/- control mice.  Similar transcriptional changes were 
observed in colonic epithelial cells following 24h stimulation with IL-22. These 
findings were also corroborated by RT-qPCR performed by Dr Anastasia Tsakmaki. 
The production of CXCL1 and CXCL5, two known neutrophil chemo-attractants, 
were also significantly increased in the supernatants of colonois treated with IL-22. 
These transcriptomic data support the hypothesis of IL-22 having an additional effect 
on the colonic epithelium by inducing chemokine production that subsequently leads 
to neutrophil accumulation to the gut.   
Interestingly, a co-culture experiment of FACS purified NCR- ILC3s isolated from 
TRUC and TRUCIl22-/- mice with murine colonoids revealed that only IL-22 
sufficient NCR- ILC3s were able to significantly induce the expression of the 
chemokine genes Cxcl1 and Cxcl5 in colonic epithelial cells, results which were also 
confirmed by ELISA on the supernatants of these cultures. These findings suggest 
that NCR- ILC3s may also contribute to TRUC pathology via neutrophil recruitment 
to the inflamed colon in TRUC mice through IL-22 mediated induction of CXCL1 
and CXCL5 production by colonic epithelial cells.  
Pro-inflammatory chemokines are highly expressed in CD and UC patients 
(Reinecker, Loh et al. 1995, Ina, Kusugami et al. 1997, Huang, Eckmann et al. 1996), 
suggesting their importance in disease pathology. Consistent with a disease-free 
phenotype TRUCIl22-/- mice had significantly lower neutrophil infiltrate in their 
spleens and colons compared to TRUC mice.  Moreover, IL-22 blockade 
significantly reduced the absolute number of neutrophils in the colonic LP of TRUC 
mice, while in vivo administration of recombinant IL-22 into TRUIl22-/- mice led to a 
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significant increased neutrophil accumulation to the colon of these mice. These 
findings suggest a key role for IL-22 in the regulation of neutrophil recruitment to 
the gut, and in particular to the colon, that may comprise another mechanism by 
which NCR- ILC3s contribute to TRUC pathology.   
Interestingly, in contrast to what was seen in the colon, administration of rIL-22 into 
TRUCIl22-/- mice resulted in a significantly decrease in the percentage of neutrophils 
found in the spleen of these mice suggesting that there may be alternative 
mechanisms that regulate neutrophil trafficking to different tissues. Whether this is 
indeed the case is yet to be determined as this experiment was only performed once 
due to limited mouse availability, so repeating these experiments is needed in order 
to confirm/validate these findings.  
Surprisingly, in vivo CXCL1 blockade didn’t affect neutrophil accumulation to the 
colonic LP of TRUC mice, although the experiment needs to be repeated in order to 
confirm the data. Similarly, in vivo blocking of the chemokine receptor for CXCL1 
and CXCL5, CXCR2, had no impact on neutrophil infiltrate in the colonic LP, which 
appears to challenge the notion of CXCR2 having an important role in neutrophil 
accumulation and disease outcome (Buanne, Di Carlo et al. 2007). However, these 
findings can only be characterized as preliminary as they came from a single 
experiment with very small n numbers.   
Finally, in an attempt to scrutinize the signalling pathway by which IL-22 induced 
CXCL1 and CXCL5 production by colonic epithelial cells, a small intestinal cell line 
(Mode K cells) was exploited. However, in vitro stimulation with IL-22 in the 
presence or absence of inhibitors that block different components of the IL-22 
signaling pathway, failed to induce CXCL1 and CXCL5 production by colonic 
epithelial cells which suggests that maybe IL-22 has different effects on small 
intestinal epithelial cells than those observed in the colonic epithelium of TRUC 
mice, and hence alternative experiments are necessary in order to understand the 
mechanisms by which IL-22 impacts on colonic epithelial cells contributing to 
TRUC pathology. 
In general, neutrophil accumulation to the gut is thought to contribute in the 
promotion of intestinal inflammation (Zimmerman, Vongsa et al. 2008). Taken all 
together, the data presented in this chapter suggest that IL-22 may regulate neutrophil 
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recruitment to the gut by inducing the production of CXCL1 and CXCL5 by colonic 
epithelial cells, which in turn may constitute an additional pro-inflammatory program 





Results: IL-22 regulated/TRUC relevant transcripts 
are increased in patients with active UC  
In the first results chapter (chapter 3), it was shown that TRUC disease is 
characterized by an IL-22 responsive transcriptional signature, and most importantly 
that IL-22 drives intestinal inflammation in the colon of TRUC mice. Moving on to 
investigate how exactly IL-22 mediates inflammation in TRUC disease, in chapter 4 
it was shown that IL-22 produced by NCR- ILC3s induced ER stress in colonic 
epithelial cells, and that that induction was significantly reduced in the presence of 
regulatory T cells (which are normally absent in TRUC mice due to Rag2 
deficiency). Moreover, in vivo blocking of ER stress attenuated inflammation in 
TRUC mice. An additional effect of IL-22 on the colonic epithelium was then 
described on chapter 5, where it was shown that IL-22 regulates neutrophil 
accumulation to the colonic LP by inducing the production of the chemokines 
CXCL1 and CXCL5 by colonic epithelial cells. Taken all together, these data point 
to IL-22 being a key regulator of colonic inflammation in TRUC disease.  
The TRUC mouse is a great model of chronic colitis that resembles many aspects of 
human UC (Garrett, Lord et al. 2007). To investigate whether the findings described 
so far in this thesis bare any relevance to human disease, and in particular to UC, 
reposited datasets with availability on whole genome expression profiles of gut tissue 
from UC patients and healthy individuals were interrogated. Among several datasets 
publicly available, the largest one published by Vanhove et al (Vanhove, Peeters et 
al. 2015) used RNA extracted from colonic biopsies of patients with active UC 
(n=74), patients with inactive disease (n=23) and healthy individuals (n=11) was 
selected for further analysis. Raw data were obtained from the Gene Expression 
Omnibus repository (accession number GSE59071) and were analysed using 
Partek® Genomics Suite software and GraphPad PRISM® version 7 software.  
156 
6.1 Upregulated genes in TRUC disease are also 
upregulated in patients with active UC 
As shown in Figure 47, some of the most upregulated genes found in TRUC mice 
(compared to healthy Rag2-/- controls) like Cxcl1, Duoxa2, S100a8 were also 
significantly increased in the mucosa of patients with active disease compared to 
healthy individuals. Notably, among them were also IL-22 responsive genes 
(highlighted with pattern in Figure 47) as defined by gene expression analysis 
(Mouse Gene 2.0 ST array, Affymetrix) in IL-22 treated colonoids compared to 





















Figure 47: Transcripts of TRUC upregulated genes are increased in patients with active UC. 
Graph showing fold change of upregulated genes in colonic biopsies from patients with active UC vs. 
healthy controls. Raw data were obtained from the Gene Expression Omnibus (GEO) repository 
(Accession number GSE59071) (Vanhove, Peeters et al. 2015). Analysis was performed using 



























































6.2 IL22 and other IBD relevant transcripts are increased 
in patients with active UC 
Supporting this hypothesis, the expression of IL22 was significantly upregulated in 
patients with active disease compared to healthy individuals (p=0.0017) or patients 
with quiescent UC (p< 0.0001) (Figure 48). As expected, transcripts of known IBD 
relevant genes were also significantly increased in patients with active disease 
compared to healthy individuals or patients with quiescent UC as shown in Figures 
48 and 49 (IL17A: p< 0.0001, IFNG: p< 0.0001, TNFA: p< 0.0001, TNFSF15: p< 
0.0001 respectively).  
Interestingly, as shown in Figures 50 and 51, IL22 expression in patients with active 
disease was significantly positively correlated with the expression of IL17A, IFNG, 
TNFA and TNFSF15 (p= 0.0031, p<0.0001, p=0.0048, and p= 0.0413 respectively) 


















Figure 48: IL-22 and other TRUC relevant cytokine expression in human UC. Graphs showing 
expression levels of IL22, IL17A and IFNG respectively in the colon of patients with active UC vs. 
patients with quiescent UC and healthy controls. Each square represents one patient. Lines depict 
means with SD. Raw data were obtained from the Gene Expression Omnibus (GEO) repository 
(Accession number GSE59071) (Vanhove, Peeters et al. 2015). Analysis was performed using 







































































































Figure 49: TNFA and TNFSF15 expression in human UC. Graphs showing expression levels of 
TNFA and TNFSF15 respectively in the colon of patients with active UC vs. patients with quiescent 
UC and healthy controls. Each square represents one patient. Lines depict means with SD. Raw data 
were obtained from the Gene Expression Omnibus (GEO) repository (Accession number GSE59071) 
(Vanhove, Peeters et al. 2015). Analysis was performed using Partek® and GraphPad PRISM® 













































































Figure 50: IL22 expression is significantly positively correlated with the expression of IL17A and 
IFNG in patients with active UC. Graphs showing how the expression levels of IL22 correlate with 
those of IL17A and IFNG respectively in the colon of patients with active UC (best-fit line with 95% 
confidence band). Each square represents a single patient. Raw data were obtained from the Gene 
Expression Omnibus (GEO) repository (Accession number GSE59071) (Vanhove, Peeters et al. 














































Figure 51: IL22 expression is significantly positively correlated with the expression of TNFA and 
TNFSF15 in patients with active UC. Graphs showing how the expression levels of IL22 correlate 
with those of TNFA and TNFSF15 respectively in the colon of patients with active UC (best-fit line 
with 95% confidence band). Each square represents a single patient. Raw data were obtained from the 
Gene Expression Omnibus (GEO) repository (Accession number GSE59071) (Vanhove, Peeters et al. 









































6.3 ER stress transcripts are increased in patients with 
active UC 
Similarly to TRUC disease, transcripts of known ER stress genes such as XBP1, 
ATF6 and ERN1 were found to be significantly increased in patients with active 
disease compared to healthy individuals or patients with quiescent UC (Figure 52).  
Moreover, as shown in Figure 53, IL22 expression was significantly positively 
correlated with the expression of the ER stress genes ATF6 and ERN1 but not with 
that of XBP1 in patients with active disease, suggesting that the IL-22 actions found 





















Figure 52: ER stress genes are upregulated in patients with active UC. Graphs showing 
expression levels of XBP1, ATF6 and ERN1 respectively in the colon of patients with active UC vs. 
patients with quiescent UC and healthy controls. Each square represents one patient. Lines depict 
means with SD. Raw data were obtained from the Gene Expression Omnibus (GEO) repository 
(Accession number GSE59071) (Vanhove, Peeters et al. 2015). Analysis was performed using 







































































































Figure 53: IL22 expression is significantly positively correlated with the expression of ATF6 and 
ERN1 in patients with active UC. Graphs showing how the expression levels of IL22 correlate with 
those of ATF6 and ERN1 respectively in the colon of patients with active UC (best-fit line with 95% 
confidence band). Each square represents a single patient. Raw data were obtained from the Gene 
Expression Omnibus (GEO) repository (Accession number GSE59071) (Vanhove, Peeters et al. 
2015). Analysis was performed using Partek® and GraphPad PRISM® version 7 software. 
Figure 53 






















































6.4 Gene expression of CXCL1 and CXCL5 is increased in 
patients with active UC 
Supporting this narrative, CXCL1 and CXCL5 transcripts were also significantly 
upregulated in patients with active disease compared to healthy individuals or 
patients with quiescent UC (Figure 54). More importantly, their expression was 
positively correlated with IL22 expression in patients with active disease as shown in 
Figure 55.  
Taking all together, these data support the notion of IL-22 being implicated in UC 
pathogenesis, possibly by inducing ER stress in the colonic epithelium and/or driving 




















Figure 54: CXCL1 and CXCL5 transcripts are increased in patients with active UC. Graphs 
showing expression levels of CXCL1and CXCL5 respectively in the colon of patients with active UC 
vs. patients with quiescent UC and healthy controls. Each square represents one patient. Lines depict 
means with SD. Raw data were obtained from the Gene Expression Omnibus (GEO) repository 
(Accession number GSE59071) (Vanhove, Peeters et al. 2015). Analysis was performed using 
















































































Figure 55: IL22 expression is significantly positively correlated with the expression of CXCL1 
and CXCL5 in patients with active UC. Graphs showing how the expression levels of IL22 correlate 
with those of CXCL1 and CXCL5 respectively in the colon of patients with active UC (best-fit line 
with 95% confidence band). Each square represents a single patient. Raw data were obtained from the 
Gene Expression Omnibus (GEO) repository (Accession number GSE59071) (Vanhove, Peeters et al. 











































In the previous chapters of this thesis, it was shown that TRUC disease is 
characterized by an IL-22 responsive transcriptional signature, and that IL-22 drived 
intestinal inflammation in the colon of TRUC mice by inducing ER stress in colonic 
epithelial cells. In addition, it was shown that IL-22 regulates neutrophil recruitment 
to the colonic LP by inducing chemokine production, and in particular the expression 
of CXCL1 and CXCL5 by colonic epithelial cells. In this chapter, it was shown that 
the pro-inflammatory pathways imprinted by NCR- ILC3s through IL-22 production 
in TRUC disease that were described so far may be also relevant in human disease.  
The TRUC mouse model of experimental colitis resembles many aspects of human 
UC (Garrett, Lord et al. 2007). Whole transcriptome analysis on colonic biopsies 
from patients with active or inactive UC and healthy controls revealed that the 
human orthologues of several transcripts, which were found highly upregulated in 
TRUC disease, were also significantly increased in patients with active UC 
compared to those with inactive disease or to healthy individuals. Within this gene 
set were also know IL-22 responsive genes suggesting that IL-22 may also be 
important in the human disease.  
Similarly to other cytokines that are known to be important in IBD pathogenesis such 
as IFNγ, IL-17A, TNFα and TL1A the transcripts of which were found to be 
significantly increased in patients with active UC compared to inactive disease or 
healthy controls, IL22 expression was also significantly higher in patients with active 
disease. Interestingly, IL22 expression in patients with active disease was 
significantly positively correlated with the expression of IFNG, IL17A, TNFA and 
TNFSF15 supporting further the possibility of IL-22 having a functional role in 
human UC.  
Several independent studies have associated ER stress with IBD 
susceptibility/pathogenesis (Kaser, Lee et al. 2008, Shkoda, Ruiz et al. 2007, 
Deuring, de Haar et al. 2012). Consistent with our pre-clinical findings, transcripts 
encoding for known ER stress genes such as ATF6, ERN1 and XBP1 were 
significantly increased in patients with active UC compared to those with quiescent 
disease and healthy individuals. Moreover, the expression of these genes was 
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positively correlated with IL22 expression in patients with active UC, suggesting that 
IL-22 may also induce ER stress in human IBD.  
In accordance with studies shown increased chemokine production in IBD patients 
(Reinecker, Loh et al. 1995, Ina, Kusugami et al. 1997, Huang, Eckmann et al. 1996), 
CXCL1 and CXCL5 transcripts were significantly upregulated in patients with active 
disease compared to those with inactive UC and healthy controls, and their 
expression was positively correlated with IL22 expression in patients with active UC, 
supporting the possibility of IL-22 regulating neutrophil recruitment to the gut by 
inducing chemokine production by colonic epithelial cells in human UC.  
Although these preliminary findings suggest that IL-22 pro-inflammatory actions in 
our pre-clinical model of IBD described in this thesis may be also relevant in human 
disease, some more systematic approaches would have been of additional value. 
GSEA would reveal in an unbiased way whether the most upregulated genes found in 
TRUC disease were enriched in patients with active disease, and similarly whether 
the IL-22 responsive genes found in our colonoid system were also enriched in 
human disease. Moreover, pathways analysis would be beneficial to identify specific 
pathways associated with human UC, and in particular all the ER stress components, 
the transcription of which may be affected in UC. Similarly, as several genetic loci 
have been associated with both CD and UC susceptibility (Jostins, Ripke et al. 2012), 
the same analysis could be extended to patients with active and inactive CD, to see 
whether IL-22 may be relevant in human CD.  
Finally, these findings are only based on transcriptomic analysis and although they 
may suggest that the pathways described in the previous chapters of this thesis could 
also be relevant in human disease, they should solely be treated as an indication of 







7.1 New insights into the pathology of TRUC disease 
The data presented in this thesis shed more light into the immunopathology of TRUC 
disease. As originally described by Garrett et al T-bet deficiency in the absence of an 
adaptive immune system leads to chronic colitis that resembles many aspects of 
human UC (Garrett, Lord et al. 2007). Previous work in the lab by Powell et al 
showed that in TRUC mice, colonic CD103-CD11b+ DCs produce excessively TNFα 
and IL-23, which leads to the activation of ILC3s that drive disease through IL-17A 
production (Powell, Walker et al. 2012). The data presented in this thesis suggest that 
NCR- ILC3s, the most abundant ILC3 subset in the colonic LP, may drive disease 
through induction of ER stress in colonic epithelial cells and regulation of neutrophil 
recruitment through induction of chemokine production by colonic epithelial cells. It 
was also shown that NCR- ILC3s mediate these pro-inflammatory functions through 
the production of IL-22. Finally, it was shown that the pro-inflammatory pathways 
found in our pre-clinical model of IBD might also be relevant in human disease. 
Taken all together, the data described in this thesis expand our current understanding 
of TRUC disease and propose new mechanisms by which NCR- ILC3s may drive 
inflammation in chronic colitis that could be further explored in order to define new 








Figure 56: Updated model of TRUC pathology. In the colonic lamina propria of TRUC mice, where 
DCs sample antigens from the lumen, CD103-CD11b+ DCs produce excessively TNFα and IL-23 that 
results in the activation of NCR- ILC3s. Upon activation, NCR- ILC3s produce high amounts of IL-
17A and IL-22. Here, it was shown that IL-22 induced ER stress in the colonic epithelial cells and 
regulated neutrophil recruitment to the colon by inducing chemokine production by colonic epithelial 



















7.2 New implications of NCR- ILC3s in IBD 
The data presented in this thesis, described for the first time new pro-inflammatory 
functions for NCR- ILC3s in TRUC disease. In contrast to NCR+ ILC3s, NCR- ILC3s 
have not been extensively studied in the IBD, and so this thesis aimed to define their 
role in chronic colitis. NCR- ILC3s were found to be the most abundant ILC3 subset 
in the colonic LP in healthy steady and during intestinal inflammation. It was shown 
that they have a crucial role in chronic colitis mediated by production of IL-22 that 
subsequently led to ER stress induction in colonic epithelial cells and neutrophil 
recruitment to the colon. In the gut, it’s suggested that IL-22 is beneficial, as it 
promotes host’s defence against commensal bacterial and foreign pathogens 
(Sonnenberg, Monticelli et al. 2012), as well as tissue regeneration (Lindemans, 
Calafiore et al. 2015), whereas the data presented in this thesis challenge that notion, 
additional work is necessary to define whether these findings could also be relevant 
in other murine models of experimental colitis where immuno-competent mice are 
used, and ultimately to whether or not are relevant in human disease.   
TRUCIl22-/- mice are protected from disease, while in vivo blockade of IL-22 
attenuated disease and reduced colonic ER stress in TRUC mice. Several 
independent studies have implicated ER stress with IBD susceptibility and 
pathogenesis (Kaser, Lee et al. 2008, Shkoda, Ruiz et al. 2007, Deuring, de Haar et 
al. 2012). For the first time, this physiological cellular process is linked with NCR- 
ILC3s, suggesting a pro-inflammatory role for these cells in chronic inflammation. 
Although during acute epithelial injury  (Zenewicz, Yancopoulos et al. 2008, 
Sugimoto, Ogawa et al. 2008) or upon intestinal infections, where homeostasis is 
quickly restored, IL-22 has beneficial properties (Zheng, Valdez et al. 2008, 
Monticelli, Sonnenberg et al. 2011), it is possible that during chronic inflammation 
IL-22 mediates more pathological functions. In psoriasis, IL-22 is thought to be 
pathogenic (Wolk, Witte et al. 2009, Wolk, Haugen et al. 2009), which could also 
support that hypothesis. IL-22 was also shown to regulate neutrophil accumulation to 
the colon possibly by inducing the production of CXCL1 and CXCL5 by colonic 
epithelial cells. Pro-inflammatory chemokines are highly expressed in IBD patients 
(Reinecker, Loh et al. 1995, Ina, Kusugami et al. 1997, Huang, Eckmann et al. 1996), 
while neutrophil infiltration in the gut is thought to be associated with disease 
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pathology (Zimmerman, Vongsa et al. 2008), highlighting the importance of this 
pathway in IBD pathogenesis.   
The pro-inflammatory pathways described in this thesis directly linking NCR- ILC3s 
with TRUC pathology, also appeared to be relevant in human disease. Transcripts 
encoding IL-22, ER stress genes and the chemokines CXCL1 and CXCL5 were 
significantly increased in patients with active UC, suggesting that the pro-
inflammatory programs triggered by IL-22 may also be important in human disease. 
Additional human studies are necessary to investigate this hypothesis and explore the 
pathways involved. 
Further exploration of these pathways may lead to the development of new 
therapeutic strategies to treat IBD. The data presented here support the hypothesis 
that blocking antibodies against IL-22 could be beneficial to patients with UC. With 
several studies describing a detrimental role for IL-22 in different cancer, and in 
particular in colorectal cancer (Huang, Cao et al. 2015, Koltsova, Grivennikov 2014, 
Kryczek, Lin et al. 2014), which in certain cases can be associated with IBD, these 
findings highlight even more the role of this effector cytokine in intestinal 
inflammation and enhance the need for additional studies.    
In summary, the data presented in this thesis provide new evidence on the role of 
NCR- ILC3s and their effector cytokine IL-22 in chronic colitis, which could be 
relevant in human disease, and offer new directions that can be explored in order to 
create novel therapeutic strategies to treat IBD.     
7.3 Future directions 
Future work will focus on identifying the exact mechanisms and signaling 
pathway(s) by which IL-22 may regulate ER stress, as well as neutrophil recruitment 
to the gut in TRUC disease. It is also important to see whether these interesting 
findings in our preclinical model of IBD can be translated to human disease.  An 
additional route that could also be explored is the link between chronic inflammation 
and colorectal cancer, as IL-22 is thought to be a major player in this context.  
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Finally, it would be interesting to investigate the role of ILC2s in chronic 
inflammation, as they seem to be the most abundant ILC subset in the murine colon, 
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